Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof

ABSTRACT

Provided herein are methods for treating or preventing a cancer, in particular solid tumors and hematological cancers, comprising administering to a subject in need thereof an effective amount of a compound of formula (I):

This application is a divisional of U.S. application Ser. No. 14/797,548, filed Jul. 13, 2015, currently allowed, which claims the benefit of U.S. Provisional Application No. 62/024,158, filed Jul. 14, 2014, the entire contents of which are incorporated herein by reference.

FIELD

Provided herein are methods for treating or preventing a cancer, in particular solid tumors and hematological cancers as described herein, comprising administering an effective amount of a pyrrolopyrimidine compounds to a subject in need thereof. Also provided herein are Pyrrolopyrimidine Compounds that can be used in said methods.

BACKGROUND

Cancer is characterized primarily by an increase in the number of abnormal cells derived from a given normal tissue, invasion of adjacent tissues by these abnormal cells, or lymphatic or blood-borne spread of malignant cells to regional lymph nodes and to distant sites (metastasis). Clinical data and molecular biologic studies indicate that cancer is a multistep process that begins with minor preneoplastic changes, which may under certain conditions progress to neoplasia. The neoplastic lesion may evolve clonally and develop an increasing capacity for invasion, growth, metastasis, and heterogeneity, especially under conditions in which the neoplastic cells escape the host's immune surveillance (Roitt, I., Brostoff, J and Kale, D., Immunology, 17.1-17.12 (3rd ed., Mosby, St. Louis, Mo., 1993)).

Cancers figure among the leading causes of death worldwide, accounting for 8.2 million deaths in 2012. It is expected that annual cancer cases will rise from 14 million in 2012 to 22 million within the next two decades (See Cancer Fact sheet No297, World Health Organization, February 2014, retrieved 10 Jun. 2014 and Globocan 2012, IARC).

The current drugs used in cancer treatment are highly toxic and often non-specific. Current anticancer therapy strategies are typically focused on rapid proliferating cells, which can shrink primary and metastatic tumors, but such effects are usually transient and tumor relapse of most metastatic cancers frequently occur. One possible reason for failure is the existence of cancer stem cells. Unlike most cells within the tumor, cancer stem cells are resistant to well-defined chemotherapy, and after treatment, they can regenerate all the cell types in the tumor through their stem cell-like behavior of largely quiescent nature and their abundant expression of drug transporters.

There is an enormous variety of cancers which are described in detail in the medical literature. The incidence of cancer continues to climb as the general population ages, as new cancers develop, and as susceptible populations (e.g., people infected with AIDS or excessively exposed to sunlight) grow. However, options for the treatment of cancer are limited. A tremendous demand therefore exists for new methods and compositions that can be used to treat patients with cancer.

SUMMARY

Provided herein are Pyrrolopyrimidine Compounds that can be used in the methods provided herein.

Provided herein are methods of treating a cancer, in particular a solid tumor or a hematological cancer. The Pyrrolopyrimidine Compound provided herein can be used in the methods for treating or preventing the cancer, in particular the solid tumor or the hematological cancer. The methods comprise administering to a subject in need thereof an effective amount of Pyrrolopyrimidine Compound. Also provided herein are methods for preventing cancer metastasis, comprising administering to a subject in need thereof an effective amount of a Pyrrolopyrimidine Compound as provided herein. The Pyrrolopyrimidine Compound provided herein can be used in the methods for preventing cancer metastasis. Additionally, provided herein are methods of eradicating cancer stem cells in a subject, comprising administering to a subject in need thereof an effective amount of a Pyrrolopyrimidine Compound as provided herein. The Pyrrolopyrimidine Compound provided herein can be used in the methods of eradicating cancer stem cells in a subject. Also provided are methods of inducing differentiation in cancer stem cells in a subject, comprising administering to a subject in need thereof an effective amount of a Pyrrolopyrimidine Compound as provided herein. The Pyrrolopyrimidine Compound provided herein can be used in the methods of inducing differentiation in cancer stem cells in a subject. In another aspect, provided are methods of inducing cancer stem cell death in a subject, comprising administering to a subject in need thereof an effective amount of a Pyrrolopyrimidine Compound as provided herein. The Pyrrolopyrimidine Compound provided herein can be used in the methods of inducing cancer stem cell death in a subject. In yet another aspect, provided herein are methods for treating or preventing a cancer, in particular a solid tumor or hematological cancer, comprising administering to a subject in need thereof an effective amount of a compound that inhibits TTK, CLK1, and CLK2 kinase activity, and optionally CAMKK2 kinase activity. The compound that inhibits TTK, CLK1, and CLK2 kinase activity, and optionally CAMKK2 kinase activity can be used in the methods for treating or preventing a cancer, in particular a solid tumor or hematological cancer. Also provided are methods for treating or preventing a cancer associated with the pathways involving TTK, CLK1, and CLK2 and mutants or isoforms thereof, comprising administering to a subject in need thereof an effective amount of a compound that inhibits TTK, CLK1, and CLK2 kinase activity, and optionally CAMKK2 kinase activity. The compound that inhibits TTK, CLK1, and CLK2 kinase activity, and optionally CAMKK2 kinase activity can be used in the methods for treating or preventing a cancer associated with the pathways involving TTK, CLK1, and CLK2 and mutants or isoforms thereof.

The compound that inhibits TTK, CLK1, and CLK2 kinase activity, and optionally CAMKK2 kinase activity is a Pyrrolopyrimidine Compound as provided herein.

Compounds useful in the methods disclosed herein are Pyrrolopyrimidine Compounds as described herein, such as, for example, in Table A, or a pharmaceutically acceptable salt, tautomer, stereoisomer, enantiomer, or isotopologue thereof.

The present embodiments can be understood more fully by reference to the detailed description and examples, which are intended to exemplify non-limiting embodiments.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1: Pyrrolopyrimidine Compounds showed anti-proliferative activity in a variety of solid tumors, namely, cancers of the bladder, breast, CNS, colon, endocrine, female GU, head and neck, kidney, liver, lung, pancreas, prostate, skin and soft-tissue (exemplified by Cmpd. 38 in FIG. 1).

FIG. 2: Pyrrolopyrimidine Compounds showed anti-proliferative activity in a variety of hematological cancers, namely, a variety of lymphomas (ST486, CRO-AP2, Faji, MHH-PREB-1, BC-1, DOHH-2, DB, SR, RamosRA1, Daudi, HT, EB-3, SKO-007) and leukemias MOLT-16, BV-173, J-RT3-T3-5, Jurkat, NALM-6, MX1, ARH-77, CIVIL-T1, CCRF-CEM, MV-4-11, EM-2, MOLT-3, CEM-C1, HEL-92-1-7, MEG-01, K-562, THP-1)/myeloma (RPMI-8226, U266B1) (exemplified by Cmpd. 38 in FIG. 2).

FIG. 3: Pyrrolopyrimidine Compounds demonstrated potency against several mesenchymal GBM CSCs (8311, 32612, 81611) with IC₅₀s in the range of 1-2 μM. The data indicated that Pyrrolopyrimidine Compounds, exemplified by Cmpd. 38, are particularly potent against two GBM CSC sphere models derived from proneural subtype GBM patients (52810 and 1912) with IC₅₀ in the range of 50-190 nM.

FIG. 4: Induction of GBM-CSC differentiation by Pyrrolopyrimidine Compounds (for example, Cmpd. 38) is shown in FIG. 4 (left panel: DMSO, right panel: Cmpd. 38). Abbreviations: DMSO=dimethyl sulfoxide; Oct4=octamer-binding transcription factor 4; Tuj1=tubulin β3; DAPI=4′,6-diamidino-2-phenylindole. The 8311 GBM CSCs and HUAEC cells were allowed to co-culture for 1 day prior to compound administration. After 3 days of compound or mock/DMSO-treatment, cells were fixed and monitored for expression of Oct4 and Tuj1 by indirect immunofluorescence. Pyrrolopyrimidine Compounds (exemplified by Cmpd. 38) induced differentiation of GBM CSCs in the context of a HUAEC co-culture model.

DETAILED DESCRIPTION Definitions

An “alkyl” group is a saturated, partially saturated, or unsaturated straight chain or branched non-cyclic hydrocarbon having from 1 to 10 carbon atoms, typically from 1 to 8 carbons or, in some embodiments, from 1 to 6, 1 to 4, or 2 to 6 or 2 to 4 carbon atoms. Representative alkyl groups include -methyl, -ethyl, -n-propyl, -n-butyl, -n-pentyl and -n-hexyl; while saturated branched alkyls include -isopropyl, -sec-butyl, -isobutyl, -tert-butyl, -isopentyl, -neopentyl, tert-pentyl, -2-methylpentyl, -3-methylpentyl, -4-methylpentyl, -2,3-dimethylbutyl and the like. Examples of unsaturated alkyl groups include, but are not limited to, vinyl, allyl, —CH═CH(CH₃), —CH═C(CH₃)₂, —C(CH₃)═CH₂, —C(CH₃)═CH(CH₃), —C(CH₂CH₃)═CH₂, —C≡CH, —C≡C(CH₃), —C≡C(CH₂CH₃), —CH₂C≡CH, —CH₂C≡C(CH₃) and —CH₂C≡C(CH₂CH₃), among others. An alkyl group can be substituted or unsubstituted. When the alkyl groups described herein are said to be “substituted,” they may be substituted with any substituent or substituents as those found in the exemplary compounds and embodiments disclosed herein, as well as halogen (chloro, iodo, bromo, or fluoro); alkyl; hydroxyl; alkoxy; alkoxyalkyl; amino; alkylamino; carboxy; nitro; cyano; thiol; thioether; imine; imide; amidine; guanidine; enamine; aminocarbonyl; acylamino; phosphonate; phosphine; thiocarbonyl; sulfinyl; sulfone; sulfonamide; ketone; aldehyde; ester; urea; urethane; oxime; hydroxyl amine; alkoxyamine; aralkoxyamine; N-oxide; hydrazine; hydrazide; hydrazone; azide; isocyanate; isothiocyanate; cyanate; thiocyanate; B(OH)₂, or O(alkyl)aminocarbonyl.

A “cycloalkyl” group is a saturated, or partially saturated cyclic alkyl group of from 3 to 10 carbon atoms having a single cyclic ring or multiple condensed or bridged rings which can be optionally substituted with from 1 to 3 alkyl groups. In some embodiments, the cycloalkyl group has 3 to 8 ring members, whereas in other embodiments the number of ring carbon atoms ranges from 3 to 5, 3 to 6, or 3 to 7. Such cycloalkyl groups include, by way of example, single ring structures such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 1-methylcyclopropyl, 2-methylcyclopentyl, 2-methylcyclooctyl, and the like, or multiple or bridged ring structures such as 1-bicyclo[1.1.1]pentyl, bicyclo[2.1.1]hexyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.2]octyl, adamantyl and the like. Examples of unsaturared cycloalkyl groups include cyclohexenyl, cyclopentenyl, cyclohexadienyl, butadienyl, pentadienyl, hexadienyl, among others. A cycloalkyl group can be substituted or unsubstituted. Such substituted cycloalkyl groups include, by way of example, cyclohexanol and the like.

An “aryl” group is an aromatic carbocyclic group of from 6 to 14 carbon atoms having a single ring (e.g., phenyl) or multiple condensed rings (e.g., naphthyl or anthryl). In some embodiments, aryl groups contain 6-14 carbons, and in others from 6 to 12 or even 6 to 10 carbon atoms in the ring portions of the groups. Particular aryls include phenyl, biphenyl, naphthyl and the like. An aryl group can be substituted or unsubstituted. The phrase “aryl groups” also includes groups containing fused rings, such as fused aromatic-aliphatic ring systems (e.g., indanyl, tetrahydronaphthyl, and the like).

A “heteroaryl” group is an aryl ring system having one to four heteroatoms as ring atoms in a heteroaromatic ring system, wherein the remainder of the atoms are carbon atoms. In some embodiments, heteroaryl groups contain 3 to 6 ring atoms, and in others from 6 to 9 or even 6 to 10 atoms in the ring portions of the groups. Suitable heteroatoms include oxygen, sulfur and nitrogen. In certain embodiments, the heteroaryl ring system is monocyclic or bicyclic. Non-limiting examples include but are not limited to, groups such as pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, benzisoxazolyl (e.g., benzo[d]isoxazolyl), thiazolyl, pyrolyl, pyridazinyl, pyrimidyl, pyrazinyl, thiophenyl, benzothiophenyl, furanyl, benzofuranyl, indolyl (e.g., indolyl-2-onyl or isoindolin-1-onyl), azaindolyl (pyrrolopyridyl or 1H-pyrrolo[2,3-b]pyridyl), indazolyl, benzimidazolyl (e.g., 1H-benzo[d]imidazolyl), imidazopyridyl (e.g., azabenzimidazolyl or 1H-imidazo[4,5-b]pyridyl), pyrazolopyridyl, triazolopyridyl, benzotriazolyl (e.g., 1H-benzo[d][1,2,3]triazolyl), benzoxazolyl (e.g., benzo[d]oxazolyl), benzothiazolyl, benzothiadiazolyl, isoxazolopyridyl, thianaphthalenyl, purinyl, xanthinyl, adeninyl, guaninyl, quinolinyl, isoquinolinyl (e.g., 3,4-dihydroisoquinolin-1(2H)-onyl), tetrahydroquinolinyl, quinoxalinyl, and quinazolinyl groups.

A “heterocyclyl” is an aromatic (also referred to as heteroaryl) or non-aromatic cycloalkyl in which one to four of the ring carbon atoms are independently replaced with a heteroatom from the group consisting of O, S and N. In some embodiments, heterocyclyl groups include 3 to 10 ring members, whereas other such groups have 3 to 5, 3 to 6, or 3 to 8 ring members. Heterocyclyls can also be bonded to other groups at any ring atom (i.e., at any carbon atom or heteroatom of the heterocyclic ring). A heterocycloalkyl group can be substituted or unsubstituted. Heterocyclyl groups encompass unsaturated, partially saturated and saturated ring systems, such as, for example, imidazolyl, imidazolinyl and imidazolidinyl (e.g., imidazolidin-4-one or imidazolidin-2,4-dionyl) groups. The phrase heterocyclyl includes fused ring species, including those comprising fused aromatic and non-aromatic groups, such as, for example, 1- and 2-aminotetraline, benzotriazolyl (e.g., 1H-benzo[d][1,2,3]triazolyl), benzimidazolyl (e.g., 1H-benzo[d]imidazolyl), 2,3-dihydrobenzo[1,4]dioxinyl, and benzo[1,3]dioxolyl. The phrase also includes bridged polycyclic ring systems containing a heteroatom such as, but not limited to, quinuclidyl. Representative examples of a heterocyclyl group include, but are not limited to, aziridinyl, azetidinyl, azepanyl, oxetanyl, pyrrolidyl, imidazolidinyl (e.g., imidazolidin-4-onyl or imidazolidin-2,4-dionyl), pyrazolidinyl, thiazolidinyl, tetrahydrothiophenyl, tetrahydrofuranyl, dioxolyl, furanyl, thiophenyl, pyrrolyl, pyrrolinyl, imidazolyl, imidazolinyl, pyrazolyl, pyrazolinyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, benzisoxazolyl (e.g., benzo[d]isoxazolyl), thiazolyl, thiazolinyl, isothiazolyl, thiadiazolyl, oxadiazolyl, piperidyl, piperazinyl (e.g., piperazin-2-onyl), morpholinyl, thiomorpholinyl, tetrahydropyranyl (e.g., tetrahydro-2H-pyranyl), tetrahydrothiopyranyl, oxathianyl, dioxyl, dithianyl, pyranyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, triazinyl, dihydropyridyl, dihydrodithiinyl, dihydrodithionyl, 1,4-dioxaspiro[4.5]decanyl, homopiperazinyl, quinuclidyl, indolyl (e.g., indolyl-2-onyl or isoindolin-1-onyl), indolinyl, isoindolyl, isoindolinyl, azaindolyl (pyrrolopyridyl or 1H-pyrrolo[2,3-b]pyridyl), indazolyl, indolizinyl, benzotriazolyl (e.g. 1H-benzo[d][1,2,3]triazolyl), benzimidazolyl (e.g., 1H-benzo[d]imidazolyl or 1H-benzo[d]imidazol-2(3H)-onyl), benzofuranyl, benzothiophenyl, benzothiazolyl, benzoxadiazolyl, benzoxazinyl, benzodithiinyl, benzoxathiinyl, benzothiazinyl, benzoxazolyl (i.e., benzo[d]oxazolyl), benzothiazolyl, benzothiadiazolyl, benzo[1,3]dioxolyl, pyrazolopyridyl (for example, 1H-pyrazolo[3,4-b]pyridyl, 1H-pyrazolo[4,3-b]pyridyl), imidazopyridyl (e.g., azabenzimidazolyl or 1H-imidazo[4,5-b]pyridyl), triazolopyridyl, isoxazolopyridyl, purinyl, xanthinyl, adeninyl, guaninyl, quinolinyl, isoquinolinyl (e.g., 3,4-dihydroisoquinolin-1(2H)-onyl), quinolizinyl, quinoxalinyl, quinazolinyl, cinnolinyl, phthalazinyl, naphthyridinyl, pteridinyl, thianaphthalenyl, dihydrobenzothiazinyl, dihydrobenzofuranyl, dihydroindolyl, dihydrobenzodioxinyl, tetrahydroindolyl, tetrahydroindazolyl, tetrahydrobenzimidazolyl, tetrahydrobenzotriazolyl, tetrahydropyrrolopyridyl, tetrahydropyrazolopyridyl, tetrahydroimidazopyridyl, tetrahydrotriazolopyridyl, tetrahydropyrimidin-2(1H)-one and tetrahydroquinolinyl groups. Representative non-aromatic heterocyclyl groups do not include fused ring species that comprise a fused aromatic group. Examples of non-aromatic heterocyclyl groups include aziridinyl, azetidinyl, azepanyl, pyrrolidyl, imidazolidinyl (e.g., imidazolidin-4-onyl or imidazolidin-2,4-dionyl), pyrazolidinyl, thiazolidinyl, tetrahydrothiophenyl, tetrahydrofuranyl, piperidyl, piperazinyl (e.g., piperazin-2-onyl), morpholinyl, thiomorpholinyl, tetrahydropyranyl (e.g., tetrahydro-2H-pyranyl), tetrahydrothiopyranyl, oxathianyl, dithianyl, 1,4-dioxaspiro[4.5]decanyl, homopiperazinyl, quinuclidyl, or tetrahydropyrimidin-2(1H)-one. Representative substituted heterocyclyl groups may be mono-substituted or substituted more than once, such as, but not limited to, pyridyl or morpholinyl groups, which are 2-, 3-, 4-, 5-, or 6-substituted, or disubstituted with various substituents such as those listed below.

A “cycloalkylalkyl” group is a radical of the formula: -alkyl-cycloalkyl, wherein alkyl and cycloalkyl are as defined above. Substituted cycloalkylalkyl groups may be substituted at the alkyl, the cycloalkyl, or both the alkyl and the cycloalkyl portions of the group. Representative cycloalkylalkyl groups include but are not limited to methylcyclopropyl, methylcyclobutyl, methylcyclopentyl, methylcyclohexyl, ethylcyclopropyl, ethylcyclobutyl, ethylcyclopentyl, ethylcyclohexyl, propylcyclopentyl, propylcyclohexyl and the like.

An “aralkyl” group is a radical of the formula: -alkyl-aryl, wherein alkyl and aryl are defined above. Substituted aralkyl groups may be substituted at the alkyl, the aryl, or both the alkyl and the aryl portions of the group. Representative aralkyl groups include but are not limited to benzyl and phenethyl groups and fused (cycloalkylaryl)alkyl groups such as 4-ethyl-indanyl.

An “heterocyclylalkyl” group is a radical of the formula: -alkyl-heterocyclyl, wherein alkyl and heterocyclyl are defined above. Substituted heterocyclylalkyl groups may be substituted at the alkyl, the heterocyclyl, or both the alkyl and the heterocyclyl portions of the group. Representative heterocylylalkyl groups include but are not limited to 4-ethyl-morpholinyl, 4-propylmorpholinyl, furan-2-yl methyl, furan-3-yl methyl, pyridin-3-yl methyl, tetrahydrofuran-2-yl ethyl, and indol-2-yl propyl.

A “halogen” is chloro, iodo, bromo, or fluoro.

A “hydroxyalkyl” group is an alkyl group as described above substituted with one or more hydroxy groups.

An “alkoxy” group is —O-(alkyl), wherein alkyl is defined above.

An “alkoxyalkyl” group is -(alkyl)-O-(alkyl), wherein alkyl is defined above.

An “amine” group is a radical of the formula: —NH₂.

A “hydroxyl amine” group is a radical of the formula: —N(R^(#))OH or —NHOH, wherein R^(#) is a substituted or unsubstituted alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl or heterocyclyl group as defined herein.

An “alkoxyamine” group is a radical of the formula: —N(R^(#))O-alkyl or —NHO-alkyl, wherein R^(#) is as defined above.

An “aralkoxyamine” group is a radical of the formula: —N(R^(#))O-aryl or —NHO-aryl, wherein R^(#) is as defined above.

An “alkylamine” group is a radical of the formula: —NH-alkyl or —N(alkyl)₂, wherein each alkyl is independently as defined above.

An “aminocarbonyl” group is a radical of the formula: —C(═O)N(R^(#))₂, —C(═O)NH(R^(#)) or —C(═O)NH₂, wherein each R^(#) is as defined above.

An “acylamino” group is a radical of the formula: —NHC(═O)(R^(#)) or —N(alkyl)C(═O)(R^(#)), wherein each alkyl and R^(#) are independently as defined above.

An “O(alkyl)aminocarbonyl” group is a radical of the formula: —O(alkyl)C(═O)N(R^(#))₂, —O(alkyl)C(═O)NH(R^(#)) or —O(alkyl)C(═O)NH₂, wherein each R^(#) is independently as defined above.

An “N-oxide” group is a radical of the formula: —N⁺—O⁻.

A “carboxy” group is a radical of the formula: —C(═O)OH.

A “ketone” group is a radical of the formula: —C(═O)(R^(#)), wherein R^(#) is as defined above.

An “aldehyde” group is a radical of the formula: —CH(═O).

An “ester” group is a radical of the formula: —C(═O)O(R^(#)) or —OC(═O)(R^(#)), wherein R^(#) is as defined above.

A “urea” group is a radical of the formula: —N(alkyl)C(═O)N(R^(#))₂, —N(alkyl)C(═O)NH(R^(#)), —N(alkyl)C(═O)NH₂, —NHC(═O)N(R^(#))₂, —NHC(═O)NH(R^(#)), or —NHC(═O)NH₂ ^(#), wherein each alkyl and R^(#) are independently as defined above.

An “imine” group is a radical of the formula: —N═C(R^(#))₂ or —C(R^(#))═N(R^(#)), wherein each R^(#) is independently as defined above.

An “imide” group is a radical of the formula: —C(═O)N(R#)C(═O)(R^(#)) or —N((C═O)(R^(#))₂, wherein each R^(#) is independently as defined above.

A “urethane” group is a radical of the formula: —OC(═O)N(R^(#))₂, —OC(═O)NH(R^(#)), —N(R^(#))C(═O)O(R^(#)), or —NHC(═O)O(R^(#)), wherein each R^(#) is independently as defined above.

An “amidine” group is a radical of the formula: —C(═N(R^(#)))N(R^(#))₂, —C(═N(R^(#)))NH(R^(#)), —C(═N(R^(#)))NH₂, —C(═NH)N(R^(#))₂, —C(═NH)NH(R^(#)), —C(═NH)NH₂, —N═C(R^(#))N(R^(#))₂, —N═C(R^(#))NH(R^(#)), —N═C(R^(#))NH₂, —N(R^(#))C(R^(#))═N(R^(#)), —NHC(R^(#))═N(R^(#)), —N(R^(#))C(R^(#))═NH, or —NHC(R^(#))═NH, wherein each R^(#) is independently as defined above.

A “guanidine” group is a radical of the formula: —N(R^(#))C(═N(R^(#)))N(R^(#))₂, —NHC(═N(R^(#)))N(R^(#))₂, —N(R^(#))C(═NH)N(R^(#))₂, —N(R^(#))C(═N(R^(#)))NH(R^(#)), —N(R^(#))C(═N(R^(#)))NH₂, —NHC(═NH)N(R^(#))₂, —NHC(═N(R^(#)))NH(R^(#)), —NHC(═N(R^(#)))NH₂, —NHC(═NH)NH(R^(#)), —NHC(═NH)NH₂, —N═C(N(R^(#))₂)₂, —N═C(NH(R^(#)))₂, or —N═C(NH₂)₂, wherein each R^(#) is independently as defined above.

A “enamine” group is a radical of the formula: —N(R^(#))C(R^(#))═C(R^(#))₂, —NHC(R^(#))═C(R^(#))₂, —C(N(R^(#))₂)═C(R^(#))₂, —C(NH(R^(#))═C(R^(#))₂, —C(NH₂)═C(R^(#))₂, —C(R^(#))═C(R^(#))(N(R^(#))₂), —C(R^(#))═C(R^(#))(NH(R^(#))) or —C(R^(#))═C(R^(#))(NH₂), wherein each R^(#) is independently as defined above.

An “oxime” group is a radical of the formula: —C(═NO(R^(#)))(R^(#)), —C(═NOH)(R^(#)), —CH(═NO(R^(#))), or —CH(═NOH), wherein each R^(#) is independently as defined above.

A “hydrazide” group is a radical of the formula: —C(═O)N(R^(#))N(R^(#))₂, —C(═O)NHN(R^(#))₂, —C(═O)N(R^(#))NH(R^(#)), —C(═O)N(R^(#))NH₂, —C(═O)NHNH(R^(#))₂, or —C(═O)NHNH₂, wherein each R^(#) is independently as defined above.

A “hydrazine” group is a radical of the formula: —N(R^(#))N(R^(#))₂, —NHN(R^(#))₂, —N(R^(#))NH(R^(#)), —N(R^(#))NH₂, —NHNH(R^(#))₂, or —NHNH₂, wherein each R^(#) is independently as defined above.

A “hydrazone” group is a radical of the formula: —C(═N—N(R^(#))₂)(R^(#))₂, —C(═N—NH(R^(#)))(R^(#))₂, —C(═N—NH₂)(R^(#))₂, —N(R^(#))(N═C(R^(#))₂), or —NH(N═C(R^(#))₂), wherein each R^(#) is independently as defined above.

An “azide” group is a radical of the formula: —N₃.

An “isocyanate” group is a radical of the formula: —N═C═O.

An “isothiocyanate” group is a radical of the formula: —N═C═S.

A “cyanate” group is a radical of the formula: —OCN.

A “thiocyanate” group is a radical of the formula: —SCN.

A “thioether” group is a radical of the formula; —S(R^(#)), wherein R^(#) is as defined above.

A “thiocarbonyl” group is a radical of the formula: —C(═S)(R^(#)), wherein R^(#) is as defined above.

A “sulfinyl” group is a radical of the formula: —S(═O)(R^(#)), wherein R^(#) is as defined above.

A “sulfone” group is a radical of the formula: —S(═O)₂(R^(#)), wherein R^(#) is as defined above.

A “sulfonylamino” group is a radical of the formula: —NHSO₂(R^(#)) or —N(alkyl)SO₂(R^(#)), wherein each alkyl and R^(#) are defined above.

A “sulfonamide” group is a radical of the formula: —S(═O)₂N(R^(#))₂, or —S(═O)₂NH(R^(#)), or —S(═O)₂NH₂, wherein each R^(#) is independently as defined above.

A “phosphonate” group is a radical of the formula: —P(═O)(O(R^(#)))₂, —P(═O)(OH)₂, —OP(═O)(O(R^(#)))(R^(#)), or —OP(═O)(OH)(R^(#)), wherein each R^(#) is independently as defined above.

A “phosphine” group is a radical of the formula: —P(R^(#))₂, wherein each R^(#) is independently as defined above.

When the groups described herein, with the exception of alkyl group, are said to be “substituted,” they may be substituted with any appropriate substituent or substituents. Illustrative examples of substituents are those found in the exemplary compounds and embodiments disclosed herein, as well as halogen (chloro, iodo, bromo, or fluoro); alkyl; hydroxyl; alkoxy; alkoxyalkyl; amine; alkylamine; carboxy; nitro; cyano; thiol; thioether; imine; imide; amidine; guanidine; enamine; aminocarbonyl; acylamino; phosphonate; phosphine; thiocarbonyl; sulfinyl; sulfone; sulfonamide; ketone; aldehyde; ester; urea; urethane; oxime; hydroxyl amine; alkoxyamine; aralkoxyamine; N-oxide; hydrazine; hydrazide; hydrazone; azide; isocyanate; isothiocyanate; cyanate; thiocyanate; oxygen (═O); B(OH)₂, O(alkyl)aminocarbonyl; cycloalkyl, which may be monocyclic or fused or non-fused polycyclic (e.g., cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl), or a heterocyclyl, which may be monocyclic or fused or non-fused polycyclic (e.g., pyrrolidyl, piperidyl, piperazinyl, morpholinyl, or thiazinyl); monocyclic or fused or non-fused polycyclic aryl or heteroaryl (e.g., phenyl, naphthyl, pyrrolyl, indolyl, furanyl, thiophenyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, tetrazolyl, pyrazolyl, pyridyl, quinolinyl, isoquinolinyl, acridinyl, pyrazinyl, pyridazinyl, pyrimidyl, benzimidazolyl, benzothiophenyl, or benzofuranyl) aryloxy; aralkyloxy; heterocyclyloxy; and heterocyclyl alkoxy.

As used herein, the term “Pyrrolopyrimidine Compound” refers to compounds of formula (I), as well as to further embodiments provided herein. In one embodiment, a “Pyrrolopyrimidine Compound” is a compound set forth in Table 1. The term “Pyrrolopyrimidine Compound” includes pharmaceutically acceptable salts, tautomers, stereoisomers, enantiomers and isotopologues of the compounds provided herein.

As used herein, the term “pharmaceutically acceptable salt(s)” refers to a salt prepared from a pharmaceutically acceptable non-toxic acid or base including an inorganic acid and base and an organic acid and base. Suitable pharmaceutically acceptable base addition salts of the compounds of formula (I) include, but are not limited to metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from lysine, N,N′-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methyl-glucamine) and procaine. Suitable non-toxic acids include, but are not limited to, inorganic and organic acids such as acetic, alginic, anthranilic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethenesulfonic, formic, fumaric, furoic, galacturonic, gluconic, glucuronic, glutamic, glycolic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phenylacetic, phosphoric, propionic, salicylic, stearic, succinic, sulfanilic, sulfuric, tartaric acid, and p-toluenesulfonic acid. Specific non-toxic acids include hydrochloric, hydrobromic, maleic, phosphoric, sulfuric, and methanesulfonic acids. Examples of specific salts thus include hydrochloride and mesylate salts. Others are well-known in the art, see for example, Remington's Pharmaceutical Sciences, 18^(th) eds., Mack Publishing, Easton Pa. (1990) or Remington: The Science and Practice of Pharmacy, 19^(th) eds., Mack Publishing, Easton Pa. (1995).

As used herein and unless otherwise indicated, the term “stereoisomer” or “stereomerically pure” means one stereoisomer of a Pyrrolopyrimidine Compound that is substantially free of other stereoisomers of that compound. For example, a stereomerically pure compound having one chiral center will be substantially free of the opposite enantiomer of the compound. A stereomerically pure compound having two chiral centers will be substantially free of other diastereomers of the compound. A typical stereomerically pure compound comprises greater than about 80% by weight of one stereoisomer of the compound and less than about 20% by weight of other stereoisomers of the compound, greater than about 90% by weight of one stereoisomer of the compound and less than about 10% by weight of the other stereoisomers of the compound, greater than about 95% by weight of one stereoisomer of the compound and less than about 5% by weight of the other stereoisomers of the compound, or greater than about 97% by weight of one stereoisomer of the compound and less than about 3% by weight of the other stereoisomers of the compound. The Pyrrolopyrimidine Compounds can have chiral centers and can occur as racemates, individual enantiomers or diastereomers, and mixtures thereof. All such isomeric forms are included within the embodiments disclosed herein, including mixtures thereof.

The use of stereomerically pure forms of such Pyrrolopyrimidine Compounds, as well as the use of mixtures of those forms, are encompassed by the embodiments disclosed herein. For example, mixtures comprising equal or unequal amounts of the enantiomers of a particular Pyrrolopyrimidine Compound may be used in methods and compositions disclosed herein. These isomers may be asymmetrically synthesized or resolved using standard techniques such as chiral columns or chiral resolving agents. See, e.g., Jacques, J., et al., Enantiomers, Racemates and Resolutions (Wiley-Interscience, New York, 1981); Wilen, S. H., et al., Tetrahedron 33:2725 (1977); Eliel, E. L., Stereochemistry of Carbon Compounds (McGraw-Hill, N Y, 1962); and Wilen, S. H., Tables of Resolving Agents and Optical Resolutions p. 268 (E. L. Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, Ind., 1972).

It should also be noted the Pyrrolopyrimidine Compounds can include E and Z isomers, or a mixture thereof, and cis and trans isomers or a mixture thereof. In certain embodiments, the Pyrrolopyrimidine Compounds are isolated as either the E or Z isomer. In other embodiments, the Pyrrolopyrimidine Compounds are a mixture of the E and Z isomers.

“Tautomers” refers to isomeric forms of a compound that are in equilibrium with each other. The concentrations of the isomeric forms will depend on the environment the compound is found in and may be different depending upon, for example, whether the compound is a solid or is in an organic or aqueous solution. For example, in aqueous solution, pyrazoles may exhibit the following isomeric forms, which are referred to as tautomers of each other:

As readily understood by one skilled in the art, a wide variety of functional groups and other structures may exhibit tautomerism and all tautomers of compounds of formula (I) are within the scope of the present invention.

It should also be noted the Pyrrolopyrimidine Compounds can contain unnatural proportions of atomic isotopes at one or more of the atoms. For example, the compounds may be radiolabeled with radioactive isotopes, such as for example tritium (³H), iodine-125 (¹²⁵I) sulfur-35 (³⁵S), or carbon-14 (¹⁴C), or may be isotopically enriched, such as with deuterium (²H), carbon-13 (¹³C), or nitrogen-15 (¹⁵N). As used herein, an “isotopologue” is an isotopically enriched compound. The term “isotopically enriched” refers to an atom having an isotopic composition other than the natural isotopic composition of that atom. “Isotopically enriched” may also refer to a compound containing at least one atom having an isotopic composition other than the natural isotopic composition of that atom. The term “isotopic composition” refers to the amount of each isotope present for a given atom. Radiolabeled and isotopically encriched compounds are useful as therapeutic agents, e.g., breast cancer therapeutic agents, research reagents, e.g., binding assay reagents, and diagnostic agents, e.g., in vivo imaging agents. All isotopic variations of the Pyrrolopyrimidine Compounds as described herein, whether radioactive or not, are intended to be encompassed within the scope of the embodiments provided herein. In some embodiments, there are provided isotopologues of the Pyrrolopyrimidine Compounds, for example, the isotopologues are deuterium, carbon-13, or nitrogen-15 enriched Pyrrolopyrimidine Compounds.

It should be noted that if there is a discrepancy between a depicted structure and a name for that structure, the depicted structure is to be accorded more weight.

“Treating” as used herein, means an alleviation, in whole or in part, of a disorder, disease or condition, or one or more of the symptoms associated with a disorder, disease, or condition, or slowing or halting of further progression or worsening of those symptoms, or alleviating or eradicating the cause(s) of the disorder, disease, or condition itself. In one embodiment, the disorder is a cancer, in particular, a solid tumor or hematological cancer. In some embodiments, “treating” means an alleviation, in whole or in part, of a cancer, or symptoms associated with a cancer, in particular, a solid tumor or hematological cancer, or a slowing, or halting of further progression or worsening of those symptoms.

“Preventing” as used herein, means a method of delaying and/or precluding the onset, recurrence or spread, in whole or in part, of a cancer, in particular, a solid tumor or hematological cancer; barring a subject from acquiring a cancer, in particular, a solid tumor or hematological cancer; or reducing a subject's risk of acquiring a cancer, in particular, a solid tumor or hematological cancer.

The term “effective amount” in connection with a Pyrrolopyrimidine Compound means an amount capable of treating or preventing cancer, in particular, a solid tumor or hematological cancer, or symptoms thereof, as disclosed herein. The effective amount of Pyrrolopyrimidine Compound, for example in a pharmaceutical composition, may be at a level that will exercise the desired effect; for example, about 0.005 mg/kg of a subject's body weight to about 100 mg/kg of a patient's body weight in unit dosage for parenteral administration. As will be apparent to those skilled in the art, it is to be expected that the effective amount of a Pyrrolopyrimidine Compound disclosed herein may vary depending on the severity of the indication being treated.

The terms “patient” and “subject” as used herein include an animal, including, but not limited to, an animal such a cow, monkey, horse, sheep, pig, chicken, turkey, quail, cat, dog, mouse, rat, rabbit or guinea pig, in one embodiment a mammal, in another embodiment a human. In one embodiment, a subject is a human having or at risk for having cancer, in particular, a solid tumor or hematological cancer, or symptoms thereof. In one embodiment, a patient is a human having histologically or cytologically-confirmed solid tumor or hematological cancer, including subjects who have progressed on (or not been able to tolerate) standard anticancer therapy or for whom no standard anticancer therapy exists.

As used herein, and unless otherwise specified, the terms “cancer” refers to or describes the physiological condition in mammals that is typically characterized by unregulated cell growth. Examples of cancer include solid tumors and hematological cancer. In some embodiments, the cancer is a primary cancer, in others, the cancer is metastasized.

As used herein “solid tumors” includes, but is not limited to, bladder cancer (including, but not limited to, superficial bladder cancer), breast cancer (including, but not limited to, luminal B type, ER+, PR+ and Her2+ breast cancer), central nervous system cancer (including, but no tlimited to, glioblastoma multiforme (GBM), glioma, medulloblastoma, and astrocytoma), colorectal cancer, gastrointestinal cancer (including, but not limited to, stomach cancer, oesophagus cancer, and rectum cancer), endocrine cancer (including, but not imited to, thyroid cancer, and adrenal gland cancer), eye cancer (including, but not limited to, retinoblastoma), female genitourinary cancer (including, but not limited to, cancer of the placenta, uterus, vulva, ovary, cervix), head and neck cancer (including, but not limited to, cancer of the pharynx, oesophagus, and tongue), liver cancer, lung cancer (including, but not limited to, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), mucoepidermoid, bronchogenic, squamous cell carcinoma (SQCC), and analplastic/NSCLC), skin cancer (including, but not limited to, melanoma, and SQCC), soft tissue cancer (including but not limited to, sarcoma, Ewing's sarcoma, and rhabdomyosarcoma), bone cancer (including, but not limited to, sarcoma, Ewing's sarcoma, and osteosarcoma), squamous cell cancer (including, but not limited to, lung, esophageal, cervical, and head and neck cancer), pancreas cancer, kidney cancer (including, but not limited to, renal Wilm's tumor and renal cell carcinoma), and prostate cancer. In one embodiment, the solid tumor is not triple negative breast cancer (TNBC). In some embodiments, the solid tumor is breast cancer, colon cancer, lung cancer or bladder cancer. In one such embodiment, the solid tumor is superficial bladder cancer. In another, the solid tumor is lung squamous cell carcinoma. In yet another embodiment, the solid tumor is luminal B type breast cancer.

As used herein “hematological cancer” includes, but is not limited to, leukemia (including, but not limited to, acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), acute T-cell leukemia, B cell precursor leukemia, acute promyelocytic leukemia (APML), plasma cell leukemia, myelomonoblastic/T-ALL, B myelomonocytic leukemia, erythroleukemia, and acute myeloid leukemia (AML)), lymphoma (including but not limited to Hodgkin's lymphoma, non-Hodgkin's lymphoma (NHL), Burkitt's lymphoma (BL), B cell lymphoma, lymphoblastic lymphoma, follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), large cell immunoblastic lymphoma), and multiple myeloma.

In the context of a cancer, inhibition may be assessed by inhibition of disease progression, inhibition of tumor growth, reduction of primary tumor, relief of tumor-related symptoms, inhibition of tumor secreted factors (including tumor secreted hormones, such as those that contribute to carcinoid syndrome), delayed appearance of primary or secondary tumors, slowed development of primary or secondary tumors, decreased occurrence of primary or secondary tumors, slowed or decreased severity of secondary effects of disease, arrested tumor growth and regression of tumors, increased Time To Progression (TTP), increased Progression Free Survival (PFS), increased Overall Survival (OS), among others. OS as used herein means the time from randomization until death from any cause, and is measured in the intent-to-treat population. TTP as used herein means the time from randomization until objective tumor progression; TTP does not include deaths. As used herein, PFS means the time from randomization until objective tumor progression or death. In one embodiment, PFS rates will be computed using the Kaplan-Meier estimates. In the extreme, complete inhibition, is referred to herein as prevention or chemoprevention. In this context, the term “prevention” includes either preventing the onset of clinically evident cancer altogether or preventing the onset of a preclinically evident stage of a cancer. Also intended to be encompassed by this definition is the prevention of transformation into malignant cells or to arrest or reverse the progression of premalignant cells to malignant cells. This includes prophylactic treatment of those at risk of developing a cancer.

In certain embodiments, the treatment of lymphoma may be assessed by the International Workshop Criteria (IWC) for non-Hodgkin lymphoma (NHL) (see Cheson B D, Pfistner B, Juweid, M E, et. al. Revised Response Criteria for Malignant Lymphoma. J. Clin. Oncol: 2007: (25) 579-586), using the response and endpoint definitions shown below:

Response Definition Nodal Masses Spleen, liver Bone Marrow CR Disappearance of (a) FDG-avid or Not palpable, Infiltrate cleared on all evidence PET positive prior nodules repeat biopsy; if of disease to therapy; mass disappeared indeterminate by of any size morphology, permitted if PET immunohistochemistry negative should be negative (b) Variably FDG- avid or PET negative; regression to normal size on CT PR Regression of ≧50% decrease in ≧50% decrease in Irrelevant if positive measurable SPD of up to 6 SPD of nodules prior to therapy; cell disease and no largest dominant (for single nodule type should be specified new sites masses; no in greatest increase in size of transverse other nodes diameter); no (a) FDG-avid or increase in size of PET positive prior liver or spleen to therapy; one or more PET positive at previously involved site (b) Variably FDG- avid or PET negative; regression on CT SD Failure to attain (a) FDG-avid or CR/PR or PD PET positive prior to therapy; PET positive at prior sites of disease and no new sites on CT or PET (b) Variably FDG- avid or PET negative; no change in size of previous lesions on CT PD or Any new lesion Appearance of a ≧50% increase New or recurrent relapsed or increase new lesion(s) ≧1.5 from nadir in the involvement disease by ≧50% of cm in any axis, ≧50% SPD of any previously increase in SPD of previous lesions involved sites more than one node, from nadir or ≧50% increase in longest diameter of a previously identifed node ≧1 cm in short axis Lesions PET positive if FDG- avid lymphoma or PET positive prior to therapy

Abbreviations: CR, complete remission; FDG, [¹⁸F]fluorodeoxyglucose; PET, positron emission tomography; CT, computed tomography; PR, partial remission; SPD, sum of the product of the diameters; SD, stable disease; PD, progressive disease.

End point Patients Definition Measured from Primary Overall All Death as a result of any Entry onto study survival cause Progression- All Disease progression or Entry onto study free survival death as a result of any cause Secondary Event-free All Failure of treatment or Entry onto study survival death as result of any cause Time to All Time to progression or Entry onto study progression death as a result of lymphoma Disease- In CR Time to relapse or death Documentation of free survival as a result of lymphoma or response acute toxicity of treatment Response In CR Time to relapse or Documentation of duration or PR progression response Lymphoma- All Time to death as a result Entry onto study specific of lymphoma survival Time to next All Time to new treatment End of primary treatment treatment Abbreviations: CR: complete remission; PR: partial remission.

In one embodiment, the end point for lymphoma is evidence of clinical benefit. Clinical benefit may reflect improvement in quality of life, or reduction in patient symptoms, transfusion requirements, frequent infections, or other parameters. Time to reappearance or progression of lymphoma-related symptoms can also be used in this end point.

In certain embodiments, the treatment of CLL may be assessed by the International Workshop Guidelines for CLL (see Hallek M, Cheson B D, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood, 2008; (111) 12: 5446-5456) using the response and endpoint definitions shown therein and in particular:

Parameter CR PR PD Group A Lymphadenopathy^(†) None >1.5 cm Decrease ≧50% Increase ≧50% Hepatomegaly None Decrease ≧50% Increase ≧50% Splenomegaly None Decrease ≧50% Increase ≧50% Blood lymphocytes <4000/μL Decrease ≧50% Increase ≧50% from baseline over baseline Marrow‡ Normocellular, <30% 50% reduction in lymphocytes, no marrow infiltrate, B-lymphoid nodules. or B-lymphoid Hypocellular nodules marrow defines CRi (5.1.6). Group B Platelet count >100 000/μL >100000/μL or Decrease of ≧50% increase ≧50% over from baseline baseline secondary to CLL Hemoglobin >11.0 g/dL >11 g/dL or Decrease of >2 g/dL increase ≧50% over from baseline baseline secondary to CLL Neutrophils^(‡) >1500/μL >1500/μL or >50% improvement over baseline

Group A criteria define the tumor load; Group B criteria define the function of the hematopoietic system (or marrow). CR (complete remission): all of the criteria have to be met, and patients have to lack disease-related constitutional symptoms; PR (partial remission): at least two of the criteria of group A plus one of the criteria of group B have to be met; SD is absence of progressive disease (PD) and failure to achieve at least a PR; PD: at least one of the above criteria of group A or group B has to be met. Sum of the products of multiple lymph nodes (as evaluated by CT scans in clinical trials, or by physical examination in general practice). These parameters are irrelevant for some response categories.

In certain embodiments, the treatment of multiple myeloma may be assessed by the International Uniform Response Criteria for Multiple Myeloma (IURC) (see Durie B G M, Harousseau J-L, Miguel J S, et al. International uniform response criteria for multiple myeloma. Leukemia, 2006; (10) 10: 1-7), using the response and endpoint definitions shown below:

Response Subcategory Response Criteria^(a) sCR CR as defined below plus Normal FLC ratio and Absence of clonal cells in bone marrow^(b) by immunohistochemistry or immunofluorescence^(c) CR Negative immunofixation on the serum and urine and Disappearance of any soft tissue plasmacytomas and <5% plasma cells in bone marrow^(b) VGPR Serum and urine M-protein detectable by immuno- fixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level <100 mg per 24 h PR ≧50% reduction of serum M-protein and reduction in 24-h urinary M-protein by ≧90% or to <200 mg per 24 h If the serum and urine M-protein are unmeasurable,^(d) a ≧50% decrease in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria If serum and urine M-protein are unmeasurable, and serum free light assay is also unmeasurable, ≧50% reduction in plasma cells is required in place of M-protein, provided baseline bone marrow plasma cell percentage was ≧30% In addition to the above listed criteria, if present at baseline, a ≧50% reduction in the size of soft tissue plasmacytomas is also required SD (not Not meeting criteria for CR, VGPR, PR or recommended progressive disease for use as an indicator of response; stability of disease is best described by providing the time to progression estimates)

Abbreviations: CR, complete response; FLC, free light chain; PR, partial response; SD, stable disease; sCR, stringent complete response; VGPR, very good partial response; ^(a)All response categories require two consecutive assessments made at anytime before the institution of any new therapy; all categories also require no known evidence of progressive or new bone lesions if radiographic studies were performed. Radiographic studies are not required to satisfy these response requirements; ^(b)Confirmation with repeat bone marrow biopsy not needed; ^(c)Presence/absence of clonal cells is based upon the κ/λ ratio. An abnormal κ/λ, ratio by immunohistochemistry and/or immunofluorescence requires a minimum of 100 plasma cells for analysis. An abnormal ratio reflecting presence of an abnormal clone is κ/λ of >4:1 or <1:2. ^(d)Measurable disease defined by at least one of the following measurements: Bone marrow plasma cells ≧30%; Serum M-protein ≧1 g/dl (≧10 gm/l)[10 g/l]; Urine M-protein ≧200 mg/24 h; Serum FLC assay: Involved FLC level ≧10 mg/dl (≧100 mg/l); provided serum FLC ratio is abnormal.

In certain embodiments, the treatment of a cancer may be assessed by Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (see Thereasse P., et al. New Guidelines to Evaluate the Response to Treatment in Solid Tumors. J. of the National Cancer Institute; 2000; (92) 205-216 and Eisenhauer E. A., Therasse P., Bogaerts J., et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European J. Cancer; 2009; (45) 228-247). Overall responses for all possible combinations of tumor responses in target and non-target lesions with our without the appearance of new lesions are as follows:

Target Non-target New Overall lesions lesions lesions response CR CR No CR CR Incomplete No PR response/SD PR Non-PD No PR SD Non-PD No SD PD Any Yes or no PD Any PD Yes or no PD Any Any Yes PD CR = complete response; PR = partial response; SD = stable disease; and PD = progressive disease.

With respect to the evaluation of target lesions, complete response (CR) is the disappearance of all target lesions, partial response (PR) is at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter, progressive disease (PD) is at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions and stable disease (SD) is neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum longest diameter since the treatment started.

With respect to the evaluation of non-target lesions, complete response (CR) is the disappearance of all non-target lesions and normalization of tumor marker level; incomplete response/stable disease (SD) is the persistence of one or more non-target lesion(s) and/or the maintenance of tumor marker level above the normal limits, and progressive disease (PD) is the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.

The procedures, conventions, and definitions described below provide guidance for implementing the recommendations from the Response Assessment for Neuro-Oncology (RANO) Working Group regarding response criteria for high-grade gliomas (Wen P., Macdonald, D R., Reardon, D A., et al. Updated response assessment criteria for highgrade gliomas: Response assessment in neuro-oncology working group. J Clin Oncol 2010; 28: 1963-1972). Primary modifications to the RANO criteria for Criteria for Time Point Responses (TPR) can include the addition of operational conventions for defining changes in glucocorticoid dose, and the removal of subjects' clinical deterioration component to focus on objective radiologic assessments. The baseline MRI scan is defined as the assessment performed at the end of the post-surgery rest period, prior to re-initiating compound treatment. The baseline MRI is used as the reference for assessing complete response (CR) and partial response (PR). Whereas, the smallest SPD (sum of the products of perpendicular diameters) obtained either at baseline or at subsequent assessments will be designated the nadir assessment and utilized as the reference for determining progression. For the 5 days preceding any protocol-defined MM scan, subjects receive either no glucocorticoids or are on a stable dose of glucocorticoids. A stable dose is defined as the same daily dose for the 5 consecutive days preceding the MM scan. If the prescribed glucocorticoid dose is changed in the 5 days before the baseline scan, a new baseline scan is required with glucocorticoid use meeting the criteria described above. The following definitions will be used.

Measurable Lesions: Measurable lesions are contrast-enhancing lesions that can be measured bidimensionally. A measurement is made of the maximal enhancing tumor diameter (also known as the longest diameter, LD). The greatest perpendicular diameter is measured on the same image. The cross hairs of bidimensional measurements should cross and the product of these diameters will be calculated.

Minimal Diameter: T1-weighted image in which the sections are 5 mm with 1 mm skip. The minimal LD of a measurable lesion is set as 5 mm by 5 mm. Larger diameters may be required for inclusion and/or designation as target lesions. After baseline, target lesions that become smaller than the minimum requirement for measurement or become no longer amenable to bidimensional measurement will be recorded at the default value of 5 mm for each diameter below 5 mm. Lesions that disappear will be recorded as 0 mm by 0 mm.

Multicentric Lesions: Lesions that are considered multicentric (as opposed to continuous) are lesions where there is normal intervening brain tissue between the two (or more) lesions. For multicentric lesions that are discrete foci of enhancement, the approach is to separately measure each enhancing lesion that meets the inclusion criteria. If there is no normal brain tissue between two (or more) lesions, they will be considered the same lesion.

Nonmeasurable Lesions: All lesions that do not meet the criteria for measurable disease as defined above will be considered non-measurable lesions, as well as all nonenhancing and other truly nonmeasurable lesions. Nonmeasurable lesions include foci of enhancement that are less than the specified smallest diameter (i.e., less than 5 mm by 5 mm), nonenhancing lesions (e.g., as seen on T1-weighted post-contrast, T2-weighted, or fluid-attenuated inversion recovery (FLAIR) images), hemorrhagic or predominantly cystic or necrotic lesions, and leptomeningeal tumor. Hemorrhagic lesions often have intrinsic T1-weighted hyperintensity that could be misinterpreted as enhancing tumor, and for this reason, the pre-contrast T1-weighted image may be examined to exclude baseline or interval sub-acute hemorrhage.

At baseline, lesions will be classified as follows: Target lesions: Up to 5 measurable lesions can be selected as target lesions with each measuring at least 10 mm by 5 mm, representative of the subject's disease; Non-target lesions: All other lesions, including all nonmeasurable lesions (including mass effects and T2/FLAIR findings) and any measurable lesion not selected as a target lesion. At baseline, target lesions are to be measured as described in the definition for measurable lesions and the SPD of all target lesions is to be determined. The presence of all other lesions is to be documented. At all post-treatment evaluations, the baseline classification of lesions as target and non-target lesions will be maintained and lesions will be documented and described in a consistent fashion over time (e.g., recorded in the same order on source documents and eCRFs). All measurable and nonmeasurable lesions must be assessed using the same technique as at baseline (e.g., subjects should be imaged on the same MM scanner or at least with the same magnet strength) for the duration of the study to reduce difficulties in interpreting changes. At each evaluation, target lesions will be measured and the SPD calculated. Non-target lesions will be assessed qualitatively and new lesions, if any, will be documented separately. At each evaluation, a time point response will be determined for target lesions, non-target lesions, and new lesion. Tumor progression can be established even if only a subset of lesions is assessed. However, unless progression is observed, objective status (stable disease, PR or CR) can only be determined when all lesions are assessed.

Confirmation assessments for overall time point responses of CR and PR will be performed at the next scheduled assessment, but confirmation may not occur if scans have an interval of <28 days. Best response, incorporating confirmation requirements, will be derived from the series of time points.

TTK (also known as Mps1, hMps1 or PYT) is a dual specificity protein kinase with the ability to phosphorylate tyrosine, serine and threonine. Associated with cell proliferation, this protein is essential for chromosome alignment at the centromere during mitosis and is required for centrosome duplication. It has been found to be a critical mitotic checkpoint protein for accurate segregation of chromosomes during mitosis. Tumorigenesis may occur when this protein fails to degrade and produces excess centrosomes resulting in aberrant mitotic spindles. Alternative splicing results in multiple transcript variants. [RefSeq, November 2009]. TTK is essential for spindle checkpoint function and its inhibition accelerates cell progression through mitosis. TTK also plays an important role for cancer stem cell survival.

CLK1 is a member of the CDC2-like (or LAMMER) family of dual specificity protein kinases. In the nucleus, the encoded protein phosphorylates serine/arginine-rich (SR) proteins involved in pre-mRNA processing, releasing them into the nucleoplasm. The choice of splice sites during pre-mRNA processing may be regulated by the concentration and localization of splicing factors, including serine/arginine rich (SR) proteins. Therefore, the encoded protein may play an indirect role in governing splice site selection. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, June 2009]

CLK2 is a member of the CLK family of dual specificity protein kinases. CLK family members have been shown to interact with, and phosphorylate, serine/arginine-rich (SR) proteins of the spliceosomal complex, which is a part of the regulatory mechanism that enables the SR proteins to control RNA splicing. This protein kinase is involved in the regulation of several cellular processes and may serve as a link between cell cycle progression, apoptosis, and telomere length regulation [RefSeq, July 2008]. Inhibition of CLK2 changes the expression of protein isoforms, many of which contribute to the oncogenic phenotype.

CAMKK2 belongs to the serine/threonine-specific protein kinase family, and to the Ca⁺⁺/calmodulin-dependent protein kinase subfamily. This protein plays a role in the calcium/calmodulin-dependent (CaM) kinase cascade by phosphorylating the downstream kinases CaMK1 and CaMK4 [RefSeq, July 2012]. CAMKK2 reportedly plays a role in tumor energy homeostasis.

Pyrrolopyrimidine Compounds

Provided herein are compounds having the following formula (I):

and pharmaceutically acceptable salts, tautomers, stereoisomers, enantiomers, and isotopologues thereof,

wherein:

R¹ is substituted or unsubstituted C₁₋₈ alkyl, substituted or unsubstituted C₃₋₈ cycloalkyl, or substituted or unsubstituted non-aromatic heterocyclyl;

R² is substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R³ is substituted or unsubstituted heterocyclyl or substituted or unsubstituted aryl, and

L is NH or O;

provided that when L is NH, R³ is not pyridyl.

Provided herein are compounds having the following formula (I):

and pharmaceutically acceptable salts, tautomers, stereoisomers, enantiomers, and isotopologues thereof,

wherein:

R¹ is substituted or unsubstituted C₁₋₈ alkyl, substituted or unsubstituted C₃₋₈ cycloalkyl, or substituted or unsubstituted non-aromatic heterocyclyl;

R² is substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R³ is substituted or unsubstituted heterocyclyl or substituted or unsubstituted aryl, and

L is NH or O;

provided

R³ is not pyridyl when L is NH or when R² is pyrazolyl; and

the compound is not

-   N-methyl-N—     [trans-3-[[5-(1-methyl-1H-pyrazol-4-yl)-2-[(1-methyl-1Hpyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]cyclobutyl]-2-propenamide;     or -   N-methyl-N—     [trans-3-[[5-(1-methyl-1H-pyrazol-3-yl)-2-[(1-methyl-1Hpyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]cyclobutyl]-2-propenamide.

The compound as described herein is not a compound selected from:

As described herein, the compound is not

In one embodiment, the compound is not N-methyl-N-[trans-3-[[5-(1-methyl-1H-pyrazol-4-yl)-2-[(1-methyl-1Hpyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]cyclobutyl]-2-propenamide (also named N-methyl-N-((1r,3r)-3-((5-(1-methyl-1H-pyrazol-4-yl)-2-(1-methyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)cyclobutyl)acrylamide)

or N-methyl-N-[trans-3-[[5-(1-methyl-1H-pyrazol-3-yl)-2-[(1-methyl-1Hpyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]cyclobutyl]-2-propenamide (also named N-methyl-N-((1r,3r)-3-((5-(1-methyl-1H-pyrazol-3-yl)-2-((1-methyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)cyclobutyl)acrylamide)

In yet another embodiment, the compound is not

In one embodiment, provided herein are compounds of formula (I), wherein L is O.

In some embodiments of compounds of formula (I), R¹ is substituted or unsubstituted alkyl, for example, le is substituted or unsubstituted methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, n-pentyl, sec-pentyl, tert-pentyl, or 2,2-dimethylpropyl. In some embodiments, R¹ is substituted or unsubstituted methyl, ethyl, isopropyl, sec-butyl, t-butyl, or 2,2-dimethylpropyl. In some embodiments of formula (I), wherein R¹ is alkyl, the alkyl is substituted with one or more —OR or —NR₂, wherein each R is independently —H or substituted or unsubstituted (C₁₋₄)alkyl. For example R¹ is —CH₂CH₂OH, —CH₂CH₂OCH₃, or —CH₂CH₂NHCH₃. In other embodiments of compounds of formula (I), le is substituted or unsubstituted C₃₋₈ cycloalkyl, for example, le is substituted or unsubstituted cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl. In some such embodiments, the cycloalkyl is substituted with one or more —CN, halogen, —OR or a substituted or unsubstituted C₁₋₃ alkyl, wherein each R is independently —H or substituted or unsubstituted (C₁₋₄)alkyl. For example, in some embodiments the cycloalkyl is substituted with one or more —CN, —F, —OH, or —CH₃. In some other embodiments of compounds of formula (I), R¹ is substituted or unsubstituted non-aromatic heterocyclyl, for example, le is substituted or unsubstituted oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, or piperidinyl.

In some other embodiments of compounds of formula (I), R¹ is substituted or unsubstituted C₁₋₈ alkyl,

wherein

each R′ is independently —CN, halogen, —OR or C₁₋₃ alkyl;

R″ is —H or C₁₋₃ alkyl;

each R is independently —H or substituted or unsubstituted (C₁₋₄)alkyl; and

n is 0-2.

In some such embodiments, le is substituted or unsubstituted methyl, ethyl, isopropyl, sec-butyl, t-butyl, or 2,2-dimethylpropyl,

and R′ is —CN, —F, —OH, or —CH₃;

R″ is —CH₃;

n is 0, 1 or 2; and

q is 0 or 1.

Also provided herein are compounds of formula (I), wherein R² is substituted phenyl. In some such embodiments, R² is phenyl, substituted with one or more substituted or unsubstituted C₁₋₆ alkyl, halogen, —CN, —OR⁵, —C(═O)NR⁵ ₂, —C(═O)(substituted or unsubstituted heterocyclyl), —C(═O)(substituted or unsubstituted alkylheterocyclyl), —NHC(═O)R⁵, —SO₂NR⁵ ₂, or substituted or unsubstituted heteroaryl, wherein each R⁵ is independently —H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, or substituted or unsubstituted alkylheterocyclyl. For example, R² is phenyl, substituted with one or more —(C₁₋₃ alkyl), —(C₁₋₃ alkyl)NR₂, —CF₃, —Cl, —F, —CN, —OCH₃, —OCF₃, —C(═O)NR₂, —C(═O)NR(substituted or unsubstituted cycloalkyl), —C(═O)NR(CH₂)₀₋₂CR₂(CH₂)₀₋₂OR, —C(═O)NR(CH₂)₀₋₂CR₂(CH₂)₀₋₂NR₂, —C(═O)NR(CH₂)₀₋₂CR₂(CH₂)₀₋₂C(═O)NR₂, —C(═O)N(substituted or unsubstituted cycloalkyl)(CH₂)₀₋₂OR, —C(═O)NR(CH₂)₀₋₃(substituted or unsubstituted heterocyclyl), —C(═O)(CH₂)₀₋₃(substituted or unsubstituted heterocyclyl), —C(═NR)NR₂, —NRC(═O)R, —SO₂NR₂, —SO₂R, or substituted or unsubstituted heterocyclyl, wherein each R is independently —H or substituted or unsubstituted (C₁₋₄)alkyl. In some such embodiments, each R is independently —H or —CH₃.

In some embodiments of compounds of formula (I), R² is phenyl, substituted with one or more —CH₃, —CH₂CH₃, —CH₂CH₂CH₃, —CH(CH₃)₂, —CH₂NH₂, —CF₃, —Cl, —F, —CN, —OCH₃, —OCF₃, —C(═O)NH₂, —C(═O)NHCH₃, —C(═O)N(CH₃)₂, —C(═O)NC(CH₃)₃, —C(═O)NHCH₂CH₂F, —C(═O)NHCH₂CHF₂, —C(═O)NHCH₂CF₃, —C(═O)NHCH₂CF₂CH₃, —C(═O)NHCH₂CN, —C(═O)N(CH₃)CH₂CN, —C(═O)NHCH₂CH₂CN, —C(═O)N(CH₃)CH₂CH₂CN, —C(═O)NH-cyclobutyl, —C(═O)NH-(hydroxy-cyclobutyl), —C(═O)NH-cyclopentyl, —C(═O)NH-(hydroxyl-cyclopentyl), —C(═O)NHCH₂CH₂OH, —C(═O)NHCH₂CH₂OCH₃, —C(═O)N(CH₃)CH₂CH₂OH, —C(═O)N(CH₃)CH₂CH₂OCH₃, —C(═O)NHCH₂CH₂CH₂OH, —C(═O)N(CH₃)CH₂CH₂CH₂OH, —C(═O)N(CH₃)CH₂CH₂CH₂OCH₃, —C(═O)NHCH₂CH(CH₃)OH, —C(═O)NHCH₂C(CH₃)₂OH, —C(═O)NHCH(CH₃)CH₂OH, —C(═O)NHC(CH₃)₂CH₂OH, —C(═O)NHCH₂CH₂NH₂, —C(═O)NHCH₂CH₂NH(CH₃), —C(═O)NHCH₂CH₂N(CH₃)₂, —C(═O)NHCH₂C(═O)NH₂, —C(═O)N(CH₃)CH₂C(═O)NH₂, —C(═O)NHCH₂CH₂C(═O)NH₂, —C(═O)N(CH₃)CH₂CH₂C(═O)NH₂, —C(═O)N(cyclopropyl)CH₂CH₂OH, —C(═O)NH-oxetanyl, —C(═O)N(CH₃)-oxetanyl, —C(═O)NH-(methyl-oxetanyl), —C(═O)NH-azetidinyl, —C(═O)NH-(methylazetidinyl), —C(═O)NH-(1-acetylazetidinyl), —C(═O)NH-pyrrolidyl, —C(═O)NH-piperidyl, —C(═O)NH-tetrahydrofuranyl, —C(═O)N(CH₃)-tetrahydrofuranyl, —C(═O)NH-tetrahydropyranyl, —C(═O)N(CH₃)-tetrahydropyranyl, —C(═O)NHCH₂-oxetanyl, —C(═O)N(CH₃)CH₂-oxetanyl, —C(═O)NHCH₂-(methyl-oxetanyl), —C(═O)N(CH₃)CH₂-(methyl-oxetanyl), —C(═O)NHCH₂-tetrahydrofuranyl, —C(═O)NHCH₂-tetrahydropyranyl, —C(═O)NHCH₂-dioxanyl, —C(═O)aziridinyl, —C(═O)(methyl-aziridinyl), —C(═O)(dimethyl-aziridinyl), —C(═O)(hydroxymethyl-aziridinyl), —C(═O)azetidinyl, —C(═O)pyrrolidinyl, —C(═O)(hydroxyl-pyrrolidinyl), —C(═O)(hydroxyl, methoxypyrrolidinyl), —C(═O)(dimethoxypyrrolidinyl), —C(═O)morpholinyl, —C(═O)piperazinyl, —C(═O)(methylpiperazinyl), —C(═O)(hydroxy-piperidyl), —C(═O)(fluoropiperidinyl), —(C═O)(methoxy-piperidyl), —C(═NH)NH₂, —NHC(═O)CH₃, —SO₂NHCH₃, —SO₂CH₃, or substituted or unsubstituted pyrazolyl. In some other embodiments, R² is phenyl, substituted with one or more —CH₃, —CH₂CH₃, —CH₂CH₂CH₃, —CH(CH₃)₂, —CH₂NH₂, —CF₃, —Cl, —F, —CN, —OCH₃, —OCF₃, —C(═O)NH₂, —C(═O)NHCH₃, —C(═O)N(CH₃)₂, —C(═O)NC(CH₃)₃, —C(═O)NHCH₂CH₂F, —C(═O)NHCH₂CF₂CH₃, —C(═O)N(CH₃)CH₂CN, —C(═O)N(CH₃)CH₂CH₂CN, —C(═O)NH-(3-hydroxy-cyclobutyl), —C(═O)NH-cyclopentyl, —C(═O)NH-(2-hydroxycyclopentyl), —C(═O)NHCH₂CH₂OH, —C(═O)NHCH₂CH₂OCH₃, —C(═O)N(CH₃)CH₂CH₂OH, —C(═O)N(CH₃)CH₂CH₂OCH₃, —C(═O)NHCH₂CH₂CH₂OH, —C(═O)N(CH₃)CH₂CH₂CH₂OH, —C(═O)NHCH₂CH(CH₃)OH, —C(═O)NHCH₂C(CH₃)₂OH, —C(═O)NHCH(CH₃)CH₂OH, —C(═O)NHC(CH₃)₂CH₂OH, —C(═O)NHCH₂CH₂NH₂, —C(═O)NHCH₂CH₂NH(CH₃), —C(═O)NHCH₂CH₂N(CH₃)₂, —C(═O)N(CH₃)CH₂C(═O)NH₂, —C(═O)N(CH₃)CH₂CH₂C(═O)NH₂, —C(═O)N(cyclopropyl)CH₂CH₂OH, —C(═O)NH-oxetanyl, —C(═O)N(CH₃)-oxetanyl, —C(═O)NH-(3-methyl-oxetanyl), —C(═O)NH-(1-methylazetidinyl), —C(═O)NH-(1-acetylazetidinyl), —C(═O)NH-piperidyl, —C(═O)NH-tetrahydrofuranyl, —C(═O)NH-tetrahydropyranyl, —C(═O)N(CH₃)-tetrahydropyranyl, —C(═O)NHCH₂-oxetanyl, —C(═O)N(CH₃)CH₂-(3-methyl-oxetanyl), —C(═O)NHCH₂-tetrahydrofuranyl, —C(═O)NHCH₂-tetrahydropyranyl, —C(═O)NHCH₂-dioxanyl, —C(═O)aziridinyl, —C(═O)(2-methyl-aziridinyl), —C(═O)(2,2-dimethyl-aziridinyl), —C(═O)(2-(hydroxymethyl)aziridinyl), —C(═O)azetidinyl, —C(═O)pyrrolidinyl, —C(═O)(3-hydroxy-4-methoxypyrrolidinyl), —C(═O)(3,4-dimethoxypyrrolidinyl), —C(═O)morpholinyl, —C(═O)piperazinyl, —C(═O)(4-methylpiperazinyl), —C(═O)(4-hydroxy-piperidyl), —C(═O)(4,4-difluoropiperidinyl), —(C═O)(4-methoxy-piperidyl), —C(═NH)NH₂, —NHC(═O)CH₃, —SO₂NHCH₃, —SO₂CH₃, or substituted or unsubstituted pyrazolyl.

In some embodiments of compounds of formula (I), R² is substituted or unsubstituted pyrazolyl, substituted or unsubstituted pyridyl, substituted or unsubstituted indazolyl or substituted or unsubstituted isoindolinone. In some such embodiments, R² is substituted with one or more halogen, substituted or unsubstituted (C₁₋₄)alkyl, —OR, —C(═O)NR₂, or substituted or unsubstituted heterocyclyl, wherein each R is independently —H or substituted or unsubstituted (C₁₋₄)alkyl. For example, R² is pyrazolyl substituted with one or more —Cl, —CH₃, —CH₂CH₃, —CH(CH₃)₂, —CH₂CH₂OCH₃, —CH₂C(CH₃)₂OH, or tetrahydropyranyl. Alternatively, R² is pyridyl, substituted with one or more —OCH₃, C(═O)NHCH₃, or tetrahydropyranyl. In yet other embodiments, R² is indazolyl or isoindolinone, substituted with one or more —CH₃.

In some such embodiments of R², R¹ is substituted or unsubstituted C₁₋₈ alkyl,

wherein

each R′ is independently —OR or C₁₋₃ alkyl;

R″ is —H or C₁₋₃ alkyl;

each R is independently —H or substituted or unsubstituted (C₁₋₄)alkyl; and

n is 0-2.

In yet other embodiments of compounds of formula (I), R³ is substituted or unsubstituted heterocyclyl, for example, substituted or unsubstituted pyrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, pyridazinyl, pyrimidyl, pyrazinyl, benztriazolyl, indazolyl, indolyl, benzoxazolyl, benzisoxazolyl, benzthiazolyl, benzoxazolonyl, benzoxadiazolyl, benzimidazolyl, or quinolyl. In some such embodiments, the heterocyclyl is substituted with one or more substituents selected from substituted or unsubstituted (C₁₋₄)alkyl, halogen, —OR, —CN, —NR₂, —C(═O)NR₂, —NRC(═O)R, or substituted or unsubstituted triazolyl, wherein each R is independently —H or substituted or unsubstituted (C₁₋₄)alkyl. For example, the heterocyclyl is substituted with one or more substituents selected from —CH₃, —CH(CH₃)₂, —F, —Cl, —OH, —OCH₃, —OCH₂CH₃, —CN, —NH₂, —NHCH₃, —N(CH₃)₂, —C(═O)NH(CH₃), —NHC(═O)CH₃, or substituted or unsubstituted triazolyl. In some such embodiments, the pyrazolyl is substituted with one or more —CH₃, or —Cl. In others, the pyridyl is substituted with one or more —CH₃, —F, —Cl, —OH, —OCH₃, —OCH₂CH₃, —CN, —NH₂, —NHCH₃, —N(CH₃)₂, —C(═O)NH(CH₃), or —NHC(═O)CH₃. In still others, the benzoxazolyl is substituted with one or more —CH₃, —CH(CH₃)₂, —F or —OCH₂CH₃.

In other embodiments of compounds of formula (I), R³ is substituted or unsubstituted aryl, for example, R³ is substituted or unsubstituted phenyl. In some such embodiments, the phenyl is substituted with one or more substituents selected from substituted or unsubstituted C₁₋₄ alkyl, halogen, —CN, —OR, —NR₂, —NRSO₂R′, —NR(C═O)NR₂, —NR(C═O)R′, —COOR, —(C═O)NR₂, —C(═NH)NR₂, —SO₂R′, or substituted or unsubstituted heteroaryl, wherein each R is independently —H or substituted or unsubstituted (C₁₋₄)alkyl, and R′ is C₁₋₃ alkyl. In yet other embodiments, the phenyl is substituted with one or more substituents selected from —CH₃, —CH₂OH, —CH(OH)CH₃, —C(CH₃)₂OH, —CN, —F, —Cl, —OH, —OCH₃, —NH₂, —N(CH₃)₂, —NHSO₂CH₃, —NH(C═O)NH₂, —NH(C═O)CH₃, —COOCH₃, —(C═O)NHCH₃, —C(═N)NH₂, —SO₂CH₃, substituted or unsubstituted triazolyl, substituted or unsubstituted pyrazolyl, or substituted or unsubstituted imidazolyl.

In some such embodiments of R³, R¹ is substituted or unsubstituted C₁₋₈ alkyl,

wherein

each R′ is independently —OR or C₁₋₃ alkyl;

R″ is —H or C₁₋₃ alkyl;

each R is independently —H or substituted or unsubstituted (C₁₋₄)alkyl; and

n is 0-2.

In some such embodiments, R² is phenyl, substituted with one or more —(C₁₋₃ alkyl), —(C₁₋₃ alkyl)NR₂, —CF₃, —Cl, —F, —CN, —OCH₃, —OCF₃, —C(═O)NR₂, —C(═O)NR(substituted or unsubstituted cycloalkyl), —C(═O)NR(CH₂)₀₋₂CR₂(CH₂)₀₋₂OR, —C(—O)NR(CH₂)₀₋₂CR₂(CH₂)₀₋₂NR₂, —C(═O)NR(CH₂)₀₋₂CR₂(CH₂)₀₋₂C(═O)NR₂, —C(═O)N(substituted or unsubstituted cycloalkyl)(CH₂)₀₋₂OR, —C(═O)NR(CH₂)₀₋₃(substituted or unsubstituted heterocyclyl), —C(═O)(CH₂)₀₋₃(substituted or unsubstituted heterocyclyl), —C(═NR)NR₂, —NRC(═O)R, —SO₂NR₂, —SO₂R, or substituted or unsubstituted heterocyclyl, wherein each R is independently —H or substituted or unsubstituted (C₁₋₄)alkyl.

Further embodiments provided herein include combinations of one or more of the particular embodiments set forth above.

In some embodiments of compounds of formula (I), the compound is selected from Table A, or a pharmaceutically acceptable salt, tautomer, stereoisomer, enantiomer, or isotopologue thereof.

Pyrrolopyrimidine Compounds set forth in Table A were tested in the assays described herein and were found to have activity as cancer treatment agents, in particular for the treatment of solid tumors and hematological cancers as described herein. In some embodiments, the solid tumor is bladder cancer (including superficial bladder cancer), breast cancer (including luminal B type, ER+, PR+ and Her2+ breast cancer), central nervous system cancer (including glioblastoma multiforme (GBM), glioma, medulloblastoma, and astrocytoma), colorectal cancer, gastrointestinal cancer (including stomach cancer, oesophagus cancer, and rectum cancer), endocrine cancer (including thyroid cancer, and adrenal gland cancer), eye cancer (including retinoblastoma), female genitourinary cancer (including cancer of the placenta, uterus, vulva, ovary, cervix), head and neck cancer (including cancer of the pharynx, oesophagus, and tongue), liver cancer, lung cancer (including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), mucoepidermoid, bronchogenic, squamous cell carcinoma (SQCC), and analplastic/NSCLC), skin cancer (including melanoma, and SQCC), soft tissue cancer (including sarcoma, Ewing's sarcoma, and rhabdomyosarcoma), bone cancer (including sarcoma, Ewing's sarcoma, and osteosarcoma), squamous cell cancer (including lung, esophageal, cervical, and head and neck cancer), pancreas cancer, kidney cancer (including renal Wilm's tumor and renal cell carcinoma), or prostate cancer. In some embodiments, the solid tumor is breast cancer, colon cancer, lung cancer or bladder cancer. In one such embodiment, the solid tumor is superficial bladder cancer. In another, the solid tumor is lung squamous cell carcinoma. In yet another embodiment, the solid tumor is luminal B type breast cancer.

In some embodiments, the hematological cancer is leukemia (including acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), acute T-cell leukemia, B cell precursor leukemia, acute promyelocytic leukemia (APML), plasma cell leukemia, myelomonoblastic/T-ALL, B myelomonocytic leukemia, erythroleukemia, and acute myeloid leukemia (AML)), lymphoma (including Hodgkin's lymphoma, non-Hodgkin's lymphoma (NHL), Burkitt's lymphoma (BL), B cell lymphoma, lymphoblastic lymphoma, follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and large cell immunoblastic lymphoma), or multiple myeloma.

In one embodiment, the Pyrrolopyrimidine Compound is a compound as described herein, wherein the compound at a concentration of 10 μM inhibits cancer cell proliferation, for example solid tumor or hematological cancer cell proliferation, as described herein, by at least about 50% or more.

TABLE A Cmpd No. Structure Name  1

4-(4-(cyclopentyloxy)-5-(4- hydroxyphenyl)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-N- methylbenzamide  2

4-(4-(cyclopentyloxy)-5-(3- hydroxyphenyl)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-N- methylbenzamide  3

4-(4-(cyclopentyloxy)-5-(4- hydroxyphenyl)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- methoxy-N-methylbenzamide  4

4-(5-(4-hydroxyphenyl)-4- methoxy-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-N- methylbenzamide  5

4-(2-(1H-indazol-5-ylamino)-4- (cyclohexyloxy)-7H-pyrrolo[2,3- d]pyrimidin-5-yl)phenol  6

4-(2-(4-(1H-pyrazol-4- yl)phenylamino)-4- (cyclohexyloxy)-7H-pyrrolo[2,3- d]pyrimidin-5-yl)phenol  7

4-(5-(2-chloro-4-hydroxyphenyl)- 4-(cyclohexyloxy)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-methylbenzamide  8

4-(2-(3-(1H-pyrazol-4- yl)phenylamino)-4- (cyclohexyloxy)-7H-pyrrolo[2,3- d]pyrimidin-5-yl)phenol  9

4-(4-(cyclopentyloxy)-5-(4- hydroxyphenyl)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-N,3- dimethylbenzamide  10

4-(4-(cyclopentyloxy)-5-(4- hydroxyphenyl)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3-ethyl- N-methylbenzamide  11

4-(4-(cyclopentyloxy)-5-(4- hydroxyphenyl)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- isopropyl-N-methylbenzamide  12

4-(4-(cyclopentyloxy)-5-(4- fluorophenyl)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- methoxy-N-methylbenzamide  13

4-(4-(cyclopentyloxy)-5-phenyl- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide  14

3-chloro-4-(4-(cyclopentyloxy)-5- (4-hydroxyphenyl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-methylbenzamide  15

4-(4-(cyclopentyloxy)-5-(4- hydroxyphenyl)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3-fluoro- N-methylbenzamide  16

4-(4-(cyclopentylamino)-5-(4- hydroxyphenyl)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- methoxy-N-methylbenzamide  17

4-(5-(4-hydroxyphenyl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide  18

4-(5-(4-hydroxyphenyl)-4- (neopentyloxy)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- methoxy-N-methylbenzamide  19

4-(5-(4-hydroxyphenyl)-4- methoxy-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- methoxy-N-methylbenzamide  20

4-(4-(cyclopentyloxy)-2-(1- methyl-1H-indazol-5-ylamino)- 7H-pyrrolo[2,3-d]pyrimidin-5- yl)phenol  21

4-(4-(cyclopentyloxy)-2-(6- methyl-1H-indazol-5-ylamino)- 7H-pyrrolo[2,3-d]pyrimidin-5- yl)phenol  22

4-(4-(cyclopentyloxy)-2-(4- methyl-1H-indazol-5-ylamino)- 7H-pyrrolo[2,3-d]pyrimidin-5- yl)phenol  23

4-(4-(cyclopentyloxy)-5-(4- (hydroxymethyl)phenyl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide  24

4-(5-(3-chloro-4-hydroxyphenyl)- 4-(cyclopentyloxy)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide  25

4-(4-(cyclopentyloxy)-5-(1H- indazol-6-yl)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- methoxy-N-methylbenzamide  26

4-(4-(cyclopentyloxy)-5-(3- (hydroxymethyl)phenyl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide  27

4-(5-(1H-benzo[d][1,2,3]triazol- 6-yl)-4-(cyclopentyloxy)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide  28

4-(5-(4-(4H-1,2,4-triazol-3- yl)phenyl)-4-(cyclopentyloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide  29

3-chloro-4-(5-(4-hydroxyphenyl)- 4-(tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-methylbenzamide  30

4-(5-(1H-benzo[d]imidazol-6-yl)- 4-(cyclopentyloxy)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide  31

4-(4-(cyclopentyloxy)-5-(4- hydroxyphenyl)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- methoxy-N,N- dimethylbenzamide  32

4-(4-(cyclopentyloxy)-5-(4- (methylsulfonamido)phenyl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide  33

4-(5-(3-cyano-4-hydroxyphenyl)- 4-(cyclopentyloxy)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide  34

3-chloro-4-(4-(cyclopentyloxy)-5- (5-methoxypyridin-3-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-methylbenzamide  35

4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-5-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide  36

4-(4-(cyclohexylamino)-5-(4- hydroxyphenyl)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- methoxy-N-methylbenzamide  37

4-(5-(4-aminophenyl)-4- (cyclopentyloxy)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- methoxy-N-methylbenzamide  38

4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide  39

4-(4-(cyclopentyloxy)-5-(4- ureidophenyl)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- methoxy-N-methylbenzamide  40

4-(5-(4-hydroxyphenyl)-4- (tetrahydro-2H-pyran-4-ylamino)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide  41

4-(5-(4-(1H-pyrazol-5-yl)phenyl)- 4-(cyclopentyloxy)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide  42

4-(4-(cyclopentyloxy)-5-(3- fluoro-4-hydroxyphenyl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide  43

4-(4-(cyclopentyloxy)-5-(4- hydroxy-3-methylphenyl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide  44

4-(4-(cyclopentyloxy)-5-(4- hydroxyphenyl)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- methoxybenzamide  45

4-(4-((1r,4r)-4- hydroxycyclohexyloxy)-5-(4- hydroxyphenyl)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- methoxy-N-methylbenzamide  46

4-(4-((1s,4s)-4- hydroxycyclohexyloxy)-5-(4- hydroxyphenyl)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- methoxy-N-methylbenzamide  47

4-(4-(cyclopentyloxy)-5-(3-(2- hydroxypropan-2-yl)phenyl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide  48

4-(5-(4-(1H-imidazol-2- yl)phenyl)-4-(cyclopentyloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide  49

4-(4-(cyclopentyloxy)-5-(4-(2- hydroxypropan-2-yl)phenyl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide  50

4-(4-(cyclopentyloxy)-2-(2- methoxy-4-(1H-pyrazol-4- yl)phenylamino)-7H-pyrrolo[2,3- d]pyrimidin-5-yl)phenol  51

4-(4-(cyclopentyloxy)-5-(5- hydroxypyridin-3-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide  52

4-(2-(4-(aminomethyl)-2- methoxyphenylamino)-4- (cyclopentyloxy)-7H-pyrrolo[2,3- d]pyrimidin-5-yl)phenol  53

4-(5-(4-(4H-1,2,4-triazol-3- yl)phenyl)-4-methoxy-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-chloro-N,N- dimethylbenzamide  54

4-(4-(cyclopentyloxy)-5-(3- fluoro-4-methoxyphenyl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide  55

4-(4-(cyclopentyloxy)-5-(6- methoxypyridin-3-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide  56

4-(5-(3-acetamidophenyl)-4- (cyclopentyloxy)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- methoxy-N-methylbenzamide  57

4-(4-(cyclopentyloxy)-5-(3- (methylsulfonamido)phenyl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide  58

4-(4-(cyclopentyloxy)-5-(pyridin- 3-yl)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- methoxy-N-methylbenzamide  59

4-(4-(cyclopentyloxy)-5-(3- (methylcarbamoyl)phenyl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide  60

4-(4-(cyclopentyloxy)-5-(3- methoxyphenyl)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- methoxy-N-methylbenzamide  61

4-(4-(cyclopentyloxy)-5-(4- (methylsulfonyl)phenyl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide  62

4-(5-(4-acetamidophenyl)-4- (cyclopentyloxy)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- methoxy-N-methylbenzamide  63

4-(4-(cyclopentyloxy)-5-(3- (methylsulfonyl)phenyl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide  64

4-(4-(cyclopentyloxy)-5-(3,4- dimethoxyphenyl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide  65

4-(5-(3-aminophenyl)-4- (cyclopentyloxy)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- methoxy-N-methylbenzamide  66

4-(4-(cyclopentyloxy)-5-(pyridin- 4-yl)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- methoxy-N-methylbenzamide  67

4-(4-(cyclopentyloxy)-5-(6- ethoxypyridin-3-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide  68

(4-(5-(4-(4H-1,2,4-triazol-3- yl)phenyl)-4-methoxy-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3- chlorophenyl)(morpholino)- methanone  69

N,N,3-trimethyl-4-(5-(2- methylbenzo[d]oxazol-6-yl)-4- (tetrahydro-2H-pyran-4-ylamino)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide  70

N,N,3-trimethyl-4-(5-(2- methylbenzo[d]oxazol-6-yl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide  71

4-(5-(2-amino-1H- benzo[d]imidazol-5-yl)-4- methoxy-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3-chloro- N,N-dimethylbenzamide  72

4-(5-(4-(4H-1,2,4-triazol-3- yl)phenyl)-4-(methylamino)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-chloro-N,N- dimethylbenzamide  73

4-(4-methoxy-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N,N,3- trimethylbenzamide  74

(3-methyl-4-(5-(2- methylbenzo[d]oxazol-6-yl)-4- (tetrahydro-2H-pyran-4-ylamino)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)phenyl)(piperazin-1- yl)methanone  75

4-(4-(cyclopentyloxy)-5-(4- (dimethylamino)phenyl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide  76

4-(4-(cyclopentyloxy)-5-(4- methoxyphenyl)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- methoxy-N-methylbenzamide  77

4-(5-(4-cyanophenyl)-4- (cyclopentyloxy)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- methoxy-N-methylbenzamide  78

4-(4-(cyclopentyloxy)-5-(1- methyl-1H-indol-5-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide  79

4-(4-(cyclopentyloxy)-5-(4- (methylcarbamoyl)phenyl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide  80

4-(4-(cyclopentyloxy)-5-(1H- pyrazol-3-yl)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- methoxy-N-methylbenzamide  81

4-(4-(cyclopentyloxy)-5-(1H- indol-5-yl)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- methoxy-N-methylbenzamide  82

4-(4-(cyclopentyloxy)-5-(1H- pyrazol-4-yl)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- methoxy-N-methylbenzamide  83

3-chloro-4-(4-methoxy-5-(2- methyl-1H-benzo[d]imidazol-5- yl)-7H-pyrrolo[2,3-d]pyrimidin- 2-ylamino)-N,N- dimethylbenzamide  84

(R)-3-chloro-4-(5-(3-(1- hydroxyethyl)phenyl)-4- (tetrahydro-2H-pyran-4-ylamino)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)-N,N- dimethylbenzamide  85

(S)-3-chloro-4-(5-(3-(1- hydroxyethyl)phenyl)-4- (tetrahydro-2H-pyran-4-ylamino)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)-N,N- dimethylbenzamide  86

(4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methyl- phenyl)(morpholino)methanone  87

N-(1H-indazol-5-yl)-4-methoxy- 5-(2-methylbenzo[d]oxazol-6-yl)- 7H-pyrrolo[2,3-d]pyrimidin-2- amine  88

N-(4-(1H-pyrazol-4-yl)phenyl)-4- methoxy-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2-amine  89

4-(4-methoxy-5-(pyridin-4-yl)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)-N,N,3- trimethylbenzamide  90

3-methoxy-N-methyl-4-(5-(2- methylbenzo[d]oxazol-6-yl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide  91

4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N,N- dimethylbenzamide  92

4-(4-((1r,4r)-4- hydroxycyclohexyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N,N,3- trimethylbenzamide  93

N,N,3-trimethyl-4-(5-(pyridin-4- yl)-4-(tetrahydro-2H-pyran-4- yloxy)-7H-pyrrolo[2,3- d]pyrimidin-2- ylamino)benzamide  94

4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N,3-dimethylbenzamide  95

N,N,3-trimethyl-4-(5-(2- methylbenzo[d]oxazol-6-yl)-4- (1-methylpiperidin-4-yloxy)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide  96

(4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy- phenyl)(morpholino)methanone  97

N,N,3-trimethyl-4-(5-(2- methylbenzo[d]oxazol-6-yl)-4- (piperidin-4-yloxy)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide  98

(S)-N,N,3-trimethyl-4-(5-(2- methylbenzo[d]oxazol-6-yl)-4- (tetrahydrofuran-3-yloxy)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide  99

(R)-N,N,3-trimethyl-4-(5-(2- methylbenzo[d]oxazol-6-yl)-4- (tetrahydrofuran-3-yloxy)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 100

N-(2-aminoethyl)-4-(4- (cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxybenzamide 101

4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-(2-hydroxyethyl)-3- methoxybenzamide 102

4-(5-(6-ethoxypyridin-3-yl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide 103

4-(cyclopentyloxy)-N-(2- methoxyphenyl)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2-amine 104

(S)-N,N,3-trimethyl-4-(5-(2- methylbenzo[d]oxazol-6-yl)-4- (tetrahydro-2H-pyran-3-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 105

N,N,3-trimethyl-4-(5-(3- (methylsulfonyl)phenyl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 106

3-methoxy-N-methyl-4-(5-(3- (methylsulfonyl)phenyl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 107

N,N,3-trimethyl-4-(5-(pyrimidin- 5-yl)-4-(tetrahydro-2H-pyran-4- yloxy)-7H-pyrrolo[2,3- d]pyrimidin-2- ylamino)benzamide 108

3-methoxy-N-methyl-4-(5-(2- methylbenzo[d]oxazol-6-yl)-4- (tetrahydro-2H-pyran-4-ylamino)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 109

4-(5-(6-ethoxypyridin-3-yl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)-N,N,3- trimethylbenzamide 110

4-(5-(2-amino-1H- benzo[d]imidazol-6-yl)-4- (cyclopentyloxy)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- methoxy-N-methylbenzamide 111

4-(5-(1,3,4-oxadiazol-2-yl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)-N,N,3- trimethylbenzamide 112

N,N,3-trimethyl-4-(5-(1-methyl- 1H-pyrazol-4-yl)-4-(tetrahydro- 2H-pyran-4-yloxy)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 113

N,N,3-trimethyl-4-(5-(1-methyl- 1H-pyrazol-3-yl)-4-(tetrahydro- 2H-pyran-4-yloxy)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 114

3-methoxy-N-methyl-4-(5- (pyridin-4-yl)-4-(tetrahydro-2H- pyran-4-yloxy)-7H-pyrrolo[2,3- d]pyrimidin-2- ylamino)benzamide 115

N,N,3-trimethyl-4-(5-(oxazol-2- yl)-4-(tetrahydro-2H-pyran-4- yloxy)-7H-pyrrolo[2,3- d]pyrimidin-2- ylamino)benzamide 116

4-(5-(2-amino-1H- benzo[d]imidazol-6-yl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)-N,N,3- trimethylbenzamide 117

N,N,3-trimethyl-4-(5-(2- methylpyridin-4-yl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 118

3-methoxy-4-(4-methoxy-5-(6- methoxypyridin-3-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-methylbenzamide 119

3-methoxy-4-(5-(6- methoxypyridin-3-yl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-methylbenzamide 120

3-methoxy-N-(2-methoxyethyl)- 4-(5-(2-methylbenzo[d]oxazol-6- yl)-4-(tetrahydro-2H-pyran-4- yloxy)-7H-pyrrolo[2,3- d]pyrimidin-2- ylamino)benzamide 121

(R)-N,N,3-trimethyl-4-(5-(2- methylbenzo[d]oxazol-6-yl)-4- (tetrahydro-2H-pyran-3-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 122

4-(5-(1H-pyrazol-4-yl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide 123

3-methoxy-N-methyl-4-(5-(4- (methylcarbamoyl)phenyl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 124

3-methoxy-4-(4-methoxy-5-(4- (methylcarbamoyl)phenyl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-methylbenzamide 125

4-(4-isopropoxy-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide 126

4-(5-(6-(dimethylamino)pyridin- 3-yl)-4-(tetrahydro-2H-pyran-4- yloxy)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- methoxy-N-methylbenzamide 127

N-(2-(dimethylamino)ethyl)-3- methoxy-4-(5-(2- methylbenzo[d]oxazol-6-yl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 128

N,N,3-trimethyl-4-(5-(2-methyl- 1H-benzo[d]imidazol-6-yl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 129

3-methoxy-4-(4-methoxy-5-(1H pyrazol-4-yl)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-N- methylbenzamide 130

3-methoxy-N-(2- (methylamino)ethyl)-4-(5-(2- methylbenzo[d]oxazol-6-yl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 131

4-(5-(2-(dimethylamino)pyridin- 4-yl)-4-(tetrahydro-2H-pyran-4- yloxy)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- methoxy-N-methylbenzamide 132

3-chloro-N-methyl-4-(5-(2- methylbenzo[d]oxazol-6-yl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 133

(S)-N,3-dimethyl-4-(5-(2- methylbenzo[d]oxazol-6-yl)-4- (tetrahydrofuran-3-yloxy)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 134

(S)-3-chloro-N-methyl-4-(5-(2- methylbenzo[d]oxazol-6-yl)-4- (tetrahydrofuran-3-yloxy)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 135

4-(5-(2,7- dimethylbenzo[d]oxazol-6-yl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide 136

4-(5-(2,5- dimethylbenzo[d]oxazol-6-yl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide 137

4-(4-((1r,4r)-4- hydroxycyclohexyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide 138

3-methoxy-N-methyl-4-(4-(2- (methylamino)ethoxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 139

3-methoxy-4-(4-(2- methoxyethoxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-methylbenzamide 140

4-(5-(2-cyanopyridin-4-yl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)-N,N,3- trimethylbenzamide 141

4-(5-(4-(1H-imidazol-2- yl)phenyl)-4-methoxy-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide 142

4-(5-(2-aminopyridin-4-yl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide 143

3-methoxy-4-(5-(2- methoxypyridin-4-yl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-methylbenzamide 144

N,3-dimethyl-4-(5-(3- (methylcarbamoyl)phenyl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 145

N,3-dimethyl-4-(5-(2- methylbenzo[d]oxazol-6-yl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 146

4-(5-(4-(1H-imidazol-2- yl)phenyl)-4-(tetrahydro-2H- pyran-4-yloxy)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- methoxy-N-methylbenzamide 147

4-(5-(2-hydroxypyridin-4-yl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide 148

4-(5-(1,2-dimethyl-1H- benzo[d]imidazol-6-yl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide 149

4-(4-methoxy-5-(3- (methylcarbamoyl)phenyl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N,3-dimethylbenzamide 150

4-(4-((1r,4r)-4-hydroxy-4- methylcyclohexyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N,3-dimethylbenzamide 151

4-(4-((1s,4s)-4-hydroxy-4- methylcyclohexyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N,3-dimethylbenzamide 152

4-(4-cyclopropoxy-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide 153

(S)-N,3-dimethyl-4-(5-(4- (methylcarbamoyl)phenyl)-4- (tetrahydrofuran-3-yloxy)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 154

3-methoxy-N-methyl-4-(5- (pyrimidin-5-yl)-4-(tetrahydro- 2H-pyran-4-yloxy)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 155

3-methoxy-N-methyl-4-(5-(2- (methylamino)pyridin-4-yl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 156

4-(4-methoxy-5-(pyridin-4-yl)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)-N,3-dimethylbenzamide 157

3-chloro-4-(4-methoxy-5- (pyridin-4-yl)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-N,N- dimethylbenzamide 158

N,3-dimethyl-4-(5-(4- (methylsulfonyl)phenyl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 159

5-(2-(4-(dimethylcarbamoyl)-2- methylphenylamino)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-5- yl)-N-methylpicolinamide 160

N-(2-hydroxyethyl)-4-(4- isopropoxy-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxybenzamide 161

(S)-4-(5-(6-ethoxypyridin-3-yl)- 4-(tetrahydrofuran-3-yloxy)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide 162

(S)-4-(5-(6-ethoxypyridin-3-yl)- 4-(tetrahydrofuran-3-yloxy)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N,3-dimethylbenzamide 163

3-methoxy-N-methyl-4-(5-(1- methyl-1H-pyrazol-3-yl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 164

(S)-N,N,3-trimethyl-4-(5-(1- methyl-1H-pyrazol-4-yl)-4- (tetrahydrofuran-3-yloxy)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 165

(S)-N,3-dimethyl-4-(5-(1-methyl- 1H-pyrazol-4-yl)-4- (tetrahydrofuran-3-yloxy)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 166

3-methoxy-4-(4-methoxy-5-(2- methylpyridin-4-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-methylbenzamide 167

3-methoxy-N-methyl-4-(5-(2- methylpyridin-4-yl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 168

4-(4-(2-hydroxyethoxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide 169

(S)-3-methoxy-N-methyl-4-(5-(2- methylbenzo[d]oxazol-6-yl)-4- (tetrahydrofuran-3-yloxy)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 170

4-(5-(2-isopropylbenzo[d]oxazol- 6-yl)-4-(tetrahydro-2H-pyran-4- yloxy)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- methoxy-N-methylbenzamide 171

3-cyano-N-methyl-4-(5-(2- methylbenzo[d]oxazol-6-yl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 172

3-methoxy-N-methyl-4-(5-(1- methyl-1H-imidazol-2-yl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 173

3-methoxy-N-methyl-4-(5- (oxazol-2-yl)-4-(tetrahydro-2H- pyran-4-yloxy)-7H-pyrrolo[2,3- d]pyrimidin-2- ylamino)benzamide 174

4-(5-(1,3,4-oxadiazol-2-yl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide 175

(S)-4-(5-(3-(1- hydroxyethyl)phenyl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide 176

(S)-N,N,3-trimethyl-4-(5- (pyridin-4-yl)-4-(tetrahydrofuran- 3-yloxy)-7H-pyrrolo[2,3- d]pyrimidin-2- ylamino)benzamide 177

3-methoxy-4-(4-methoxy-5-(1- methyl-1H-pyrazol-4-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-methylbenzamide 178

(S)-3-methoxy-N-methyl-4-(5-(2- methylpyridin-4-yl)-4- (tetrahydrofuran-3-yloxy)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 179

3-methoxy-N-methyl-4-(5-(2- methylbenzo[d]oxazol-6-yl)-4- (oxetan-3-yloxy)-7H-pyrrolo[2,3- d]pyrimidin-2- ylamino)benzamide 180

3-(4-isopropoxy-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-4-methoxy-N- methylbenzamide 181

4-methoxy-N-methyl-3-(5-(2- methylbenzo[d]oxazol-6-yl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 182

(S)-3-methoxy-N-methyl-4-(5-(4- (methylcarbamoyl)phenyl)-4- (tetrahydrofuran-3-yloxy)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 183

6-methoxy-N-methyl-5-(5-(2- methylbenzo[d]oxazol-6-yl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)picolinamide 184

3-methoxy-N-methyl-4-(5-(1- methyl-1H-pyrazol-4-yl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 185

4-(4-isopropoxy-5-(2- methoxypyridin-4-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide 186

3-methoxy-N-methyl-4-(5- (pyrazin-2-yl)-4-(tetrahydro-2H- pyran-4-yloxy)-7H-pyrrolo[2,3- d]pyrimidin-2- ylamino)benzamide 187

4-(4-isopropoxy-5-(3- (methylsulfonyl)phenyl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide 188

4-(4-isopropoxy-5-(4- (methylcarbamoyl)phenyl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide 189

4-(4-isopropoxy-5-(1-methyl-1H- pyrazol-4-yl)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- methoxy-N-methylbenzamide 190

3-methoxy-4-(4-methoxy-5- (pyridin-4-yl)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-N- methylbenzamide 191

N-methyl-4-(5-(2- methylbenzo[d]oxazol-6-yl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)-3- (trifluoromethyl)benzamide 192

N-methyl-4-(5-(2- methylbenzo[d]oxazol-6-yl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)-3- (trifluoromethoxy)benzamide 193

4-(5-(4-(1H-imidazol-2- yl)phenyl)-4-isopropoxy-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide 194

4-(5-(2-aminopyridin-4-yl)-4- isopropoxy-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- methoxy-N-methylbenzamide 195

3-methoxy-N-methyl-4-(5-(4-(1- methyl-1H-imidazol-2- yl)phenyl)-4-(tetrahydro-2H- pyran-4-yloxy)-7H-pyrrolo[2,3- d]pyrimidin-2- ylamino)benzamide 196

4-(5-(6-ethoxypyridin-3-yl)-4- isopropoxy-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- methoxy-N-methylbenzamide 197

4-(5-(4-(4,5-dimethyl-1H- imidazol-2-yl)phenyl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide 198

4-(4-cyclobutoxy-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide 199

4-(4-isopropoxy-5-(2- (methylamino)pyridin-4-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide 200

3-isopropyl-N-methyl-4-(5- (pyridin-4-yl)-4-(tetrahydro-2H- pyran-4-yloxy)-7H-pyrrolo[2,3- d]pyrimidin-2- ylamino)benzamide 201

4-(4-isopropoxy-5-(2- methylpyridin-4-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide 202

4-(4-(isopropylamino)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide 203

(R)-4-(4-sec-butoxy-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide 204

(S)-4-(4-sec-butoxy-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide 205

4-(4-((1r,4r)-4-hydroxy-4- methylcyclohexyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide 206

4-(4-((1s,4s)-4-hydroxy-4- methylcyclohexyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide 207

3-methoxy-N-methyl-4-(5-(4-(4- methyl-1H-imidazol-2- yl)phenyl)-4-(tetrahydro-2H- pyran-4-yloxy)-7H-pyrrolo[2,3- d]pyrimidin-2- ylamino)benzamide 208

(S)-3-isopropyl-N-methyl-4-(5- (1-methyl-1H-pyrazol-4-yl)-4- (tetrahydrofuran-3-yloxy)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 209

(S)-3-isopropyl-N-methyl-4-(5- (2-methylbenzo[d]oxazol-6-yl)-4- (tetrahydrofuran-3-yloxy)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 210

3-methoxy-N-methyl-4-(5-(1- methyl-1H-pyrazol-4-yl)-4- (tetrahydro-2H-pyran-4-ylamino)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 211

4-(4-(cyclopropylamino)-5-(1- methyl-1H-pyrazol-4-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide 212

4-(4-(cyclopropylamino)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide 213

N-(2-hydroxyethyl)-3-methoxy-4- (5-(2-methylbenzo[d]oxazol-6- yl)-4-(tetrahydro-2H-pyran-4- yloxy)-7H-pyrrolo[2,3- d]pyrimidin-2- ylamino)benzamide 214

(R)-4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-(1-hydroxypropan-2- yl)-3-methoxybenzamide 215

(S)-4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-(1-hydroxypropan-2- yl)-3-methoxybenzamide 216

4-(4-cyclopropoxy-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-(2-hydroxyethyl)-3- methoxybenzamide 217

4-(4-cyclopropoxy-5-(1-methyl- 1H-pyrazol-4-yl)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-N-(2- hydroxyethyl)-3- methoxybenzamide 218

4-(4-cyclopropoxy-5-(1-methyl- 1H-pyrazol-3-yl)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- methoxy-N-methylbenzamide 219

3-methoxy-N-methyl-4-(5-(2- methylbenzo[d]oxazol-6-yl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)benzenesulfonamide 220

4-(4-isopropoxy-5-(1-methyl-1H- pyrazol-3-yl)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- methoxy-N-methylbenzamide 221

3-methoxy-4-(4-(2- methoxyethoxy)-5-(1-methyl-1H- pyrazol-4-yl)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-N,N- dimethylbenzamide 222

(R)-3-methoxy-N,N-dimethyl-4- (5-(2-methylbenzo[d]oxazol-6- yl)-4-(tetrahydrofuran-3-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 223

3-methoxy-N-methyl-4-(5-(2- methylbenzo[d]thiazol-6-yl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 224

N-tert-butyl-4-(4- (cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxybenzamide 225

(S)-3-isopropyl-N-methyl-4-(5- (1-methyl-1H-pyrazol-5-yl)-4- (tetrahydrofuran-3-yloxy)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 226

4-(4-isopropoxy-5-(1-methyl-1H- pyrazol-5-yl)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- methoxy-N-methylbenzamide 227

4-(cyclopentyloxy)-N-(2- methoxy-4-(1-methyl-1H- pyrazol-4-yl)phenyl)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2-amine 228

4-(cyclopentyloxy)-N-(2- methoxy-4-(1H-pyrazol-1- yl)phenyl)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2-amine 229

N-cyclopentyl-4-(4- (cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxybenzamide 230

(R)-4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-(2-hydroxypropyl)-3- methoxybenzamide 231

(4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxyphenyl)(4- hydroxypiperidin-1-yl)methanone 232

4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-(3-hydroxypropyl)-3- methoxybenzamide 233

4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-(2-hydroxyethyl)-3- methoxy-N-methylbenzamide 234

4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-(1-hydroxy-2- methylpropan-2-yl)-3- methoxybenzamide 235

5-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)isoindolin-1-one 236

4-(5-(2-acetamidopyridin-4-yl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide 237

4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-2-fluoro-5-methoxy-N- methylbenzamide 238

4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-((1s,3s)-3- hydroxycyclobutyl)-3- methoxybenzamide 239

4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-((1r,3r)-3- hydroxycyclobutyl)-3- methoxybenzamide 240

(S)-4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-(2-hydroxypropyl)-3- methoxybenzamide 241

azetidin-1-yl(4-(4- (cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3- methoxyphenyl)methanone 242

(R)-4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- ((tetrahydrofuran-2- yl)methyl)benzamide 243

4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- ((tetrahydro-2H-pyran-4- yl)methyl)benzamide 244

5-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-2-methylisoindolin-1- one 245

4-(5-(4-carbamimidoylphenyl)-4- (cyclopentyloxy)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- methoxy-N-methylbenzamide 246

4-(4-tert-butoxy-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide 247

N-(4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3- methoxyphenyl)acetamide 248

N-(2-cyanoethyl)-4-(4- (cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide 249

(4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3- methoxyphenyl)(pyrrolidin-1- yl)methanone 250

4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N-methyl- N-(tetrahydro-2H-pyran-4- yl)benzamide 251

4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-cyclopropyl-N-(2- hydroxyethyl)-3- methoxybenzamide 252

4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- (tetrahydro-2H-pyran-4- yl)benzamide 253

4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-((1R,2S)-2- hydroxycyclopentyl)-3- methoxybenzamide 254

(S)-4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- ((tetrahydrofuran-2- yl)methyl)benzamide 255

4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N-(oxetan- 3-yl)benzamide 256

4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-(2-fluoroethyl)-3- methoxybenzamide 257

N-(3-amino-3-oxopropyl)-4-(4- (cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide 258

4-(4-(cyclopentyloxy)-5-(4- (methylcarbamoyl)phenyl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-(2-hydroxyethyl)-3- methoxybenzamide 259

(4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxyphenyl)(4- methylpiperazin-1-yl)methanone 260

4-(5-(benzo[c][1,2,5]oxadiazol-5- yl)-4-(cyclopentyloxy)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide 261

4-(cyclopentyloxy)-N-(5-fluoro- 2-methoxy-4- (methylsulfonyl)phenyl)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2-amine 262

aziridin-1-yl(4-(4- (cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3- methoxyphenyl)methanone 263

N-(cyanomethyl)-4-(4- (cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide 264

4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-((1S,2R)-2- hydroxycyclopentyl)-3- methoxybenzamide 265

4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-((1S,2S)-2- hydroxycyclopentyl)-3- methoxybenzamide 266

4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-((1R,2R)-2- hydroxycyclopentyl)-3- methoxybenzamide 267

(S)-4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- (tetrahydrofuran-3-yl)benzamide 268

N-(2-amino-2-oxoethyl)-4-(4- (cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide 269

3-methoxy-N-methyl-4-(5- (pyridazin-4-yl)-4-(tetrahydro- 2H-pyran-4-yloxy)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 270

3-methoxy-N-methyl-4-(5- (pyrimidin-4-yl)-4-(tetrahydro- 2H-pyran-4-yloxy)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 271

4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N-methyl- N-((3-methyloxetan-3- yl)methyl)benzamide 272

4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N-methyl- N-(oxetan-3-yl)benzamide 273

4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- (tetrahydro-2H-pyran-3- yl)benzamide 274

4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- (tetrahydro-2H-pyran-3- yl)benzamide 275

(4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxyphenyl)(4- methoxypiperidin-1- yl)methanone 276

(S)-4-(4-sec-butoxy-5-(1-methyl- 1H-pyrazol-4-yl)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- methoxy-N-methylbenzamide 277

4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxybenzonitrile 278

4-(4-(cyclopentyloxy)-5-(1- methyl-1H-indazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide 279

4-(4-(cyclopentyloxy)-5-(3- methylbenzo[d]isoxazol-6-yl)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide 280

5-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-4-methoxy-N- methylpicolinamide 281

N-((1,4-dioxan-2-yl)methyl)-4- (4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxybenzamide 282

4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N-(oxetan- 3-ylmethyl)benzamide 283

4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-(3-hydroxypropyl)-3- methoxy-N-methylbenzamide 284

4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N-(2- methoxyethyl)-N- methylbenzamide 285

4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-(2-hydroxy-2- methylpropyl)-3- methoxybenzamide 286

(S)-4-(4-sec-butoxy-5-(1-methyl- 1H-pyrazol-4-yl)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-N-(2- hydroxyethyl)-3- methoxybenzamide 287

4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3- methoxybenzimidamide 288

4-(2-(2-methoxy-4- (methylcarbamoyl)phenylamino)- 4-(tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-5- yl)-N-methylpicolinamide 289

(4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxyphenyl)(4,4- difluoropiperidin-1-yl)methanone 290

4-(5-(4-acetamido-3- hydroxyphenyl)-4- (cyclopentyloxy)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- methoxy-N-methylbenzamide 291

(4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3- methoxyphenyl)((3R,4R)-3- hydroxy-4-methoxypyrrolidin-1- yl)methanone 292

4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- (piperidin-1-yl)benzamide 293

4-(4-(cyclopentyloxy)-5-(2- ethoxybenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide 294

4-(5-(4-amino-3-hydroxyphenyl)- 4-(cyclopentyloxy)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide 295

4-(cyclopentyloxy)-N-(1-methyl- 1H-pyrazol-5-yl)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2-amine 296

4-(cyclopentyloxy)-N-(1,5- dimethyl-1H-pyrazol-4-yl)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2-amine 297

4-(cyclopentyloxy)-N-(1,4- dimethyl-1H-pyrazol-3-yl)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2-amine 298

4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N,5- dimethylbenzamide 299

4-(4-(cyclopentyloxy)-5-(2-oxo- 2,3-dihydrobenzo[d]oxazol-6-yl)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide 300

4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N-(1- methylazetidin-3-yl)benzamide 301

4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N-(3- methyloxetan-3-yl)benzamide 302

4-(4-cyclobutoxy-5-(1-methyl- 1H-pyrazol-4-yl)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- methoxy-N-(oxetan-3- yl)benzamide 303

4-(4-(cyclopentyloxy)-5-(1- methyl-1H-pyrazol-4-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N-(oxetan- 3-yl)benzamide 304

4-(4-cyclobutoxy-5-(4- (methylcarbamoyl)phenyl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N-(oxetan- 3-yl)benzamide 305

4-(4-(cyclopentyloxy)-5-(4- (methylcarbamoyl)phenyl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N-(oxetan- 3-yl)benzamide 306

4-(4-(cyclopentyloxy)-5- (quinolin-6-yl)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- methoxy-N-methylbenzamide 307

4-(cyclopentyloxy)-N-(1,3- dimethyl-1H-pyrazol-4-yl)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2-amine 308

N-(1-acetylazetidin-3-yl)-4-(4- (cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxybenzamide 309

4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-(2,2-difluoropropyl)- 3-methoxybenzamide 310

3-methoxy-4-(5-(4- (methylcarbamoyl)phenyl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-(oxetan-3- yl)benzamide 311

(4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3- methoxyphenyl)((3R,4R)-3,4- dimethoxypyrrolidin-1- yl)methanone 312

(4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxyphenyl)(2,2- dimethylaziridin-1-yl)methanone 313

(S)-(4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxyphenyl)(2- methylaziridin-1-yl)methanone 314

4-(4-((1s,4s)-4-hydroxy-4- methylcyclohexyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N-(oxetan- 3-yl)benzamide 315

aziridin-1-yl(4-(4-((1s,4s)-4- hydroxy-4- methylcyclohexyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3- methoxyphenyl)methanone 316

4-(4-(cyclopentyloxy)-2-(1- methyl-1H-pyrazol-5-ylamino)- 7H-pyrrolo[2,3-d]pyrimidin-5- yl)-N-methylbenzamide 317

N-methyl-4-(2-(1-methyl-1H- pyrazol-5-ylamino)-4-(tetrahydro- 2H-pyran-4-yloxy)-7H- pyrrolo[2,3-d]pyrimidin-5- yl)benzamide 318

methyl 4-(4-(cyclopentyloxy)-2- (2-methoxy-4- (methylcarbamoyl)phenylamino)- 7H-pyrrolo[2,3-d]pyrimidin-5- yl)benzoate 319

4-(4-(cyclopentyloxy)-5-(4- fluoro-2-methylphenyl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide 320

4-(4-(cyclopentyloxy)-5-(2,4- dimethoxyphenyl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide 321

4-(4-(cyclopentyloxy)-5-(3,5- dimethylisoxazol-4-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide 322

4-(4-(cyclopentyloxy)-5-(3- (dimethylamino)phenyl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide 323

4-(4-(cyclopentyloxy)-5-(3- hydroxyphenyl)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- methoxy-N-methylbenzamide 324

4-(5-(3-cyanophenyl)-4- (cyclopentyloxy)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- methoxy-N-methylbenzamide 325

3-methoxy-4-(5-(5- methoxypyridin-3-yl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-methylbenzamide 326

3-methoxy-4-(4-(2- methoxyethoxy)-5-(1-methyl-1H- pyrazol-4-yl)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-N- methylbenzamide 327

N-(2-hydroxyethyl)-3-methoxy-4- (5-(1-methyl-1H-pyrazol-4-yl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 328

(S)-3-methoxy-N-methyl-4-(5-(1- methyl-1H-pyrazol-4-yl)-4- (tetrahydrofuran-3-yloxy)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 329

N-methyl-4-(2-(1-methyl-1H- pyrazol-5-ylamino)-4-(tetrahydro- 2H-pyran-4-yloxy)-7H- pyrrolo[2,3-d]pyrimidin-5- yl)benzamide 330

4-(4-(cyclopentyloxy)-5-(4- fluoro-2-methylbenzo[d]oxazol- 6-yl)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- methoxy-N-methylbenzamide 331

4-(4-cyclobutoxy-5-(4- (methylcarbamoyl)phenyl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-(2-hydroxyethyl)-3- methoxybenzamide 332

4-(4-cyclobutoxy-5-(4- (methylcarbamoyl)phenyl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methyl-N-(oxetan-3- yl)benzamide 333

3-chloro-4-(4-cyclobutoxy-5-(4- (methylcarbamoyl)phenyl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-(oxetan-3- yl)benzamide 334

4-(4-isopropoxy-5-(4- (methylcarbamoyl)phenyl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N-(oxetan- 3-yl)benzamide 335

(R)-(4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxyphenyl)(2- methylaziridin-1-yl)methanone 336

4-(2-(4-(aziridine-1-carbonyl)-2- methoxyphenylamino)-4-((1s,4s)- 4-hydroxy-4- methylcyclohexyloxy)-7H- pyrrolo[2,3-d]pyrimidin-5-yl)-N- methylbenzamide 337

4-(4-((1s,4s)-4-hydroxy-4- methylcyclohexyloxy)-5-(4- (methylcarbamoyl)phenyl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N-(oxetan- 3-yl)benzamide 338

aziridin-1-yl(3-methoxy-4-(4- methoxy-5-(pyridin-4-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)phenyl)methanone 339

4-(4-cyclobutoxy-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N-(oxetan- 3-yl)benzamide 340

4-(4-cyclobutoxy-2-(1,3- dimethyl-1H-pyrazol-4-ylamino)- 7H-pyrrolo[2,3-d]pyrimidin-5- yl)-N-methylbenzamide 341

4-(4-(3-cyanocyclobutoxy)-5-(4- (methylcarbamoyl)phenyl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N-(oxetan- 3-yl)benzamide 342

4-(2-(5-chloro-1-methyl-1H- pyrazol-4-ylamino)-4- cyclobutoxy-7H-pyrrolo[2,3- d]pyrimidin-5-yl)-N- methylbenzamide 343

(S)-3-methoxy-4-(5-(2- methylbenzo[d]oxazol-6-yl)-4- (tetrahydrofuran-3-yloxy)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-(oxetan-3- yl)benzamide 344

4-(4-cyclopropoxy-5-(4- (methylcarbamoyl)phenyl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N-(oxetan- 3-yl)benzamide 345

4-(4-(3,3-difluorocyclobutoxy)-5- (4-(methylcarbamoyl)phenyl)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N-(oxetan- 3-yl)benzamide 346

(R)-(4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxyphenyl)(2- (hydroxymethyl)aziridin-1- yl)methanone 347

3-methoxy-4-(4-methoxy-5- (pyridin-4-yl)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-N- (oxetan-3-yl)benzamide 348

4-(4-cyclobutoxy-5-(4- (methylcarbamoyl)phenyl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N-(1- methylazetidin-3-yl)benzamide 349

4-(4-((1s,4s)-4-hydroxy-4- methylcyclohexyloxy)-5-(4- (methylcarbamoyl)phenyl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N-(1- methylazetidin-3-yl)benzamide 350

(S)-(4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxyphenyl)(2- (hydroxymethyl)aziridin-1- yl)methanone 351

N-(5-chloro-1-isopropyl-1H- pyrazol-4-yl)-4-(cyclopentyloxy)- 5-(2-methylbenzo[d]oxazol-6-yl)- 7H-pyrrolo[2,3-d]pyrimidin-2- amine 352

5-(4-cyclobutoxy-2-(2-methoxy- 4-(oxetan-3- ylcarbamoyl)phenylamino)-7H- pyrrolo[2,3-d]pyrimidin-5-yl)-N- methylpicolinamide 353

4-(4-cyclobutoxy-2-(2-methoxy- 4-(oxetan-3- ylcarbamoyl)phenylamino)-7H- pyrrolo[2,3-d]pyrimidin-5-yl)-2- fluoro-N-methylbenzamide 354

4-(4-tert-butoxy-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N-(1- methylazetidin-3-yl)benzamide 355

4-(4-tert-butoxy-5-(4- (methylcarbamoyl)phenyl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N-(1- methylazetidin-3-yl)benzamide 356

4-(4-isopropoxy-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N-(1- methylazetidin-3-yl)benzamide 357

4-(4-isopropoxy-5-(4- (methylcarbamoyl)phenyl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N-(1- methylazetidin-3-yl)benzamide 358

4-(4-((1s,4s)-4-hydroxy-4- methylcyclohexyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N-(1- methylazetidin-3-yl)benzamide 359

3-methoxy-4-(5-(4- (methylcarbamoyl)phenyl)-4- (oxetan-3-yloxy)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-N- (oxetan-3-yl)benzamide 360

4-(5-(4-(1H-imidazol-2- yl)phenyl)-4-cyclobutoxy-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N-(oxetan- 3-yl)benzamide 361

4-(5-(4-(1H-imidazol-2- yl)phenyl)-4-(cyclopentyloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N-(1- methylazetidin-3-yl)benzamide 362

4-(4-isopropoxy-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N-(oxetan- 3-yl)benzamide 363

4-(4-cyclopropoxy-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N-(1- methylazetidin-3-yl)benzamide 364

4-(4-cyclopropoxy-5-(4- (methylcarbamoyl)phenyl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N-(1- methylazetidin-3-yl)benzamide 365

3-methoxy-4-(4-(2- methoxyethoxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-(oxetan-3- yl)benzamide 366

3-methoxy-N-(1-methylazetidin- 3-yl)-4-(5-(4- (methylcarbamoyl)phenyl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 367

3-methoxy-N-(1-methylazetidin- 3-yl)-4-(5-(2- methylbenzo[d]oxazol-6-yl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 368

3-methoxy-4-(5-(2- methylbenzo[d]oxazol-6-yl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-(oxetan-3- yl)benzamide 369

4-(4-cyclopropoxy-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N-(oxetan- 3-yl)benzamide 370

4-(4-tert-butoxy-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N-(oxetan- 3-yl)benzamide 371

1-(5-chloro-4-(4- (cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-1H-pyrazol-1-yl)-2- methylpropan-2-ol 372

4-(2-(5-chloro-1-(2-hydroxy-2- methylpropyl)-1H-pyrazol-4- ylamino)-4-cyclobutoxy-7H- pyrrolo[2,3-d]pyrimidin-5-yl)-N- methylbenzamide 373

3-methoxy-4-(4-(2- methoxyethoxy)-5-(4- (methylcarbamoyl)phenyl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-(oxetan-3- yl)benzamide 374

(S)-3-methoxy-N-(1- methylazetidin-3-yl)-4-(5-(2- methylbenzo[d]oxazol-6-yl)-4- (tetrahydrofuran-3-yloxy)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 375

(S)-3-methoxy-N-(1- methylazetidin-3-yl)-4-(5-(4- (methylcarbamoyl)phenyl)-4- (tetrahydrofuran-3-yloxy)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 376

(S)-3-methoxy-4-(5-(4- (methylcarbamoyl)phenyl)-4- (tetrahydrofuran-3-yloxy)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-(oxetan-3- yl)benzamide 377

N-(5-chloro-1-(tetrahydro-2H- pyran-4-yl)-1H-pyrazol-4-yl)-4- (cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2-amine 378

N-(5-chloro-1-(2-methoxyethyl)- 1H-pyrazol-4-yl)-4- (cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2-amine 379

3-methoxy-4-(5-(2- methylbenzo[d]oxazol-6-yl)-4- (1-methylcyclobutoxy)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-(oxetan-3- yl)benzamide 380

3-methoxy-4-(4-methoxy-5-(3- methylbenzo[d]isoxazol-6-yl)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-(oxetan-3- yl)benzamide 381

4-(5-(2-fluoropyridin-4-yl)-4- methoxy-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- methoxy-N-(oxetan-3- yl)benzamide 382

3-methoxy-4-(4-methoxy-5-(1- methyl-1H-pyrazol-4-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-(oxetan-3- yl)benzamide 383

3-methoxy-4-(4-methoxy-5-(2- methylpyridin-4-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-(oxetan-3- yl)benzamide 384

4-(5-(2,6-dimethylpyridin-4-yl)- 4-methoxy-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- methoxy-N-(oxetan-3- yl)benzamide 385

N-(5-chloro-1-ethyl-1H-pyrazol- 4-yl)-4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2-amine 386

3-methoxy-4-(4-(2- methoxyethoxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-(1-methylazetidin-3- yl)benzamide 387

4-(5-(1,3-dimethyl-1H-pyrazol-4- yl)-4-methoxy-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- methoxy-N-(oxetan-3- yl)benzamide 388

3-methoxy-4-(4-methoxy-5-(3- methylbenzo[d]isoxazol-6-yl)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-methylbenzamide 389

3-methoxy-4-(4-methoxy-5-(2- methoxypyridin-4-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-(oxetan-3- yl)benzamide 390

4-(5-(4-fluorophenyl)-4-methoxy- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)-N,N,3- trimethylbenzamide 391

4-(4-methoxy-5-(4- methoxyphenyl)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-N,N,3- trimethylbenzamide 392

3-methoxy-4-(4-methoxy-5- (pyridin-4-yl)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-N,N- dimethylbenzamide 393

N-(1,3-dimethyl-1H-pyrazol-4- yl)-4-methoxy-5-(pyridin-4-yl)- 7H-pyrrolo[2,3-d]pyrimidin-2- amine 394

4-(5-(2-chloropyridin-4-yl)-4- methoxy-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- methoxy-N-(oxetan-3- yl)benzamide 395

3-methoxy-4-(4-methoxy-5- (pyrimidin-4-yl)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-N- (oxetan-3-yl)benzamide 396

4-(4-methoxy-5-(pyridin-4-yl)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methyl-N-(oxetan-3- yl)benzamide 397

4-(5-(4-(1H-imidazol-2- yl)phenyl)-4-methoxy-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N,N,3- trimethylbenzamide 398

4-(4-methoxy-5-(1-methyl-1H- pyrazol-4-yl)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-N,N,3- trimethylbenzamide 399

4-(4-methoxy-5-(2-methyl-1H- benzo[d]imidazol-5-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N,N,3- trimethylbenzamide 400

4-(4-methoxy-5-(3- methylbenzo[d]isoxazol-6-yl)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)-N,N,3- trimethylbenzamide 401

4-methoxy-N-(1-methyl-1H- pyrazol-5-yl)-5-(pyridin-4-yl)- 7H-pyrrolo[2,3-d]pyrimidin-2- amine 402

4-(5-(2-fluoropyridin-4-yl)-4- isopropoxy-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-N,N,3- trimethylbenzamide 403

4-(5-(2-fluoropyridin-4-yl)-4- isopropoxy-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- methoxy-N,N- dimethylbenzamide 404

3-methoxy-4-(4-methoxy-5-(2- methyl-1H-benzo[d]imidazol-5- yl)-7H-pyrrolo[2,3-d]pyrimidin- 2-ylamino)-N-(oxetan-3- yl)benzamide 405

3-methoxy-4-(4-methoxy-5- (pyridazin-4-yl)-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-N- (oxetan-3-yl)benzamide 406

4-(4-methoxy-5-(pyridin-4-yl)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)-N,3-dimethyl-N- (oxetan-3-yl)benzamide 407

4-(5-(1,2-dimethyl-1H- benzo[d]imidazol-6-yl)-4- methoxy-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-N,N,3- trimethylbenzamide 408

3-methoxy-4-(4-methoxy-5-(3- methylbenzo[d]isoxazol-6-yl)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)-N,N- dimethylbenzamide 409

4-(5-(2-fluoropyridin-4-yl)-4- methoxy-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-N,N,3- trimethylbenzamide 410

4-(5-(1,2-dimethyl-1H- benzo[d]imidazol-5-yl)-4- methoxy-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-N,N,3- trimethylbenzamide 411

4-(4-methoxy-5-(4- (methylsulfonyl)phenyl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N,N,3- trimethylbenzamide 412

4-(5-(2-fluoropyridin-4-yl)-4- methoxy-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- methoxy-N,N- dimethylbenzamide 413

4-(5-(2-fluoropyridin-4-yl)-4- methoxy-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- methoxy-N-methyl-N-(oxetan-3- yl)benzamide 414

4-methoxy-N-(4-methyl-1H- indazol-5-yl)-5-(pyridin-4-yl)- 7H-pyrrolo[2,3-d]pyrimidin-2- amine 415

5-(5-(2-fluoropyridin-4-yl)-4- methoxy-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-4- methoxy-N,N- dimethylpicolinamide 416

5-(2-fluoropyridin-4-yl)-4- methoxy-N-(4-methoxy-6- (tetrahydro-2H-pyran-4- yl)pyridin-3-yl)-7H-pyrrolo[2,3- d]pyrimidin-2-amine 417

4-(5-(3-chloro-1-methyl-1H- pyrazol-4-yl)-4-methoxy-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N-(oxetan- 3-yl)benzamide 418

4-(5-(2-fluoro-6-methylpyridin-4- yl)-4-methoxy-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- methoxy-N,N- dimethylbenzamide 419

N-(1,4-dimethyl-1H-indazol-5- yl)-4-methoxy-5-(pyridin-4-yl)- 7H-pyrrolo[2,3-d]pyrimidin-2- amine 420

4-(5-(2-fluoro-6-methylpyridin-4- yl)-4-methoxy-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-N,N,3- trimethylbenzamide 421

3-chloro-N-methyl-4-(5-(4- (methylcarbamoyl)phenyl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 422

3-chloro-4-(4-(cyclopentyloxy)-5- (2-methylbenzo[d]oxazol-6-yl)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-methylbenzamide 423

3-chloro-N-methyl-4-(5-(1- methyl-1H-pyrazol-4-yl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 424

4-(5-(2-fluoro-6-methylpyridin-4- yl)-4-methoxy-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- methoxy-N-(oxetan-3- yl)benzamide 425

3-chloro-4-(4-(cyclopentyloxy)-5- (4-(methylcarbamoyl)phenyl)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-methylbenzamide 426

3-chloro-4-(4-isopropoxy-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-methylbenzamide 427

3-chloro-4-(4-methoxy-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-methylbenzamide 428

3-chloro-4-(4-methoxy-5-(4- (methylcarbamoyl)phenyl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-methylbenzamide 429

3-chloro-4-(4-((1s,4s)-4-hydroxy- 4-methylcyclohexyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-methylbenzamide 430

3-chloro-N-methyl-4-(5-(2- methylbenzo[d]oxazol-6-yl)-4- (tetrahydro-2H-pyran-4-ylamino)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 431

3-chloro-N-(2-hydroxyethyl)-4- (5-(2-methylbenzo[d]oxazol-6- yl)-4-(tetrahydro-2H-pyran-4- yloxy)-7H-pyrrolo[2,3- d]pyrimidin-2- ylamino)benzamide 432

3-chloro-4-(4-isopropoxy-5-(4- (methylcarbamoyl)phenyl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-methylbenzamide 433

3-chloro-N-methyl-4-(5-(4- (methylcarbamoyl)phenyl)-4- (tetrahydro-2H-pyran-4-ylamino)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 434

(R)-3-chloro-N-methyl-4-(5-(4- (methylcarbamoyl)phenyl)-4- (tetrahydrofuran-3-yloxy)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 435

3-ethyl-N-methyl-4-(5-(2- methylbenzo[d]oxazol-6-yl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)benzamide 436

N-methyl-4-(5-(2- methylbenzo[d]oxazol-6-yl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-propylbenzamide 437

4-(5-(2-chloro-6-methylpyridin-4- yl)-4-methoxy-7H-pyrrolo[2,3- d]pyrimidin-2-ylamino)-3- methoxy-N-(oxetan-3- yl)benzamide 438

3-chloro-4-(5-(2- methylbenzo[d]oxazol-6-yl)-4- (tetrahydro-2H-pyran-4-yloxy)- 7H-pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-(oxetan-3- yl)benzamide

Methods for Making Pyrrolopyrimidine Compounds

The Pyrrolopyrimidine Compounds described herein can be obtained using conventional organic syntheses and commercially available starting materials.

Starting materials useful for preparing compounds of formula (I) and intermediates therefore, are commercially available or can be prepared from commercially available materials using known synthetic methods and reagents.

Particular methods for preparing compounds of formula (I) are disclosed in U.S. patent application Ser. No. 14/155,485, filed Jan. 15, 2014, and U.S. patent application Ser. No. 14/155,498, filed Jan. 15, 2014, each incorporated by reference herein in their entirety.

Methods of Use

The Pyrrolopyrimidine Compounds have utility as pharmaceuticals to treat, prevent or improve cancer in animals or humans. Accordingly, the Pyrrolopyrimidine Compounds provided herein can be used in all the methods as provided herein. Particularly, the Pyrrolopyrimidine Compounds provided herein can be used in the treatment, prevention or improvement of all diseases disorders, or conditions provided herein. Accordingly, provided herein are uses of the Pyrrolopyrimidine Compounds, including the treatment or prevention of those cancers set forth below. The methods provided herein comprise the administration of an effective amount of one or more Pyrrolopyrimidine Compound(s) to a subject in need thereof.

In another aspect, provided herein are methods for treating or preventing a cancer, comprising administering to a subject in need thereof an effective amount of a Pyrrolopyrimidine Compound, as described herein. In some embodiments, the cancer is a solid tumor or a hematological tumor. In some embodiments, the cancer is not triple negative breast cancer (TNBC).

In some embodiments, the solid tumor is bladder cancer (including superficial bladder cancer), breast cancer (including luminal B type, ER+, PR+ and Her2+ breast cancer), central nervous system cancer (including glioblastoma multiforme (GBM), glioma, medulloblastoma, and astrocytoma), colorectal cancer, gastrointestinal cancer (including stomach cancer, oesophagus cancer, and rectum cancer), endocrine cancer (including thyroid cancer, and adrenal gland cancer), eye cancer (including retinoblastoma), female genitourinary cancer (including cancer of the placenta, uterus, vulva, ovary, cervix), head and neck cancer (including cancer of the pharynx, oesophagus, and tongue), liver cancer, lung cancer (including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), mucoepidermoid, bronchogenic, squamous cell carcinoma (SQCC), and analplastic/NSCLC), skin cancer (including melanoma, and SQCC), soft tissue cancer (including sarcoma, Ewing's sarcoma, and rhabdomyosarcoma), bone cancer (including sarcoma, Ewing's sarcoma, and osteosarcoma), squamous cell cancer (including lung, esophageal, cervical, and head and neck cancer), pancreas cancer, kidney cancer (including renal Wilm's tumor and renal cell carcinoma), or prostate cancer. In some embodiments, the solid tumor is breast cancer, colon cancer, lung cancer or bladder cancer. In one such embodiment, the solid tumor is superficial bladder cancer. In another, the solid tumor is lung squamous cell carcinoma. In yet another embodiment, the solid tumor is luminal B type breast cancer.

In some embodiments, the hematological cancer is leukemia (including acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), acute T-cell leukemia, B cell precursor leukemia, acute promyelocytic leukemia (APML), plasma cell leukemia, myelomonoblastic/T-ALL, B myelomonocytic leukemia, erythroleukemia, and acute myeloid leukemia (AML)), lymphoma (including Hodgkin's lymphoma, non-Hodgkin's lymphoma (NHL), Burkitt's lymphoma (BL), B cell lymphoma, lymphoblastic lymphoma, follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and large cell immunoblastic lymphoma), or multiple myeloma.

In some embodiments, provided herein are methods for preventing cancer metastasis, comprising administering to a subject in need thereof an effective amount of a Pyrrolopyrimidine Compound, as described herein. In some embodiments, the cancer is a metastatic cancer, in particular, a metastatic solid tumor or metastatic hematologic cancer, wherein the solid tumor and hematologic cancer is as described herein. In other embodiments, provided herein are methods of preventing cancer metastasis, comprising administering to a subject in need thereof an effective amount of a Pyrrolopyrimidine Compound, as described herein. In yet another aspect, provided herein are methods of eradicating cancer stem cells in a subject, comprising administering to a subject in need thereof an effective amount of a Pyrrolopyrimidine Compound, as described herein. In other embodiments, provided herein are methods of inducing differentiation in cancer stem cells in a subject, comprising administering to a subject in need thereof an effective amount of a Pyrrolopyrimidine Compound, as described herein. In other embodiments, provided herein are methods of inducing cancer stem cell death in a subject, comprising administering to a subject in need thereof an effective amount of a Pyrrolopyrimidine Compound, as described herein. In some such embodiments, the cancer is a solid tumor, for example a CNS cancer (e.g. GBM) or breast cancer, or a hematological cancer, such as leukemia.

In another aspect, provided herein are methods for treating or preventing a cancer, in particular a solid tumor or a hematological tumor as described herein, comprising administering to a subject in need thereof an effective amount of a compound that inhibits TTK, CLK1, and CLK2 kinase activity, and optionally CAMKK2 kinase activity. In some embodiments, provided are methods for treating or preventing a cancer, in particular a solid tumor or a hematological tumor as described herein, comprising administering to a subject in need thereof an effective amount of a compound that inhibits TTK, CLK1, and CLK2 kinase activity. In some embodiments, the TTK, CLK1, and CLK2 kinase activity is inhibited in a cell. In some embodiments, the TTK, CLK1, and CLK2 kinase activity is inhibited in vivo. In some embodiments, the compound that inhibits TTK, CLK1, and CLK2 kinase activity is a Pyrrolopyrimidine Compound as described herein. In another aspect, provided herein are methods for treating or preventing a cancer associated with the pathways involving TTK, CLK1, and CLK2, and optionally CAMKK2, and mutants or isoforms thereof, comprising administering to a subject in need thereof an effective amount of a compound that inhibits TTK, CLK1, and CLK2 kinase activity, and optionally CAMKK2 kinase activity. In some embodiments, the cancer associated with the TTK, CLK1, and CLK2, and optionally CAMKK2, pathways include a solid tumor or a hematological tumor as described herein. In some embodiments, the TTK, CLK1, and CLK2, and optionally CAMKK2, pathway is inhibited in a cell. In some embodiments, the TTK, CLK1, and CLK2, and optionally CAMKK2, pathway is inhibited in vivo. In some embodiments, the compound that inhibits TTK, CLK1, and CLK2, and optionally CAMKK2, pathway is a Pyrrolopyrimidine Compound as described herein.

In certain embodiments, provided herein are methods for measuring inhibition of TTK, CLK1, and CLK2 kinase activity, and optionally CAMKK2 kinase activity, in a patient having a cancer, for example a solid tumor or a hematological tumor as described herein, comprising administering an effective amount of a Pyrrolopyrimidine Compound to said patient, measuring the amount of TTK, CLK1, and CLK2 kinase activity in said patient, and comparing said amount of TTK, CLK1, and CLK2 kinase activity to that of said patient prior to administration of an effective amount of a Pyrrolopyrimidine Compound. In certain embodiments, less TTK, CLK1, and CLK2 kinase activity, and optionally CAMKK2 kinase activity, in said biological sample obtained after administration of said Pyrrolopyrimidine Compound relative to the amount of TTK, CLK1, and CLK2 kinase activity, and optionally CAMKK2 kinase activity, in said biological sample obtained prior to administration of said Pyrrolopyrimidine Compound indicates inhibition.

In one embodiment, the kinase activity is measured using a radioactivity based kinase assay, which measures the incorporation of a radioactively labeled phosphate moiety (for example, ³³P labeled phosphate) into a substrate, for example, a peptide substrate. Reduced levels of radioactively labeled phosphate incorporation into the substrate indicates inhibition of kinase activity. In another embodiment, the kinase activity is measured using a time-resolved-fluorescence resonance energy transfer (TR-FRET) based kinase assay, which measures loss of fluorescence as a result of substrate phosphorylation, for example, a peptide substrate (see for example Invitrogen Z′-Lyte Assay®). Increased levels of fluorescence indicates inhibition of kinase activity. In another embodiment, the kinase activity is measured using a competitive tracer binding assay (for example, Invitrogen Lanthascreen® Eu binding assay), which measures fluorescence as a result of tracer binding (for example ATP site binding). Reduced fluorescence indicates displacement of tracer binding, which indicates inhibition of kinase activity. In yet another embodiment, the kinase activity is measured using a cellular biomarker assay, which measures the phosphorylation of a substrate, for example a downstream substrate, using Western Blot, ELISA or Mesoscale. Reduced phosphorylation of the substrate indicates inhibition of kinase activity.

In some embodiments, the inhibition of TTK, CLK1, and CLK2 kinase activity, and optionally CAMKK2 kinase activity, is assessed in a biological sample of the patient, such as in circulating blood cells, or tumor or skin biopsies. In such embodiments, the amount of inhibition of kinase activity is assessed by comparison of the amount of phosphorylated substrate (for example for TTK: phospho-TTK, such as p-TTK T686, or phosphorylated borealin, BubR1, Chk2, c-Abl, p53, Mip1 or TACC2; and for CLK2 (phospho-SRp75, or phosphorylated PP2A regulatory subunit B56β (PPP2R5B, B′β) or PGC-1α) before and after administration of the Pyrrolopyrimidine Compound to the patient. In some such embodiments, less phosphorylated TTK substrate and less phosphorylated CLK2 substrate, in said biological sample, obtained after administration of said Pyrrolopyrimidine Compound relative to the amount of phosphorylated TTK substrate and phosphorylated CLK2 substrate, in said biological sample obtained prior to administration of said Pyrrolopyrimidine Compound indicates inhibition. In some such embodiments, less phospho-TTK (for example p-TTK T686) and phospho-SRp75, in said biological sample obtained after administration of said Pyrrolopyrimidine Compound relative to the amount of phospho-TTK (for example p-TTK T686) and phospho-SRp75, in said biological sample obtained prior to administration of said Pyrrolopyrimidine Compound indicates inhibition.

In certain embodiments, provided herein are methods for inhibiting TTK, CLK1, and CLK2 kinase activity, and optionally CAMKK2 kinase activity, in a patient having a cancer, in particular a solid tumor or a hematological tumor as described herein, comprising administering an effective amount of a Pyrrolopyrimidine Compound to said patient. In some embodiments, the methods additionally comprise comparing the amount of TTK, CLK1, and CLK2 kinase activity, and optionally CAMKK2 activity, in a biological sample of a patient obtained prior to and after administration of said Pyrrolopyrimidine Compound, wherein less TTK, CLK1, and CLK2 kinase activity, and optionally CAMKK2 kinase activity, in said biological sample obtained after administration of said Pyrrolopyrimidine Compound relative to the amount of TTK, CLK1, and CLK2 kinase activity, and optionally CAMKK2 kinase activity, in said biological sample obtained prior to administration of said Pyrrolopyrimidine Compound indicates inhibition.

In some embodiments, the methods additionally comprise comparing the amount of phosphorylated substrate (for example for TTK: phospho-TTK, such as p-TTK T686, or phosphorylated borealin, BubR1, Chk2, c-Abl, p53, Mipl or TACC2; and for CLK2 (phospho-SRp75, or phosphorylated PP2A regulatory subunit B56β (PPP2R5B, B′β) or PGC-1α) in a biological sample of a patient obtained prior to and after administration of said Pyrrolopyrimidine Compound, wherein less phosphorylated substrate in said biological sample obtained after administration of said Pyrrolopyrimidine Compound relative to the amount of phosphorylated substrate in said biological sample obtained prior to administration of said Pyrrolopyrimidine Compound indicates inhibition. In other embodiments, the methods additionally comprise comparing the amount of phospho-TTK (for example p-TTK T686) and phospho-SRp75, in a biological sample of a patient obtained prior to and after administration of said Pyrrolopyrimidine Compound, wherein less phospho-TTK (for example p-TTK T686) and phospho-SRp75, in said biological sample obtained after administration of said Pyrrolopyrimidine Compound relative to the amount of phospho-TTK (for example p-TTK T686) and phospho-SRp75, in said biological sample obtained prior to administration of said Pyrrolopyrimidine Compound indicates inhibition.

In some embodiments, the TTK kinase activity is inhibited with an IC₅₀ no greater than about 20 nM. In another, the TTK kinase activity is inhibited with an IC₅₀ between about 0.01 nM and about 20 nM. In others, the TTK kinase activity is inhibited with an IC₅₀ between about 0.01 nM and about 100 nM. In still others, the TTK kinase activity is inhibited with an IC₅₀ between about 0.01 nM and about 200 nM. In yet others, the TTK kinase activity is inhibited with an IC₅₀ between about 0.1 nM and about 500 nM. In some embodiments, the CLK1 kinase activity is inhibited with an IC₅₀ no greater than about 300 nM. In some embodiments, the CLK1 kinase activity is inhibited with an IC₅₀ between about 1 nM and about 100 nM. In others, the CLK1 kinase activity is inhibited with an IC₅₀ between about 1 nM and about 500 nM. In yet others, the CLK1 kinase activity is inhibited with an IC₅₀ between about 1 nM and about 1000 nM. In some embodiments, the CLK2 kinase activity is inhibited with an IC₅₀ no greater than about 10 nM. In another, the CLK2 kinase activity is inhibited with an IC₅₀ between about 0.01 nM and about 20 nM. In others, the CLK2 kinase activity is inhibited with an IC₅₀ between about 0.01 nM and about 100 nM. In still others, the CLK2 kinase activity is inhibited with an IC₅₀ between about 0.01 nM and about 200 nM. In yet others, the CLK2 kinase activity is inhibited with an IC₅₀ between about 0.1 nM and about 500 nM. In some embodiments, the CAMKK2 kinase activity is inhibited with an IC₅₀ no greater than about 1000 nM. In another, the CAMKK2 kinase activity is inhibited with an IC₅₀ between about 1 nM and about 500 nM. In others, the CAMKK2 kinase activity is inhibited with an IC₅₀ between about 1 nM and about 1000 nM. In still others, the CAMKK2 kinase activity is inhibited with an IC₅₀ between about 1 nM and about 2000 nM. In yet others, the CAMKK2 kinase activity is inhibited with an IC₅₀ between about 1 nM and about 5000 nM.

In one embodiment, provided herein are methods for achieving a Response Evaluation Criteria in Solid Tumors (RECIST 1.1) of complete response, partial response or stable disease in a patient comprising administering an effective amount of a Pyrrolopyrimidine Compound to a patient having a cancer, in particular a solid tumor as described herein. In another embodiment, provided herein are methods to increase Progression Free Survival rates, as determined by Kaplan-Meier estimates.

In one embodiment, provided herein are methods for preventing or delaying a Response Evaluation Criteria in Solid Tumors (RECIST 1.1) of progressive disease in a patient, comprising administering an effective amount of a Pyrrolopyrimidine Compound to a patient having a solid tumor as described herein. In one embodiment the prevention or delaying of progressive disease is characterized or achieved by a change in overall size of the target lesions, of for example, between −30% and +20% compared to pre-treatment. In another embodiment, the change in size of the target lesions is a reduction in overall size of more than 30%, for example, more than 50% reduction in target lesion size compared to pre-treatment. In another, the prevention is characterized or achieved by a reduction in size or a delay in progression of non-target lesions compared to pre-treatment. In one embodiment, the prevention is achieved or characterized by a reduction in the number of target lesions compared to pre-treatment. In another, the prevention is achieved or characterized by a reduction in the number or quality of non-target lesions compared to pre-treatment. In one embodiment, the prevention is achieved or characterized by the absence or the disappearance of target lesions compared to pre-treatment. In another, the prevention is achieved or characterized by the absence or the disappearance of non-target lesions compared to pre-treatment. In another embodiment, the prevention is achieved or characterized by the prevention of new lesions compared to pre-treatment. In yet another embodiment, the prevention is achieved or characterized by the prevention of clinical signs or symptoms of disease progression compared to pre-treatment, such as cancer-related cachexia or increased pain.

In certain embodiments, provided herein are methods for decreasing the size of target lesions in a patient compared to pre-treatment, comprising administering an effective amount of a Pyrrolopyrimidine Compound to a patient having a cancer, in particular a solid tumor as described herein.

In certain embodiments, provided herein are methods for decreasing the size of a non-target lesion in a patient compared to pre-treatment, comprising administering an effective amount of a Pyrrolopyrimidine Compound to a patient having a cancer, in particular a solid tumor as described herein.

In certain embodiments, provided herein are methods for achieving a reduction in the number of target lesions in a patient compared to pre-treatment, comprising administering an effective amount of a Pyrrolopyrimidine Compound to a patient having a cancer, in particular a solid tumor as described herein.

In certain embodiments, provided herein are methods for achieving a reduction in the number of non-target lesions in a patient compared to pre-treatment, comprising administering an effective amount a Pyrrolopyrimidine Compound to a patient having a cancer, in particular a solid tumor as described herein.

In certain embodiments, provided herein are methods for achieving an absence of all target lesions in a patient, comprising administering an effective amount of a Pyrrolopyrimidine Compound to a patient having a cancer, in particular a solid tumor as described herein.

In certain embodiments, provided herein are methods for achieving an absence of all non-target lesions in a patient, comprising administering an effective amount of a Pyrrolopyrimidine Compound to a patient having a cancer, in particular a solid tumor as described herein.

In certain embodiments, provided herein are methods for treating a cancer, in particular a solid tumor as described herein, the methods comprising administering an effective amount of a Pyrrolopyrimidine Compound to a patient having a cancer, in particular a solid tumor, wherein the treatment results in a complete response, partial response or stable disease, as determined by Response Evaluation Criteria in Solid Tumors (RECIST 1.1).

In certain embodiments, provided herein are methods for treating a cancer, in particular a solid tumor as described herein, the methods comprising administering an effective amount of a Pyrrolopyrimidine Compound to a patient having a cancer, in particular a solid tumor as described herein, wherein the treatment results in a reduction in target lesion size, a reduction in non-target lesion size and/or the absence of new target and/or non-target lesions, compared to pre-treatment.

In certain embodiments, provided herein are methods for treating a cancer, in particular a solid tumor as described herein, the methods comprising administering an effective amount a Pyrrolopyrimidine Compound to a patient having a cancer, in particular a solid tumor as described herein, wherein the treatment results in prevention or retarding of clinical progression, such as cancer-related cachexia or increased pain.

In another embodiment, provided herein are methods for inducing a therapeutic response characterized with the International Workshop Criteria (IWC) for NHL (see Cheson B D, Pfistner B, Juweid, M E, et. al. Revised Response Criteria for Malignant Lymphoma. J. Clin. Oncol: 2007: (25) 579-586) of a patient, comprising administering an effective amount a Pyrrolopyrimidine Compound to a patient having a cancer, in particular hematological cancers such as lymphoma, as described herein. In another embodiment, provided herein are methods for achieving complete remission, partial remission or stable disease, as determined by the International Workshop Criteria (IWC) for NHL in a patient, comprising administering an effective amount of a Pyrrolopyrimidine Compound to a patient having a cancer, in particular hematological cancers such as lymphoma, as described herein. In another embodiment, provided herein are methods for achieving an increase in overall survival, progression-free survival, event-free survival, time to progression, disease-free survival or lymphoma-free survival as determined by the International Workshop Criteria (IWC) for NHL in a patient, comprising administering an effective amount of a Pyrrolopyrimidine Compound to a patient having a cancer, in particular hematological cancers such as lymphoma, as described herein.

In another embodiment, provided herein are methods for inducing a therapeutic response assessed with the International Uniform Response Criteria for Multiple Myeloma (IURC) (see Durie B G M, Harousseau J-L, Miguel J S, et al. International uniform response criteria for multiple myeloma. Leukemia, 2006; (10) 10: 1-7) of a patient, comprising administering an effective amount of a Pyrrolopyrimidine Compound to a patient having a cancer, in particular multiple myeloma. In another embodiment, provided herein are methods for achieving a stringent complete response, complete response, or very good partial response, as determined by the International Uniform Response Criteria for Multiple Myeloma (IURC) in a patient, comprising administering an effective amount of a Pyrrolopyrimidine Compound to a patient having a cancer, in particular multiple myeloma. In another embodiment, provided herein are methods for achieving an increase in overall survival, progression-free survival, event-free survival, time to progression, or disease-free survival in a patient, comprising administering an effective amount of a Pyrrolopyrimidine Compound to a patient having a cancer, in particular multiple myeloma.

In another embodiment, provided herein are methods for inducing a therapeutic response assessed with the Response Assessment for Neuro-Oncology (RANO) Working Group for GBM (see Wen P., Macdonald, D R., Reardon, D A., et al. Updated response assessment criteria for highgrade gliomas: Response assessment in neuro-oncology working group. J. Clin. Oncol. 2010; 28: 1963-1972) of a patient, comprising administering an effective amount of a Pyrrolopyrimidine Compound to a patient having a cancer, in particular glioblastoma multiforme (GBM). In one embodiment, RANO will be used to establish the proportion of subjects progression-free at 6 months from Day 1 relative to efficacy evaluable subjects in the GBM type.

In another embodiment, provided herein are methods for improving the Eastern Cooperative Oncology Group Performance Status (ECOG) of a patient, comprising administering an effective amount a Pyrrolopyrimidine Compound to a patient having a cancer, in particular a solid tumor or hematological cancer as described herein.

In another embodiment, provided herein are methods for inducing a therapeutic response assessed by Positron Emission Tomography (PET) outcome of a patient, comprising administering an effective amount of a Pyrrolopyrimidine Compound to a patient having a cancer, in particular a solid tumor or hematological cancer as described herein. In certain embodiments, provided herein are methods for treating a cancer, in particular a solid tumor or hematological cancer as described herein, the methods comprising administering an effective amount of a Pyrrolopyrimidine Compound to a patient having a cancer, in particular a solid tumor or hematological cancer as described herein, wherein the treatment results in a reduction in tumor metabolic activity, for example, as measured by PET imaging.

In some embodiments of the methods described herein, the Pyrrolopyrimidine Compound is a compound as described herein. In one embodiment, the Pyrrolopyrimidine Compound is a compound of formula (I). In another embodiment, the Pyrrolopyrimidine Compound is a compound from Table A. In one embodiment, the Pyrrolopyrimidine Compound is a Pyrrolopyrimidine Compound set forth herein having molecular formula C₂₆H₂₄N₆O₄. In another, the Pyrrolopyrimidine Compound is a Pyrrolopyrimidine Compound set forth herein having molecular formula C₂₆H₂₆N₆O₄. In yet another, the Pyrrolopyrimidine Compound is a Pyrrolopyrimidine Compound set forth herein having molecular formula C₂₆H₂₇N₅O₄. In yet another, the Pyrrolopyrimidine Compound is a Pyrrolopyrimidine Compound set forth herein having molecular formula C₂₈H₂₈N₆O₄. In still another, the Pyrrolopyrimidine Compound is a Pyrrolopyrimidine Compound set forth herein having molecular formula C₂₈H₃₀N₆O₄. In another embodiment, the Pyrrolopyrimidine Compound is a Pyrrolopyrimidine Compound set forth herein having molecular formula C₂₉H₃₀N₆O₅. In one embodiment, the Pyrrolopyrimidine Compound is 4-((4-(cyclopentyloxy)-5-(4-hydroxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-N-methylbenzamide (Compound 3). In another, the Pyrrolopyrimidine Compound is 4-((4-cyclopropoxy-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-N-methylbenzamide (Compound 152). In yet another, the Pyrolopyrimidine is 4-((4-isopropoxy-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-N-methylbenzamide (Compound 125). In still another, the Pyrolopyrimidine is 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-N-methylbenzamide (Compound 38). In another embodiment, the Pyrolopyrimidine is 4-((4-(cyclopentyloxy)-5-(4-(methylcarbamoyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-N-methylbenzamide (Compound 79). In yet another embodiment, the Pyrolopyrimidine is 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-N-(2-hydroxyethyl)-3-methoxybenzamide (Compound 101).

Further provided herein are methods for treating patients who have been previously treated for a cancer, in particular a solid tumor or a hematological cancer as described herein, as well as those who have not previously been treated. Because patients with a cancer have heterogenous clinical manifestations and varying clinical outcomes, the treatment given to a patient may vary, depending on his/her prognosis. The skilled clinician will be able to readily determine without undue experimentation specific secondary agents, types of surgery, and types of non-drug based standard therapy that can be effectively used to treat an individual patient with a cancer.

Pharmaceutical Compositions and Routes of Administration

The Pyrrolopyrimidine Compounds can be administered to a subject parenterally in the conventional form of preparations, such as injections, suspensions, solutions and emulsions. Suitable vehicles that can be used to provide intravenous formulations of a Pyrrolopyrimidine Compound are well known to those skilled in the art. Examples include, but are not limited to: Water for Injection USP; aqueous vehicles such as, but not limited to, Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, and Lactated Ringer's Injection; water-miscible vehicles such as, but not limited to, ethyl alcohol, polyethylene glycol, and polypropylene glycol; and non-aqueous vehicles such as, but not limited to, corn oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate. An intravenous formulation can be prepared by reconstituting a Pyrrolopyrimidine Compound with such a suitable liquid vehicle. A desired concentration of the intravenous formulation can be obtained by reconstituting an appropriate amount of a Pyrrolopyrimidine Compound with an appropriate volume of liquid vehicle. A desired concentration of the intravenous formulation provides a therapeutically effective amount of a Pyrrolopyrimidine Compound to the patient in need of the intravenous formulation and maintains a therapeutically effective level of a Pyrrolopyrimidine Compound in the patient. The dose which is therapeutically effective will depend on the rate at which the intravenous formulation is delivered to the patient and the concentration of the intravenous formulation.

The effective amount of the Pyrrolopyrimidine Compound in the pharmaceutical composition may be at a level that will exercise the desired effect; for example, about 0.005 mg/kg of a subject's body weight to about 100 mg/kg of a subject's body weight in unit dosage for parenteral administration.

The dose of a Pyrrolopyrimidine Compound to be administered to a subject is rather widely variable and can be subject to the judgment of a health-care practitioner. In general, the Pyrrolopyrimidine Compounds can be administered one to seven times a week, once every two weeks, once every three weeks or once every four weeks in a dose of about 0.005 mg/kg of a subject's body weight to about 10 mg/kg of a subject's body weight in a subject, but the above dosage may be properly varied depending on the age, body weight and medical condition of the subject and the type of administration. In one embodiment, the dose is about 0.01 mg/kg of a subject's body weight to about 5 mg/kg of a subject's body weight, about 0.05 mg/kg of a subject's body weight to about 1 mg/kg of a subject's body weight, about 0.1 mg/kg of a subject's body weight to about 0.75 mg/kg of a subject's body weight or about 0.25 mg/kg of a subject's body weight to about 0.5 mg/kg of a subject's body weight. In one embodiment, one dose is given per week. In others, one dose is given two, three or four times per week. In still others, one dose is given per two weeks, per three weeks or per four weeks. In any given case, the amount of the Pyrrolopyrimidine Compound administered will depend on such factors as the solubility of the active component, the formulation used and the route of administration.

In another embodiment, provided herein are methods for the treatment or prevention of a disease or disorder comprising the administration of about 0.375 mg/dose to about 750 mg/dose, about 0.75 mg/dose to about 375 mg/dose, about 3.75 mg/dose to about 75 mg/dose, about 7.5 mg/dose to about 55 mg/dose or about 18 mg/dose to about 37 mg/dose of a Pyrrolopyrimidine Compound to a subject in need thereof.

In another embodiment, provided herein are methods for the treatment or prevention of a disease or disorder comprising the administration of about 1 mg/dose to about 1200 mg/dose, about 10 mg/dose to about 1200 mg/dose, about 100 mg/dose to about 1200 mg/dose, about 400 mg/dose to about 1200 mg/dose, about 600 mg/dose to about 1200 mg/dose, about 400 mg/dose to about 800 mg/dose or about 600 mg/dose to about 800 mg/dose of a Pyrrolopyrimidine Compound to a subject in need thereof. In a particular embodiment, the methods disclosed herein comprise the administration of 400 mg/dose, 600 mg/dose or 800 mg/dose of a Pyrrolopyrimidine Compound to a subject in need thereof.

In another embodiment, provided herein are unit dosage formulations that comprise between about 1 mg and 200 mg, about 35 mg and about 1400 mg, about 125 mg and about 1000 mg, about 250 mg and about 1000 mg, or about 500 mg and about 1000 mg of a Pyrrolopyrimidine Compound.

In a particular embodiment, provided herein are unit dosage formulations comprising about 100 mg or 400 mg of a Pyrrolopyrimidine Compound.

In another embodiment, provided herein are unit dosage formulations that comprise 1 mg, 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 35 mg, 50 mg, 70 mg, 100 mg, 125 mg, 140 mg, 175 mg, 200 mg, 250 mg, 280 mg, 350 mg, 500 mg, 560 mg, 700 mg, 750 mg, 1000 mg or 1400 mg of a Pyrrolopyrimidine Compound.

A Pyrrolopyrimidine Compound can be administered once, twice, three, four or more times daily. In a particular embodiment, doses of 600 mg or less are administered as a once daily dose and doses of more than 600 mg are administered twice daily in an amount equal to one half of the total daily dose.

In another embodiment, provided herein are compositions comprising an effective amount of a Pyrrolopyrimidine Compound and a pharmaceutically acceptable carrier or vehicle, wherein a pharmaceutically acceptable carrier or vehicle can comprise an excipient, diluent, or a mixture thereof. In one embodiment, the composition is a pharmaceutical composition.

The compositions can be in the form of solutions, parenteral solutions, and suspensions and the like. Compositions can be formulated to contain a single dose, or a convenient fraction of a single dose, in a dosage unit, which may be a single vial or convenient volume of a liquid. In one embodiment, the solutions are prepared from water-soluble salts, such as the hydrochloride salt. In general, all of the compositions are prepared according to known methods in pharmaceutical chemistry.

The effect of the Pyrrolopyrimidine Compound can be delayed or prolonged by proper formulation. The parenteral preparations can be made long-acting, by dissolving or suspending the Pyrrolopyrimidine Compound in oily or emulsified vehicles that allow it to disperse slowly in the serum.

Examples

The following Examples are presented by way of illustration, not limitation.

Enzyme Assays

CLK1 Kinase Assay.

A fluorescence resonance energy transfer-based Z′-LYTE® kinase assay kit-Ser/Thr 09 (Invitrogen, Carlsbad, Calif., cat.# PV3324) was used to determine the IC₅₀ values for inhibition of CLK1 kinase activity. The reactions were performed in a 384-well plate with a 10 μl reaction volume per well containing CLK1 enzyme (16.2-128 ng), 25 μM adenosine triphosphate (ATP), 2 μM Z′-Lyte® Ser/Thr 9 peptide substrate in 50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH 7.5, 0.01% Brij-35, 10 mM magnesium chloride (MgCl₂), 1 mM ethylene glycol tetraacetic acid (EGTA) buffer with a serial 3-fold dilution of the test compounds. After a 1 hour incubation, 5 μL of Development Reagent A (1:256 dilution) was added, and the fluorescence ratio was calculated. The dose-response curves were fitted to a sigmoidal dose-response model using XLfit from IDBS. The IC₅₀ values were determined as the concentration of compound resulting in 50% of remaining enzyme activity. Results for certain Pyrrolopyrimidine Compounds are shown in Tables B and C.

CLK2 Kinase Assay.

A fluorescence resonance energy transfer-based Z′-LYTE kinase assay kit-Ser/Thr 6 peptide (Invitrogen, Carlsbad, Calif., cat.# PV3179) was used to determine the IC₅₀ values for inhibition of CLK2 kinase activity. The reactions were performed in a 384-well plate with a 10 μl reaction volume per well containing CLK2 enzyme (ranging from 0.97-11.5 ng), 25 μM ATP, 2 μM Z′-Lyte® Ser/Thr 6 peptide substrate in 50 mM HEPES, pH 7.5, 0.01% Brij-35, 10 mM MgCl₂, 1 mM EGTA buffer with a serial 3-fold dilution of the test compounds. After a 1 hour incubation, 5 μL of Development Reagent A (1:2048 dilution) was added, and the fluorescence ratio was calculated. A dose-response curves were fitted to a sigmoidal dose-response model using XLfit from IDBS. The IC₅₀ values were determined as the concentration of compound resulting in 50% of remaining enzyme activity. Results for certain Pyrrolopyrimidine Compounds are shown in Tables B and C.

TTK Kinase Assay.

The LanthaScreen® Eu Kinase Binding Assay (Invitrogen, Carlsbad, Calif. cat.#) was used to determine the IC₅₀ values for inhibition of TTK kinase activity. The reaction was performed in a 384-well plate with a 16 μL reaction volume per well containing 5 nM TTK enzyme, 30 nM of Tracer 236 (Invitrogen PV5592), and 2 nM LanthaScreen® Eu-anti-GST antibody in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl₂, 1 mM EGTA buffer with a serial 3-fold dilution of test compound. The reaction was incubated for 1 hour at room temperature and then read on a fluoresence plate reader (Excitation 340 nm, Kinase Tracer 236 Emission: 665 nm, LanthaScreen™ Eu-anti-Tag Antibody: Emission 615 nm). The TR-FRET ratio was calculated as the intensity of the acceptor signal (665 nm) divided by the intensity of the donor signal (615 nm). The dose-response curves were fitted to a sigmoidal dose-response model using XLfit from IDBS. The IC₅₀ values were determined as the concentration of compound resulting in 50% of displaced Tracer 236 (ATP competive inhibitor). Results for certain Pyrrolopyrimidine Compounds are shown in Tables B and C.

CAMKK2 Kinase Assay.

The LanthaScreen® Eu Kinase Binding Assay (Invitrogen, Carlsbad, Calif.) was used to determine the IC₅₀ values for inhibition of CAMKK2 kinase activity. The reaction was performed in a 384-well plate with a 16 μL reaction volume per well containing 5 nM CAMKK2 enzyme, 10 nM of Kinase Tracer 236, and 2 nM LanthaScreen®Eu-anti-GST antibody in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA buffer with a serial 3-fold dilution of test compound. The reaction was incubated for 1 hour at room temperature and then read on a fluoresence plate reader (Excitation 340 nm, Kinase Tracer 236 Emission: 665 nm, and LanthaScreen™ Eu-anti-Tag Antibody: Emission 615 nm). The TR-FRET ratio was calculated as the intensity of the acceptor signal (665 nm) divided by the intensity of the donor signal (615 nm). The dose-response curves were fitted to a sigmoidal dose-response model using XLfit from IDBS. The IC₅₀ values were determined as the concentration of compound resulting in 50% of displaced Tracer 236 (ATP competive inhibitor).

Alternative CAMKK2 Kinase Assay.

CAMKK2 enzyme was mixed with 1 μM of Ca²⁺-Calmodulin and 10 μM of the Mylein Basic Protein (MBP) substrate in reaction buffer; 20 mM 4-(2-hydroxyethyl)-1-piperazineethane sulfonic acid (HEPES), 10 mM magnesium chloride (MgCl₂), 1 mM ethyleneglycoltetraacetic acid (EGTA), 0.02% Brij35, 0.02 mg/ml bovine serum albumin (BSA), 0.1 mM sodium orthovanadate, 2 mM dithiothreitol (DTT), 1% dimethyl sulfoxide (DMSO) at pH 7.5. Compounds were delivered into the reaction, followed 20 min later by addition of a mixture of ATP (Sigma) and ³³P ATP (PerkinElmer) to a final concentration of 10 μM. Reactions were carried out at 25° C. for 120 min, followed by spotting of the reactions onto P81 ion exchange filter paper (Whatman). Unbound phosphate was removed by extensive washing of filters in 0.75% phosphoric acid. After subtraction of background derived from control reactions containing inactive enzyme, kinase activity data were expressed as the percent remaining kinase activity in test samples compared to the DMSO vehicle reactions. IC₅₀ values and curve fits were obtained using Prism (GraphPad Software). Results for certain Pyrrolopyrimidine Compounds are shown in Tables C.

TABLE B Inhibition by Pyrrolopyrimidine Compounds of TTK, CLK1, and CLK2 kinase activity (% inhibition at 3 μM. Cmpd TTK CLK1 CLK2 No. (% Inh.) (% Inh.) (% Inh.) 3 91 104 11 95 94 16 92 90 17 97 98 38 99 98 58 96 103 64 68 99 79 97 97 89 101 100 90 101 101 98 103 104 101 95 98 118 102 98 98 132 92 98 133 104 101 134 101 100 139 104 99 140 97 103 145 96 97 146 103 100 148 99 106 150 99 111 152 99 100 157 95 105 160 98 108 162 100 106 163 100 102 169 100 105 171 97 102 184 101 98 185 98 106 191 100 99 192 102 101 103 193 100 99 197 100 103 198 93 100 201 100 103 202 99 99 203 98 99 204 98 99 205 99 103 206 92 97 207 99 99 213 99 100 214 97 100 216 99 99 237 93 100 296 101 104 300 100 100 304 53 101 307 99 103 334 95 104 339 100 63 98 340 105 100 99 349 95 101 102 371 100 100 377 99 100 384 102 57 88 392 99 106 99 421 99 101 422 94 99 423 99 100 426 98 101 101 429 101 96 101 435 100 100 101

TABLE C Inhibition by Pyrrolopyrimidine Compounds of TTK, CLK1, CLK2 and CAMKK2 kinase activity. Cmpd TTK CLK1 CLK2 CAMKK2 No. (IC₅₀, μM) (IC₅₀, μM) (IC₅₀, μM) (IC₅₀, μM) 3 1.435624 0.05389 11 0.298738 0.034896 16 0.225404 0.025999 17 0.082369 0.00433 38 0.014 0.267 0.008168 0.728 55 0.013312 67 0.016027 79 0.002379 0.058587 0.001911 0.034 89 <1.5e−003 0.041473 0.004557 90 0.001675 0.12394 0.003497 101 0.002128 0.099779 0.003377 0.501 118 0.005136 0.002294 132 0.004116 0.225986 0.029057 134 0.001678 0.130033 0.00227 145 0.002451 0.219809 0.040123 146 0.002121 152 0.00296 171 0.001471 0.082812 0.002317 191 0.003653 0.172406 0.009409 237 0.008062 0.237221 0.010372 300 0.004536 304 0.00235 334 0.001418 339 0.007004 0.526142 0.005915 349 0.001145 0.059278 0.001429 421 0.084639 0.002095 422 0.011578 0.504877 0.012494 423 0.001904 0.097765 0.003294

Conclusion.

Tables B and C show that Pyrrolopyrimidine Compounds, as described herein, inhibit the kinase activity of TTK, CLK1, and CLK2. In some embodiments, the Pyrrolopyrimidine Compounds also inhibit the kinase activity of CAMKK2.

Cell Assays

Breast Cancer Cell Line Growth Inhibition.

The 49 breast cancer cell lines used in the study are shown in Table 1. The luminal and basal subtype classification was based upon public information that was verified internally. The estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status of each cell line was based upon public information that was verified internally.

TABLE 1 Breast Cancer Cell Lines Cell Line Subtype1 Subtype2 Vendor Media AU565 Luminal Her2+ ATCC RPMI + 10% FBS BT-20 Basal TN ATCC DMEM + 10% FBS BT-474 Luminal Her2+ ATCC RPMI + 10% FBS BT-483 Luminal ER+/PR+ ATCC RPMI + 10% FBS BT-549 Basal TN ATCC RPMI + 10% FBS CAL-120 Basal TN DSMZ DMEM + 10% FBS CAL-148 Luminal TN DSMZ DMEM + 10% FBS CAL-51 Basal TN DSMZ DMEM + 10% FBS CAL-85-1 Basal TN DSMZ DMEM + 10% FBS CAMA-1 Luminal ER+/PR+ ATCC DMEM + 10% FBS DU4475 Basal TN ATCC RPMI + 10% FBS EFM-19 Luminal ER+/PR+ DSMZ RPMI + 10% FBS EFM-192A Luminal Her2+ DSMZ RPMI + 10% FBS EVSA-T Luminal ER+/PR+ DSMZ DMEM + 10% FBS HCC1143 Basal TN ATCC RPMI + 10% FBS HCC1187 Basal TN ATCC RPMI + 10% FBS HCC1419 Luminal Her2+ ATCC RPMI + 10% FBS HCC1428 Luminal ER+/PR+ ATCC RPMI + 10% FBS HCC1500 Luminal ER+/PR+ ATCC RPMI + 10% FBS HCC1569 Basal Her2+ ATCC RPMI + 10% FBS HCC1806 Basal TN ATCC RPMI + 10% FBS HCC1937 Basal TN ATCC RPMI + 10% FBS HCC1954 Basal Her2+ ATCC RPMI + 10% FBS HCC202 Luminal Her2+ ATCC RPMI + 10% FBS HCC38 Basal TN ATCC RPMI + 10% FBS HCC70 Basal TN ATCC RPMI + 10% FBS HCC2157 Basal TN ATCC RPMI + 10% FBS HDQ-P1 Basal TN DSMZ DMEM + 10% FBS HS578T Basal TN ATCC RPMI + 10% FBS JIMT-1 Basal Her2+ DSMZ DMEM + 10% FBS KPL-1 Luminal ER+/PR+ DSMZ DMEM + 10% FBS MB157 Basal TN ATCC DMEM + 10% FBS MCF7 Luminal ER+/PR+ NCI RPMI + 10% FBS MCF10A Basal TN ATCC RPMI + 10% FBS MCF12A Basal TN ATCC DMEM + 10% FBS MDA-MB- Luminal ER+/PR+ ATCC DMEM + 10% FBS 134-VI MDA-MB- Basal TN ATCC DMEM + 10% FBS 157 MDA-MB- Luminal ER+/PR+ ATCC RPMI + 10% FBS 175-VII MDA-MB- Basal TN ATCC RPMI + 10% FBS 231 MDA-MB- Luminal Her2+ ATCC DMEM + 10% FBS 361 MDA-MB- Luminal ER+/PR+ ATCC DMEM + 10% FBS 415 MDA-MB- Basal TN ATCC DMEM + 10% FBS 436 MDA-MB- Luminal Her2+ ATCC DMEM + 10% FBS 453 MDA-MB- Basal TN ATCC DMEM + 10% FBS 468 MFM-223 Luminal ER+/PR+ DSMZ DMEM + 10% FBS MT-3 Basal TN DSMZ RPMI + 10% FBS SK-BR-3 Luminal Her2+ ATCC RPMI + 10% FBS T47D Luminal ER+/PR+ ATCC RPMI + 10% FBS UACC-812 Luminal Her2+ ATCC DMEM + 10% FBS UACC-893 Luminal Her2+ ATCC DMEM + 10% FBS ZR-75-1 Luminal ER+/PR+ ATCC RPMI + 10% FBS ZR-75-30 Luminal Her2+ ATCC RPMI + 10% FBS ATCC = American Type Culture Collection; DMEM = Dulbecco's Modified Eagle's Medium; DSMZ = Deutsche Sammlung von. Mikroorganismen und Zellkulturen; ER = estrogen receptor; FBS = fetal bovine serum; HER2 = human epidermal growth factor receptor 2; NCI = National Cancer Institute; PR = progesterone receptor; TN = triple negative breast cancer: ER−, PR−, and HER2−.

Experimental Procedures.

All breast cancer cell lines were maintained and tested in the culture media indicated in Table 1. The seeding density for each cell line was optimized to ensure assay linearity in 384-well plates. Increasing concentrations of compound were spotted via an acoustic dispenser (EDC ATS-100) into an empty 384-well plate. Compound was spotted in a 10-point serial dilution fashion (3-fold dilution) in duplicate within the plate. The dimethyl sulfoxide (DMSO) concentration was kept constant for a final assay concentration of 0.1% DMSO. Plates were replicated for use against different cell lines and testing periods. After compound plate replication, all plates were sealed (Agilent ThermoLoc) and stored at −20° C. for up to 1 month. When ready for testing, plates were removed from the freezer, thawed, and unsealed just prior to the addition of the test cell. Prior to testing, cells were grown and expanded in culture flasks to provide sufficient amounts of starting material. Cells were then diluted to their desired densities and added directly to the compound-spotted 384-well plates. Cells were allowed to grow for 96 hours at 37° C./5% CO₂. At the time of setup (t₀), initial cell number was assessed via a viability assay (Cell Titer-Glo) and read for luminescence. After 96 hours, viability of compound-treated cells was assessed via Cell Titer-Glo and read for luminescence.

Cell lines were assayed for growth inhibition by the Pyrrolopyrimidine Compounds for at least two independent tests. To ensure a comparable compound response throughout the assay period to complete all 49 cell lines, a control cell line (A549) was included in each of the assays. All data was normalized and represented as a percentage of the DMSO-treated control cells. Results were then expressed as an IC₅₀ (Table 2). In addition, GI₅₀ was calculated (Table 3).

All statistical analyses were implemented using R software (R Development Core Team, 2009).

Determination of Inhibitory Concentration and Growth Inhibition (IC₅₀ and GI₅₀).

IC₅₀ is the concentration of the compound when Y=50% of DMSO control. GI₅₀ is the concentration of the compound when Y═(YMax+Yt₀)/2. All growth inhibition curves were processed and evaluated using Activity Base XE (IDBS).

TABLE 2 Growth Inhibition IC₅₀ (μM) Cmpd Cmpd Cmpd Cmpd Cmpd Cmpd Cell Line 79 101 125 38 152 3 AU565 0.019 0.213 0.021 0.038 0.047 1.099 BT-20 0.053 0.897 0.044 0.049 0.094 0.608 BT-474 0.358 10.000 0.595 10.000 5.423 16.345 BT-483 10.000 10.000 3.402 10.000 10.000 10.000 BT-549 0.013 0.292 0.066 0.051 0.079 0.180 CAL-120 0.592 10.000 0.272 10.000 4.638 10.000 CAL-148 0.003 0.074 0.168 0.065 0.069 CAL-51 0.001 0.069 0.010 0.010 0.018 0.009 CAL-85-1 0.029 0.423 0.093 0.052 0.087 0.076 CAMA-1 10.000 10.000 0.763 10.000 10.000 10.706 DU4475 0.087 0.248 0.246 2.253 0.244 0.560 EFM-19 0.083 0.263 0.181 0.196 0.221 0.730 EFM-192A 2.085 10.000 1.279 10.000 5.042 10.000 EVSA-T 0.311 9.438 0.206 10.000 1.720 HCC1143 0.308 0.685 0.481 0.579 0.711 17.483 HCC1187 0.002 0.119 0.031 0.042 0.066 0.881 HCC1419 10.000 10.000 2.511 10.000 10.000 HCC1428 0.523 8.149 0.472 10.000 0.945 4.967 HCC1500 10.000 10.000 2.279 10.000 10.000 13.857 HCC1569 0.170 0.327 0.408 0.288 1.037 5.434 HCC1806 0.001 0.062 0.011 0.009 0.022 HCC1937 0.695 10.000 0.311 10.000 5.646 10.000 HCC1954 0.016 0.258 0.068 0.039 0.102 0.482 HCC202 0.216 2.104 0.190 3.072 0.462 15.961 HCC2157 0.120 HCC38 0.001 0.052 0.012 0.011 0.021 0.047 HCC70 0.047 6.705 0.268 1.300 1.023 1.950 HDQ-P1 0.128 1.775 0.083 0.326 0.204 HS578T 0.012 0.221 0.041 0.052 0.059 0.183 JIMT-1 5.336 9.074 0.165 0.111 0.215 KPL-1 0.429 6.464 0.064 5.202 0.318 0.693 MB157 0.351 9.404 0.419 10.000 5.318 MCF10A 17.449 MCF12A 3.151 MCF7 0.002 0.079 0.012 0.012 0.025 0.170 MDA-MB- 10.000 10.000 3.168 10.000 10.000 1.386 134-VI MDA-MB- 1.636 10.000 0.631 6.290 10.000 0.695 157 MDA-MB- 10.000 10.000 2.843 10.000 10.000 8.497 175-VII MDA-MB- 0.004 0.135 0.031 0.024 0.054 0.038 231 MDA-MB- 2.830 10.000 1.472 10.000 10.000 18.751 361 MDA-MB- 10.000 10.000 5.512 10.000 10.000 13.454 415 MDA-MB- 1.108 4.194 0.510 7.821 0.718 2.100 436 MDA-MB- 0.316 10.000 0.668 10.000 0.443 2.788 453 MDA-MB- 0.001 0.096 0.024 0.027 0.057 0.032 468 MFM-223 0.355 0.984 0.172 1.879 0.429 MT-3 10.000 10.000 8.500 10.000 10.000 SK-BR-3 0.323 0.570 0.272 0.578 0.417 3.688 T47D 0.419 10.000 0.336 1.651 0.715 0.418 UACC-812 4.375 8.030 0.296 10.000 0.888 1.794 UACC-893 10.000 10.000 0.787 10.000 1.833 ZR-75-1 10.000 10.000 3.314 10.000 10.000 6.386 ZR-75-30 1.268 3.413 0.715 10.000 1.576 30.000

TABLE 3 Growth inhibition GI₅₀ (μM) Cmpd Cmpd Cmpd Cmpd Cmpd Cmpd Cell Line 79 101 125 38 152 3 AU565 0.005 0.100 0.016 0.011 0.024 0.426 BT-20 0.019 0.553 0.028 0.028 0.057 0.289 BT-474 0.106 7.373 10.000  0.202 0.645 6.016 BT-483 n/a n/a n/a n/a n/a 0.704 BT-549 0.006 0.166 0.034 0.043 0.055 0.085 CAL-120 0.521 10.000  10.000  0.245 3.462 10.000 CAL-148 0.002 0.048 0.047 0.060 0.052 CAL-51 0.001 0.059 0.009 0.009 0.016 0.008 CAL-85-1 0.014 0.218 0.029 0.061 0.055 0.025 CAMA-1 1.066 0.628 0.590 0.261 0.308 4.895 DU4475 0.004 0.046 0.038 0.058 0.059 0.082 EFM-19 0.006 0.051 0.035 0.047 0.065 0.067 EFM-192A 0.309 0.451 0.294 0.424 0.411 10.000 EVSA-T 0.121 6.665 6.000 0.130 0.557 HCC1143 0.093 0.325 0.215 0.275 0.374 0.286 HCC1187 0.002 0.083 0.027 0.021 0.044 0.470 HCC1419 1.684 6.162 10.000  1.008 1.491 HCC1428 0.215 0.516 0.326 0.206 0.288 1.086 HCC1500 0.058 0.090 0.103 0.112 0.103 0.053 HCC1569 0.036 0.116 0.088 0.140 0.102 0.073 HCC1806 0.001 0.057 0.008 0.010 0.020 HCC1937 0.245 8.128 6.376 0.161 0.426 7.460 HCC1954 0.007 0.159 0.027 0.041 0.061 0.131 HCC202 0.009 0.052 0.028 0.018 0.044 15.026 HCC2157 0.024 HCC38 0.001 0.040 0.009 0.010 0.017 0.017 HCC70 0.005 0.128 0.047 0.080 0.086 0.442 HDQ-P1 0.037 0.890 0.106 0.046 0.108 HS578T 0.010 0.203 0.047 0.038 0.055 0.104 JIMT-1 2.098 2.498 0.061 0.116 0.154 KPL-1 0.136 2.884 0.126 0.034 0.108 0.245 MCF10A 0.426 MCF12A 0.486 MB157 0.026 0.425 0.116 0.067 0.123 MCF7 0.001 0.070 0.011 0.010 0.021 0.124 MDA-MB- n/a n/a n/a n/a n/a 0.874 134-VI MDA-MB- 0.018 5.117 0.114 0.176 0.110 0.225 157 MDA-MB- 0.700 0.534 5.285 0.523 1.087 0.400 175-VII MDA-MB- 0.003 0.104 0.019 0.022 0.041 0.022 231 MDA-MB- 0.043 0.110 0.091 0.231 0.143 5.481 361 MDA-MB- 10.000  9.995 10.000  0.441 10.000  11.707 415 MDA-MB- 0.433 1.020 0.999 0.289 0.327 1.382 436 MDA-MB- 0.212 5.387 10.000  0.475 0.390 0.799 453 MDA-MB- 0.001 0.083 0.023 0.020 0.049 0.027 468 MFM-223 0.009 0.050 0.043 0.035 0.058 MT-3 1.093 1.117 5.757 1.659 10.000  SK-BR-3 0.051 0.102 0.081 0.082 0.124 1.181 T47D 0.040 0.386 0.081 0.106 0.140 0.162 UACC-812 0.369 0.748 0.319 0.110 0.201 0.842 UACC-893 n/a n/a n/a n/a n/a ZR-75-1 0.002 0.039 0.032 0.050 0.062 1.136 ZR-75-30 n/a n/a n/a n/a n/a 11.619 n/a: not applicable

Conclusions.

As can be seen from Tables 2 and 3, Pyrrolopyrimidine Compounds inhibited breast cancer cell line growth, as measured by IC₅₀ and GI₅₀. Cell proliferation inhibition was shown in TNBC, as well as ER+/PR+ and Her2+, to variying degrees.

Non-Small Cell Lung Cancer Cell Line Growth Inhibition.

Sixteen non small cell lung cancer (NSCLC) cell lines were purchased from the American Tissue Culture Collection and maintained in growth media consisting of 90% RPMI1640 (Invitrogen) and 10% fetal bovine serum (Hyclone). All cells were cultured at 37° C. in 95% air and 5% CO₂. Cells were plated at optimal density for each cell line (see Table 5) per well in a 96-well plate in 100 μL of growth media. After overnight culture, compound stock solutions (30 mM) were diluted serially in DMSO, further diluted in growth media, and was added to each well as a 10× concentrated solution in a volume of 11 μL, mixed, and allowed to incubate with cells. The compound vehicle (DMSO) was maintained at a final concentration of 0.2% in all wells. After 72 hrs, 100 μL of Cell Titer Glo solution (Promega) were added to each well of the 96-well plate. The plate was placed on a shaker for 2 minutes. After 10 minutes incubation, luminescence signal was detected with Envision microplate reader (Perkin Elmer). The IC₅₀ values were calculated as the concentration of compound at which the level of luminescence signal was reduced to 50% of the signal window. Table 4 shows the results for Compound 3. Compounds show or will show an IC₅₀ value ranging from 0.01-30 μM in this assay.

TABLE 4 Growth Inhibition IC₅₀ Values and Growth Conditions Plating Average Cell Line Density IC₅₀ (μM) SD H1734 16000 0.91 0.59 H1838 12000 16.11 19.65 H2228 20000 1.58 0.41 H441 16000 2.10 0.32 H1437 12000 0.39 0.33 Hop62 2800 0.05 N/A H1650 8000 0.62 0.02 HOP92 6000 1.27 0.62 H520 32000 1.45 0.18 H1299 2800 0.36 0.34 H2291 16000 16.29 19.39 H1563 6000 1.77 0.09 SK-LU-1 5000 0.83 0.10 SW1573 5000 0.96 0.23 A549 2500 0.05 0.04 H460 1500 0.04 0.01

Conclusion.

Pyrrolopyrimidine Compounds demonstrated potent growth inhibition over a panel of non small cell lung cancer cell (NSCLC) lines profiled, as shown in Table 4. The majority of NSCLC lines (14 out of 16) are sensitive to growth inhibition by Pyrrolopyrimidine Compounds (for example, Compound 3) with a IC₅₀ values ≦2 μM.

Multiplexed Cytotoxicity Assay.

Cells were grown in RPMI1640, 10% FBS, 2 mM L-alanyl-L-Glutamine, 1 mM Na pyruvate or a special medium in a humidified atmosphere of 5% CO₂ at 37° C. Cells were seeded into 384-well plates and incubated in a humidified atmosphere of 5% CO₂ at 37° C. Compounds were added 24 hours post cell seeding. At the same time, a time zero untreated cell plate was generated. After a 72 hour incubation period, cells were fixed and stained with fluorescently labeled antibodies and nuclear dye to allow visualization of nuclei, apoptotic cells and mitotic cells. Apoptotic cells were detected using an anti-active caspase-3 antibody. Mitotic cells were detected using an anti phospho-histone-3 antibody. Compounds were serially diluted 3.16-fold and assayed over 10 concentrations in a final assay concentration of 0.1% DMSO from the highest test concentration of 10 μM. Automated fluorescence microscopy was carried out using a GE Healthcare IN Cell Analyzer 1000, and images were collected with a 4× objective.

Data Analysis.

Twelve bit tiff images were acquired using the InCell Analyzer 1000 3.2 and analyzed with Developer Toolbox 1.6 software. Cell proliferation was measured by the signal intensity of the incorporated nuclear dye. Results for Compound 38 are shown in Table 6. The cell proliferation assay output is referred to as the relative cell count. To determine the cell proliferation end point, the cell proliferation data output is transformed to percentage of control (POC) using the following formula:

POC=relative cell count (compound wells)/relative cell count (vehicle wells)×100

Relative cell count IC₅₀ is the test compound concentration at 50% of maximal possible response relative to the DMSO control. GI₅₀ is the concentration needed to reduce the observed growth by half. This is the concentration that inhibits the growth to the level midway between growth in untreated cells and the number of cells seeded in the well (Time zero value). The IC₅₀ values were calculated using nonlinear regression to fit data to a sigmoidal 4 point, 4 parameter One-Site dose response model, where:

y(fit)=A+[(B−A)/(1+((C/x)̂D))].

The activated caspase-3 marker labels cells from early to late stage apoptosis. The output is shown as a fold increase of apoptotic cells over vehicle background normalized to the relative cell count in each well. Concentrations of test compound that cause a 5-fold induction in the caspase-3 signal (Cal_X5) indicate significant apoptosis induction. The maximal induction of caspase 3 by compound in comparison with DMSO control is reported as Max_Fold_Change.

TABLE 5 Cell lines Cell line Tumor Type Subtype Classification 5637 Bladder 639-V Bladder 647-V Bladder BFTC-905 Bladder HT1197 Bladder HT1376 Bladder J82 Bladder SCaBER Bladder T24 Bladder TCCSUP Bladder UM-UC-3 Bladder AU565 Breast Luminal Luminal BT-20 Breast Basal Basal BT-474 Breast Luminal Luminal BT-549 Breast Basal Basal CAMA-1 Breast Luminal Luminal EFM-19 Breast Luminal Luminal HS578T Breast Basal Basal KPL-1 Breast Luminal Luminal MCF7 Breast Luminal Luminal MDA-MB-231 Breast Basal Basal MDA-MB-436 Breast Basal Basal MDA-MB-453 Breast Luminal Luminal MDA-MB-468 Breast Basal Basal MT-3 Breast Basal Basal SK-BR-3 Breast Luminal Luminal T47D Breast Luminal Luminal A172 CNS Glioblastoma Glioblastoma BE(2)C CNS CCF-STTG1 CNS Astrocytoma Astrocytoma CHP-212 CNS D-283MED CNS Daoy CNS Medulloblastoma Medulloblastoma DBTRG-05MG CNS Glioblastoma Glioblastoma DK-MG CNS Glioblastoma Glioblastoma H4 CNS Neuroglioma Neuroglioma MC-IXC CNS SK-N-AS CNS SK-N-DZ CNS SK-N-FI CNS SNB-19 CNS Glioblastoma Glioblastoma SW1088 CNS Astrocytoma Astrocytoma SW1783 CNS Astrocytoma Astrocytoma T98G CNS Glioblastoma Glioblastoma U-138MG CNS Glioblastoma Glioblastoma U-87-MG CNS Astrocytoma Astrocytoma COLO- Colon Large Intestine 201 COLO- Colon Large Intestine 205 COLO- Colon Large Intestine 320DM COLO- Colon Large Intestine 320-HSR DLD-1 Colon Large Intestine HCT-116 Colon Large Intestine HCT-15 Colon Large Intestine HCT-8 Colon Large Intestine HT29 Colon Large Intestine LS-1034 Colon Large Intestine LS-174T Colon Large Intestine NCI-H508 Colon Large Intestine NCI-H747 Colon Large Intestine RKO Colon Large Intestine RKO- Colon Large Intestine AS45-1 RKO-E6 Colon Large Intestine SW1417 Colon Large Intestine SW403 Colon Large Intestine SW48 Colon Large Intestine SW480 Colon Large Intestine SW620 Colon Large Intestine SW837 Colon Large Intestine SW948 Colon Large Intestine WiDr Colon Large Intestine AGS Colon/GI Stomach HS746T Colon/GI Stomach KATOIII Colon/GI Stomach OE19 Colon/GI Oesophagus SNU-1 Colon/GI Stomach SNU-16 Colon/GI Stomach SNU-5 Colon/GI Stomach SW1463 Colon Rectum BHT-101 Endocrine Thyroid CAL-62 Endocrine Thyroid CGTH-W-1 Endocrine Thyroid NCI-H295 Endocrine Adrenal cortex SW13 Endocrine Adrenal gland SW579 Endocrine Thyroid Y79 Eye Retinoblastoma AN3 CA Female GU Uterus BeWo Female GU Placenta C-33-A Female GU Cervix C4-1 Female GU Cervix C4-2 Female GU Cervix Caov-3 Female GU Ovary DoTc2-4510 Female GU Cervix ES-2 Female GU Ovary HEC-1-A Female GU Uterus HeLa Female GU Cervix HT3 Female GU Cervix JAR Female GU Placenta JEG-3 Female GU Placenta KLE Female GU Uterus Ovcar-3 Female GU Ovary RL95-2 Female GU Uterus SiHa Female GU Cervix SK-OV-3 Female GU Ovary SW954 Female GU Vulva SW962 Female GU Vulva CAL-27 Head and Neck Tongue Detroit562 Head and Neck Pharynx FADU Head and Neck Pharynx OE21 Head and Neck OE33 Head and Neck Oesophagus SCC-25 Head and Neck Tongue SCC-4 Head and Neck Tongue SCC-9 Head and Neck Tongue L428 Hodgkin's lymphoma RPMI- Hodgkin's 6666 lymphoma 769-P Kidney 786-0 Kidney A498 Kidney ACHN Kidney CAKI-1 Kidney CAKI-2 Kidney G-401 kidney G-402 Kidney SK-NEP-1 Kidney ARH-77 Myeloma Plasma cell BV-173 Leukemia CML CCRF-CEM Leukemia myelomonoblastic T-ALL CEM-C1 Leukemia ALL CML-T1 Leukemia CML EM-2 Leukemia CML HEL-92-1-7 Leukemia Erythroleukemia J-RT3-T3-5 Leukemia Acute T cell Jurkat Leukemia Acute T cell K-562 Leukemia CML CML MEG-01 Leukemia CML MOLT-16 Leukemia ALL MOLT-3 Leukemia ALL MV-4-11 Leukemia B myelomonocytic MX1 Leukemia APML NALM-6 Leukemia B cell precursor THP-1 Leukemia AML AML HepG2 Liver HLE Liver HLF Liver HuCCT1 Liver HUH-6- Liver clone5 OCUG-1 Liver SNU-423 Liver A427 Lung A549 Lung NSCLC Calu-1 Lung SQCC NSCLC Calu-6 Lung Anaplastic NSCLC ChaGo-K-1 Lung Bronchogenic COR-L105 Lung COR-L23 Lung NSCLC DMS-114 Lung SCLC SCLC DMS-273 Lung SCLC DMS-53 Lung SCLC SCLC NCI-H292 Lung Mucoepidermoid NCI-H441 Lung NSCLC NSCLC NCI-H446 Lung SCLC NCI-H460 Lung NSCLC NCI-H520 Lung NSCLC NSCLC NCI-H596 Lung NSCLC NSCLC NCI-H661 Lung NSCLC NCI-H69 Lung SCLC SHP-77 Lung SCLC SK-MES-1 Lung SQCC SQCC SW900 Lung SQCC NSCLC Wi38 Lung Normal Normal fibroblasts Fibroblasts BC-1 Lymphoma CRO-AP2 Lymphoma B cell Daudi Lymphoma BL BL DB Lymphoma Large cell DLBCL DOHH-2 Lymphoma B cell FL EB-3 Lymphoma BL HT Lymphoma Diffuse mixed DLBCL MHH- Lymphoma B cell Lymphoblastic PREB-1 Raji Lymphoma BL BL Ramos RA1 Lymphoma BL BL SKO-007 Lymphoma B lymphocyte SR Lymphoma Large cell Large immunoblastic ST486 Lymphoma BL RPMI- Myeloma Plasmacytoma; B-cell 8226 myeloma U266B1 Myeloma Myeloma B-cell AsPC-1 Pancreas BxPC-3 Pancreas CAPAN-1 Pancreas CAPAN-2 Pancreas CFPAC-1 Pancreas HPAF-II Pancreas HS766T Pancreas HuP-T4 Pancreas MIA-PaCa-2 Pancreas PANC-1 Pancreas SU.86.86 Pancreas YAPC Pancreas 22RV1 Prostate BM-1604 Prostate BPH-1 Prostate BPH-1 Prostate BPH-1 Prostate DU-145 Prostate LNCaP Prostate PC-3 Prostate A101D Skin Melanoma A375 Skin Melanoma A431 Skin SQCC A7 Skin Melanoma C32 Skin Melanoma C32TG Skin Melanoma CHL-1 Skin Melanoma COLO-829 Skin Melanoma HMCB Skin Melanoma HS294T Skin Melanoma HS695T Skin Melanoma MALME-3M Skin Melanoma Mewo Skin Melanoma RPMI-7951 Skin Melanoma SH-4 Skin Melanoma SK-MEL-1 Skin Melanoma SK-MEL-28 Skin Melanoma SK-MEL-3 Skin Melanoma A204 Soft Tissue Rhabdomyosarcoma A673 Soft Tissue Sarcoma HOS Bone Sarcoma HT1080 Soft Tissue Sarcoma KHOS- Bone Osteosarcoma 240S MES-SA Soft Tissue Sarcoma MG-63 Bone Sarcoma RD Soft Tissue Sarcoma Saos-2 Bone Sarcoma SJRH30 Soft Tissue Rhabdomyosarcoma SJSA-1 Bone Osteosarcoma SK-LMS-1 Soft Tissue Sarcoma SK-UT-1 Soft Tissue Sarcoma SW1353 Bone Sarcoma SW684 Soft Tissue Sarcoma SW872 Soft Tissue Sarcoma SW982 Soft Tissue Sarcoma TE 381.T Soft Tissue Rhabdomyosarcoma U-2-OS Bone Sarcoma

TABLE 6 Cell line screening results GI₅₀ IC₅₀ Max. Fold. Cell Line (μM) (μM) Change Cal_X 5637 0.0905 0.0946 51.0 0.1026 639-V 0.0855 0.0904 13.5 0.0540 647-V 0.1022 0.1177 12.4 0.0757 BFTC-905 0.0626 0.0649 22.1 0.0428 HT1197 1.7581 5.7255 5.5 8.8398 HT1376 0.9204 1.9883 5.3 9.1659 J82 1.0029 10.0000 4.9 10.0000 SCaBER 0.0894 0.0927 16.3 0.0581 T24 0.0941 0.0960 68.3 0.0008 TCCSUP 0.0657 0.0958 5.2 0.0974 UM-UC-3 0.1021 0.1314 70.6 0.0372 AU565 0.4598 1.2290 33.8 0.2656 BT-20 0.4591 1.2935 4.4 10.0000 BT-474 0.0837 4.3719 20.0 1.1580 BT-549 1.7310 4.8054 5.6 0.2720 CAMA-1 0.4279 1.1890 7.5 5.2170 EFM-19 0.0618 0.1036 32.5 0.0686 HS578T 10.0000 10.0000 3.8 10.0000 KPL-1 0.8217 2.4194 67.2 0.0888 MCF7 0.1287 0.8192 26.2 0.0625 MDA-MB-231 0.3690 0.7750 5.6 0.2184 MDA-MB-436 0.8881 1.8798 1.8 10.0000 MDA-MB-453 0.0810 0.1111 9.7 0.1290 MDA-MB-468 0.0928 0.1017 14.1 0.1679 MT-3 0.0395 0.0478 7.3 0.0696 SK-BR-3 0.2868 1.3152 4.4 10.0000 T47D 0.2919 1.1604 10.4 4.9403 A172 0.0457 10.0000 11.9 0.0521 BE(2)C 0.0796 0.0893 29.6 0.0468 CCF-STTG1 4.4267 5.6280 5.0 10.0000 CHP-212 0.0278 0.0364 11.4 0.0458 D-283MED 0.0584 0.0654 26.0 0.0580 Daoy 0.0887 0.1043 13.1 0.0849 DBTRG-05MG 4.2986 10.0000 4.4 10.0000 DK-MG 10.0000 10.0000 9.2 5.4460 H4 0.0718 0.0736 44.9 0.0422 MC-IXC 0.0471 0.0539 51.6 0.0439 SK-N-AS 0.4244 1.5168 14.5 0.0515 SK-N-DZ 0.1618 0.2077 34.8 0.2178 SK-N-FI 2.2181 9.5496 3.2 10.0000 SNB-19 10.0000 10.0000 1.6 10.0000 SW1088 0.0469 10.0000 13.1 0.0560 SW1783 10.0000 10.0000 3.1 10.0000 T98G 2.6239 10.0000 61.2 0.0426 U-138MG 10.0000 10.0000 4.8 10.0000 U-87-MG 0.1044 10.0000 11.2 0.0659 COLO-201 0.1052 0.1272 8.2 0.3152 COLO-205 0.0824 0.0838 182.5 0.0440 COLO-320DM 0.0927 0.1254 75.6 0.0723 COLO-320-HSR 0.1034 0.1261 37.3 0.0717 DLD-1 0.0473 0.0496 45.1 0.0338 HCT-116 0.0479 0.0488 37.9 0.0385 HCT-15 0.0531 0.0559 58.9 0.0377 HCT-8 0.0298 0.0312 282.4 0.0138 HT29 0.1156 0.1265 35.8 0.0632 LS-1034 0.1033 0.1061 6.7 0.2283 LS-174T 0.0665 0.0914 16.1 0.0479 NCI-H508 0.2291 0.5928 30.5 0.0649 NCI-H747 0.3733 1.6297 3.3 10.0000 RKO 0.0504 0.0526 35.1 0.0394 RKO-AS45-1 0.0415 0.0445 24.5 0.0371 RKO-E6 0.0513 0.0527 14.4 0.0490 SW1417 4.5665 10.0000 6.5 6.7147 SW403 0.2573 0.2969 12.2 0.4506 SW48 0.0459 0.0497 12.0 0.0623 SW480 1.0169 2.1065 25.3 3.9577 SW620 0.0572 0.0636 20.3 0.0559 SW837 0.3301 0.8362 34.9 0.0815 SW948 0.2469 0.2875 26.6 0.2257 WiDr 0.3583 0.6266 22.3 0.1700 AGS 0.0308 0.0328 12.1 0.0312 HS746T 10.0000 10.0000 2.6 10.0000 KATOIII 1.0051 1.9453 31.3 0.0715 OE19 0.0575 0.0636 33.6 0.0524 SNU-1 0.2788 0.4798 12.6 0.0473 SNU-16 0.1487 0.2269 3.9 10.0000 SNU-5 5.9807 10.0000 2.3 10.0000 SW1463 5.0067 10.0000 4.3 10.0000 BHT-101 0.3120 0.4093 64.6 0.1877 CAL-62 0.0972 0.0987 35.2 0.0450 CGTH-W-1 0.1027 0.1096 32.2 0.0429 NCI-H295 10.0000 10.0000 3.1 10.0000 SW13 0.1621 0.2426 19.3 0.0657 SW579 2.6704 10.0000 6.6 0.0772 Y79 0.1843 0.2576 6.4 1.6819 AN3CA 0.5117 1.1664 14.1 3.7957 BeWo 0.5064 0.7466 5.2 9.4738 C-33-A 0.0745 0.1220 33.7 0.3941 C4-1 0.0804 0.1144 20.8 0.0827 C4-2 0.2487 0.4270 16.3 1.1314 Caov-3 0.0666 0.1061 4.0 10.0000 DoTc2-4510 0.3552 0.7875 12.9 0.7698 ES-2 0.0915 0.0936 33.3 0.0487 HEC-1-A 0.1656 0.4534 4.3 10.0000 HeLa 0.3882 0.6010 6.5 0.8340 HT3 1.3798 2.5017 6.2 7.0920 JAR 0.0495 0.0519 24.8 0.0576 JEG-3 0.0859 0.0954 15.8 0.0726 KLE 2.3130 6.4698 15.4 4.5020 Ovcar-3 0.4434 0.8643 135.6 0.7343 RL95-2 0.0455 0.0649 4.0 10.0000 SiHa 10.0000 10.0000 6.0 8.3919 SK-OV-3 10.0000 10.0000 8.0 1.8718 SW954 0.0866 0.0887 11.0 0.1179 SW962 10.0000 10.0000 3.6 10.0000 CAL-27 0.0538 0.0567 15.5 0.0493 Detroit562 0.0471 0.0537 22.6 0.0553 FADU 0.1223 0.1661 8.0 0.0792 OE21 0.0651 0.0682 12.3 0.0738 OE33 0.1965 0.3052 8.8 0.2006 SCC-25 0.0673 0.0731 19.5 0.0894 SCC-4 8.3155 10.0000 3.0 10.0000 SCC-9 0.2650 0.5288 17.0 0.2767 L428 3.2804 4.5993 4.8 10.0000 RPMI-6666 0.1481 0.1535 7.8 0.2252 769-P 0.2663 0.3597 4.9 10.0000 786-0 0.1115 0.1199 22.1 0.0690 A498 0.4915 1.3982 7.3 0.0728 ACHN 0.3960 0.8495 60.4 0.0460 CAKI-1 0.1284 10.0000 3.9 10.0000 CAKI-2 10.0000 10.0000 3.0 10.0000 G-401 0.0794 0.0817 12.7 0.7392 G-402 0.0378 0.0431 16.3 0.0566 SK-NEP-1 0.1270 0.1681 17.4 0.3116 ARH-77 0.0594 0.0618 26.4 0.0525 BV-173 0.0444 0.0454 29.4 0.0427 CCRF-CEM 0.0813 0.0819 16.6 0.0617 CEM-C1 0.4524 0.4805 18.3 0.0529 CML-T1 0.0689 0.0716 29.8 0.0430 EM-2 0.0903 0.0988 13.5 0.0766 HEL-92-1-7 0.5351 0.6301 20.7 1.1545 J-RT3-T3-5 0.0463 0.0534 13.4 0.0286 Jurkat 0.0501 0.0551 19.0 0.0460 K-562 2.6980 4.7723 13.7 0.6802 MEG-01 2.1931 3.8366 3.1 10.0000 MOLT-16 0.0383 0.0388 12.0 0.0798 MOLT-3 0.1187 0.4689 4.5 10.0000 MV-4-11 0.0906 0.0940 14.8 0.3032 MX1 0.0576 0.0589 44.7 0.0394 NALM-6 0.0547 0.0560 72.7 0.0359 THP-1 10.0000 10.0000 4.8 10.0000 HepG2 0.1366 0.2124 18.1 0.0853 HLE 0.1020 0.1067 4.5 10.0000 HLF 0.1232 0.1817 29.3 0.0430 HuCCT1 1.4582 2.6967 13.2 0.0503 HUH-6-clone5 0.1433 0.1756 31.2 0.1025 OCUG-1 1.2036 3.9346 11.5 0.2126 SNU-423 10.0000 10.0000 3.2 10.0000 A427 0.0794 0.1168 15.7 0.0238 A549 0.0528 0.0602 61.6 0.0287 Calu-1 2.9029 9.0678 11.7 0.1295 Calu-6 4.6564 8.1661 5.2 8.9974 ChaGo-K-1 0.1465 0.3720 4.4 10.0000 COR-L105 0.1447 0.5875 4.7 10.0000 COR-L23 0.1414 0.1531 7.2 0.1411 DMS-114 1.3925 4.6519 4.0 10.0000 DMS-273 0.0674 0.0690 15.9 0.0568 DMS-53 1.7366 6.6828 48.7 0.2879 NCI-H292 0.0817 0.0921 30.5 0.0722 NCI-H441 0.8207 3.0855 4.2 10.0000 NCI-H446 0.3539 0.4244 6.5 1.9460 NCI-H460 0.0870 0.0877 98.0 0.0407 NCI-H520 0.3189 0.4497 7.9 1.2581 NCI-H596 0.2824 10.0000 2.2 10.0000 NCI-H661 1.7213 4.2789 10.7 0.0680 NCI-H69 NaN NaN 3.0 10.0000 SHP-77 0.1818 0.2783 6.9 1.9384 SK-MES-1 0.4135 0.9021 18.5 0.1941 SW900 10.0000 10.0000 2.1 10.0000 Wi38 0.6851 1.8760 6.8 0.0772 BC-1 0.0621 0.0655 60.2 0.0548 CRO-AP2 0.0458 0.0494 87.5 0.0602 Daudi 0.0953 0.0974 14.8 0.0573 DB 0.0758 0.0833 40.8 0.0742 DOHH-2 0.0677 0.0714 17.5 0.0971 EB-3 0.2738 0.4248 8.4 0.2986 HT 0.1784 0.2437 3.1 10.0000 MHH-PREB-1 0.0637 0.0653 44.2 0.0422 Raji 0.0511 0.0544 21.3 0.0504 RamosRA1 0.0871 0.0881 50.0 0.0617 SKO-007 0.9528 1.2076 10.7 2.0090 SR 0.0855 0.0867 33.0 0.0603 ST486 0.0361 0.0401 27.5 0.0584 RPMI-8226 0.1150 0.1836 13.8 0.5722 U266B1 0.1590 0.3756 7.6 4.1758 AsPC-1 1.5312 10.0000 6.9 5.2046 BxPC-3 0.0814 0.1361 8.8 0.0630 CAPAN-1 0.9358 2.4121 3.1 10.0000 CAPAN-2 0.2937 10.0000 28.8 0.0583 CFPAC-1 10.0000 10.0000 15.2 0.0568 HPAF-II 0.2492 0.3684 11.5 0.2588 HS766T 10.0000 10.0000 5.7 0.7781 HuP-T4 0.1092 0.1366 12.6 0.2143 MIA-PaCa-2 0.3260 0.5436 15.6 0.0639 PANC-1 3.3504 9.5585 3.4 10.0000 SU.86.86 0.8641 1.9177 17.9 0.0704 YAPC 0.8691 3.1871 51.2 0.0322 22RV1 0.1405 0.2485 39.2 0.0361 BM-1604 1.1194 2.0149 20.8 0.2011 BPH-1 0.1498 0.1669 7.5 0.2422 DU-145 0.0958 0.0991 394.0 0.0382 LNCaP 9.6042 10.0000 2.9 10.0000 PC-3 1.2048 2.3542 14.1 1.2528 A101D 0.3510 0.8607 18.1 0.1754 A375 0.0460 0.0475 38.5 0.0356 A431 0.0924 0.0986 13.5 0.1298 A7 0.1262 0.2490 9.0 0.0468 C32 1.1087 10.0000 13.0 1.9676 C32TG 0.8305 2.0288 15.1 0.2294 CHL-1 0.0972 0.1044 41.1 0.0180 COLO-829 2.0590 8.5007 6.8 0.7345 HMCB 0.0964 0.0988 20.4 0.0619 HS294T 0.0970 0.1178 16.5 0.0567 HS695T 0.7708 3.0838 18.4 3.0148 MALME-3M 1.6636 10.0000 1.8 10.0000 Mewo 10.0000 10.0000 4.5 10.0000 RPMI-7951 0.0999 0.1052 5.1 0.2834 SH-4 0.0565 0.3220 9.9 0.0396 SK-MEL-1 10.0000 10.0000 1.9 10.0000 SK-MEL-28 10.0000 10.0000 6.6 0.2632 SK-MEL-3 2.5742 10.0000 4.1 10.0000 A204 0.0579 0.1457 9.2 0.0629 A673 0.0560 0.0735 4.3 10.0000 HOS 0.0737 0.0756 85.6 0.0362 HT1080 0.0855 0.0899 17.5 0.0672 KHOS-240S 0.0991 0.1100 16.3 0.0789 MES-SA 0.0354 0.0379 47.3 0.0241 MG-63 2.0387 4.6830 7.5 0.4768 RD 0.4567 0.7541 26.7 0.1603 Saos-2 1.8273 4.5508 3.6 10.0000 SJRH30 0.5334 1.3424 6.9 0.0992 SJSA-1 10.0000 10.0000 89.2 0.0538 SK-LMS-1 4.4020 10.0000 4.5 10.0000 SK-UT-1 0.2891 0.9592 10.1 0.3581 SW1353 10.0000 10.0000 8.3 0.2769 SW684 10.0000 10.0000 3.0 10.0000 SW872 0.1001 0.1204 53.3 0.0551 SW982 3.6570 10.0000 2.7 10.0000 TE 381.T 4.8712 10.0000 6.8 0.2981 U-2-OS 0.0821 0.0887 35.6 0.0438 Note: NaN: variable data

Conclusion.

As shown in Table 6 and FIGS. 1 and 2, Pyrrolopyrimidine Compounds (exemplified by Compound 38) showed anti-proliferative activity in a variety of cancers, comprising solid tumors (FIG. 1), for example, cancers of the bladder, breast, CNS, colon, endocrine, female GU, head and neck, kidney, liver, lung, pancreas, prostate, skin, bone and soft-tissue, and hematological cancers (FIG. 2), for example, lymphomas, leukemias and multiple myeloma.

GBM Cancer Stem Cell Viability Assay.

Five high grade glioblastoma-derived tumor cultures in defined serum-free medium that enriches the GBM-CSC tumor subfraction were established, as described previously [Mao P, et al. Proc Nat Acad Sci 2013; 110(21): 8644-9]. Clinical diagnoses and stem cell marker analyses were performed. The cancer stem cells (CSCs) (8311, 81611, 32612, 1912, and 52810), were plated in a 20 μL/well volume of serum-free growth medium at a density of 800 cells/well in a 384-well format. GBM CSCs were mechanically-dissociated by trituration prior to counting and plating. As a normal cell control, 1200 HUVECs were plated in 20 μL per well of a 384-well plate in Endothelial Growth Media Microvascular-2. After 1 day of cultivation, 20 μL/well of respective fresh medium for each cell type was added and the cells were treated with Pyrrolopyrimidine Compounds at multiple concentrations or 0.04 μL DMSO for 3 days under 5% CO₂/37° C. culture conditions. After 3 days of compound treatment, cells were lysed through the addition of 30 μL of CellTiter-Glo (CTG) reagent to evaluate relative cell density. The plate was placed at room temperature for 30 minutes after which luminescent signal was monitored.

Results.

Table 7 summarizes the GBM subtype affiliation of each GBM-CSC model utilized. The impact of Pyrrolopyrimidine Compounds on the growth of GBM-CSCs was tested under defined serum-free culture conditions by CTG. The concentration of compound that inhibited the cell growth by 50% was determined in those five models (data for Compound 38 is summarized in FIG. 3). Pyrrolopyrimidine Compounds (exemplified by Compound 38) demonstrated potency against mesenchymal GBM CSCs with IC₅₀s in the range of 1-2 μM. This data also indicated that Pyrrolopyrimdine Compounds (as shown for Compound 38) were particularly potent against two GBM CSC sphere models derived from proneural subtype GBM patients with IC₅₀ in the range of 50-190 nM.

TABLE 7 Characteristics of GBM-Cancer Stem Cells Patient Clinical CSCs Diagnosis Subtype 8311 GBM Mesenchymal (Mes) 52810 GBM Proneural (PN) 81611 GBM PN/Relapse 32612 GBM Mesenchymal (Mes) 1912 GBM Proneural (PN)

Stem Cell Marker Oct-4 Assay.

1200 HUAECs were plated per well of a 384-well plate. After 1 day 8311 GBM CSCs were mechanically-dissociated by trituration and added at a density of 600 cells per well. The cells were allowed to co-culture for 1 day and then treated with various concentrations of Pyrrolopyrimidine Compound or DMSO for 3 days in 5% CO₂ at 37° C. After incubation with compound, 40 μL of 4% paraformaldehyde was added. Cell fixation was allowed to proceed at room temperature for 1 hour and each well was washed 5 times with a 50 μL volume of PBS. Each well was treated overnight at 4° C. with a 50 μL volume of PBS supplemented with 3% goat serum and 0.25% triton X-100. Cells were the incubated overnight at 4° C. with anti Oct4 and anti Tuj1 antibodies diluted 1:100 and 1:1000 respectively in PBS/3% goat serum/0.25% triton. Cells were washed 5 times with PBS/0.25% triton and incubated with AlexaFluor-labeled secondary antibodies for 3 hours at room temperature after which the wells were washed 5 times with PBS/0.25% Triton. Images of 4 randomly chosen fields were acquired using an EVOS Cell Imaging System at 10× magnification. Adobe Photoshop (Adobe Systems Incorporated) was used to process raw images, assign and merge channels. Representative images are shown in FIG. 4.

Results.

A defining property of stem cells is their capacity to generate differentiated progeny. GBM CSCs demonstrated the ability to undergo neuronal and astrocytic differentiation upon growth factor withdrawal or following exposure to BMP-4 [Pollard et al Cell Stem Cell 2009; 4(6):568-80]. We evaluated the impact of Pyrrolopyrimidine Compounds on 8311 glioma stem cells in a pathologically relevant GBM-CSC/HUAEC co-culture model. Endothelial cells are known to interact closely with self-renewal GBM-CSC and secret factors maintaining these cells in stem-cell like state [Calabrese et al. Cancer cell 2007; 11(1):69-82]. In this assay, Oct 4 was used as stem cell marker and Tuj-1 was used as neuronal marker for GBM-CSC and differentiated neuronal cell populations, respectively. As shown in FIG. 4, upon Pyrrolopyrimidine Compound treatment (as shown for Compound 38), the Oct4 positive GBM CSC population was decreased while the proportion of Tuj-1 positive neuronal cells was increased. This data indicates that Pyrrolopyrimidine Compounds can eliminate the Oct-4 positive cancer stem cell population and induce neuronal differentiation in the 8311/HUAEC co-culture model.

Conclusions.

Pyrrolopyrimidine Compounds were shown to impair the proliferation of GBM CSC models. Five models isolated from primary GBM patient specimens, representative of mesenchymal and proneural GBM subclasses, were utilized to test Pyrrolopyrimidine Compound activity upon GBM CSCs. Pyrrolopyrimidine Compounds (as exemplified by Compound 38) potently inhibited proliferation of proneural 52810 and 1912 cells with IC₅₀ values of 0.048 and 0.19 respectively. Pyrrolopyrimidine Compounds (exemplified by Compound 38) had less potency in the inhibition of mesenchymal models 8311 and 32612 cells with IC₅₀ values of 1.6 and 1.8 respectively. Furthermore, Pyrrolopyrimidine Compounds (exemplified by Compound 38) induced differentiation of GBM CSCs in the context of a HUAEC co-culture model. Hence, our data indicates that Pyrrolopyrimidine Compounds can both inhibit proliferation and induce neuronal differentiation of GBM CSCs.

Animal Models

Cancer Xenograft Model.

For xenograft model studies human cancer cell lines were injected into SCID (severe combined immunodeficiency) mice. Cancer cell lines were propagated in culture in vitro. Tumor bearing animals were generated by injecting precisely determined numbers of cells into mice. Following inoculation of animals, the tumors were allowed to grow to a certain size prior to randomization. The mice bearing xenograft tumors, typically ranging between 100 and 400 mm³, were pooled together and randomized into various treatment groups. Primary tumorgrafts were propagated in vivo. Tumor fragments from donor mice were implanted into small numbers of mice for maintenance, or larger numbers of mice for study initiation. A typical efficacy study design involved administering one or more compounds at various dose levels to tumor-bearing mice. Additionally, reference chemotherapeutic agents (positive control) and negative controls were similarly administered and maintained. Routes of administration can include subcutaneous (SC), intraperitoneal (IP), intravenous (IV), intramuscular (IM) and oral (PO). Tumor measurements and body weights were taken over the course of the study and morbidity and mortality were recorded. Necropsy, histopathology, and PCR can also be performed to enhance understanding of disease and drug action.

Some of the typical human bladder cancer cell lines, for example transitional cell carcinoma, that were or can be used in the above xenograft models are: HT-1376, HT-1197, UMUC-3, KU-7, and KU-19-19 cell lines.

Some of the typical human breast cancer cell lines that were or can be used in the above xenograft models are: luminal-B type cell lines, for example BT-474, or ZR-75, and basal type cell lines, for example, MDA-MB-231, T47D, and Cal-51 cell lines.

Some of the typical human lung squamous cell carcinoma cell lines, that were or can be used in the above xenograft models are: SK-MES-1, NCI-H1703, HCC-15, and Calu-1 cell line.

Some of the typical human esophageal squamous carcinoma cell lines that were or can be used in the above xenograft models are: Kyse-140 and KYSE-510 cell lines.

Some of the typical human squamous cervical cancer cell lines that were or can be used in the above xenograft models are: A-431 and SiHa cell lines.

Some of the typical human squamous head and neck cancer cell lines that were or can be used in the above xenograft models are: FaDu and SCC-15 cell lines.

Some of the typical human leukemia cell lines that were or can be used in the above xenograft models are: CCRF-CEM and MOLT-4.

Some of the typical human lymphoma cell lines that were or can be used in the above xenograft models are: WSU-DLCL2 and OCI-Ly10.

Some of the typical human colorectal cancer (CRC) cell lines that were or can be used in the above xenograft models are: HCT-116, HT-29, and LOVO.

Some of the typical human thyroid cáncer cell lines that were or can be used in the above xenograft models are: TT and 8305C.

Some of the typical human central nervous system (CNS) cáncer cell lines that were or can be used in the above xenograft models are: U87MG and U-118.

Some of the typical human pancreas cancer cell lines that were or can be used in the above xenograft models are: PANC-1 and BxPC3.

For a typical xenograft study, SCID mice bearing tumors were randomized and dosed with compounds ranging from, for example, 100 mg/kg to 0.1 mg/kg with different dose scheduling. The mice were dosed for 2-4 weeks. Tumors were measured twice a week using calipers and tumor volumes were calculated using the formula of W²×L/2.

In thesexenograft cancer models, Pyrrolopyrimidine Compounds have, or are expected to have, an ED₅₀ value of <100 mg/kg, with some compounds having an ED₅₀ of <10 mg/kg and others an ED₅₀ of <1 mg/kg.

A number of references have been cited, the disclosures of which are incorporated herein by reference in their entirety. 

What is claimed is:
 1. A method for treating lung cancer, comprising administering to a subject having lung cancer an effective amount of Pyrrolopyrimidine Compound, wherein the Pyrrolopyrimidine Compound is a compound of formula (I):

or a pharmaceutically acceptable salt, tautomer, stereoisomer, enantiomer, or isotopologue thereof, wherein: R¹ is substituted or unsubstituted C₁₋₈ alkyl, substituted or unsubstituted C₃₋₈ cycloalkyl, or substituted or unsubstituted non-aromatic heterocyclyl; R² is substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R³ is substituted or unsubstituted heterocyclyl or substituted or unsubstituted aryl, and L is NH or O; provided that R³ is not pyridyl when L is NH or when R² is pyrazolyl; and the compound is not N-methyl-N-[trans-3-[[5-(1-methyl-1H-pyrazol-4-yl)-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]cyclobutyl]-2-propenamide; or N-methyl-N-[trans-3-[[5-(1-methyl-1H-pyrazol-3-yl)-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]cyclobutyl]-2-propenamide.
 2. The method of claim 1, wherein L is O.
 3. The method of claim 1, wherein R¹ is substituted or unsubstituted C₃₋₈ cycloalkyl.
 4. The method of claim 1, wherein R¹ is substituted or unsubstituted cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl.
 5. The method of claim 3, wherein the cycloalkyl is substituted with one or more —CN, halogen, —OR or a substituted or unsubstituted C₁₋₃ alkyl, wherein each R is independently —H or substituted or unsubstituted (C₁₋₄)alkyl.
 6. The method of claim 1, wherein R¹ is substituted or unsubstituted C₁₋₈ alkyl,

wherein each R′ is independently —CN, halogen, —OR or C₁₋₃ alkyl; R″ is —H or C₁₋₃ alkyl; each R is independently —H or substituted or unsubstituted (C₁₋₄)alkyl; and n is 0-2.
 7. The method of claim 1, wherein R² is substituted phenyl.
 8. The method of claim 7, wherein R² is phenyl, substituted with one or more substituted or unsubstituted C₁₋₆ alkyl, halogen, —CN, —OR⁵, —C(═O)NR⁵ ₂, —C(═O)(substituted or unsubstituted heterocyclyl), —C(═O)(substituted or unsubstituted alkylheterocyclyl), —NHC(═O)R⁵, —SO₂NR⁵ ₂, or substituted or unsubstituted heteroaryl, wherein each R⁵ is independently —H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, or substituted or unsubstituted alkylheterocyclyl.
 9. The method of claim 7, wherein R² is phenyl, substituted with one or more —(C₁₋₃ alkyl), —(C₁₋₃ alkyl)NR₂, —CF₃, —Cl, —F, —CN, —OCH₃, —OCF₃, —C(═O)NR₂, —C(═O)NR(substituted or unsubstituted cycloalkyl), —C(═O)NR(CH₂)₀₋₂CR₂(CH₂)₀₋₂OR, —C(═O)NR(CH₂)₀₋₂CR₂(CH₂)₀₋₂NR₂, —C(═O)NR(CH₂)₀₋₂CR₂(CH₂)₀₋₂C(═O)NR₂, —C(═O)N(substituted or unsubstituted cycloalkyl)(CH₂)₀₋₂OR, —C(═O)NR(CH₂)₀₋₃(substituted or unsubstituted heterocyclyl), —C(═O)(CH₂)₀₋₃ (substituted or unsubstituted heterocyclyl), —C(═NR)NR₂, —NRC(═O)R, —SO₂NR₂, —SO₂R, or substituted or unsubstituted heterocyclyl, wherein each R is independently —H or substituted or unsubstituted (C₁₋₄)alkyl.
 10. The method of claim 9, wherein each R is independently —H or —CH₃.
 11. The method of claim 7, wherein R² is phenyl, substituted with one or more —CH₃, —CH₂CH₃, —CH₂CH₂CH₃, —CH(CH₃)₂, —CH₂NH₂, —CF₃, —Cl, —F, —CN, —OCH₃, —OCF₃, —C(═O)NH₂, —C(═O)NHCH₃, —C(═O)N(CH₃)₂, —C(═O)NC(CH₃)₃, —C(═O)NHCH₂CH₂F, —C(═O)NHCH₂CHF₂, —C(═O)NHCH₂CF₃, —C(═O)NHCH₂CF₂CH₃, —C(═O)NHCH₂CN, —C(═O)N(CH₃)CH₂CN, —C(═O)NHCH₂CH₂CN, —C(═O)N(CH₃)CH₂CH₂CN, —C(═O)NH-cyclobutyl, —C(═O)NH-(hydroxy-cyclobutyl), —C(═O)NH-cyclopentyl, —C(═O)NH-(hydroxy-cyclopentyl), —C(═O)NHCH₂CH₂OH, —C(═O)NHCH₂CH₂OCH₃, —C(═O)N(CH₃)CH₂CH₂OH, —C(═O)N(CH₃)CH₂CH₂OCH₃, —C(═O)NHCH₂CH₂CH₂OH, —C(═O)N(CH₃)CH₂CH₂CH₂OH, —C(═O)N(CH₃)CH₂CH₂CH₂OCH₃, —C(═O)NHCH₂CH(CH₃)OH, —C(═O)NHCH₂C(CH₃)₂OH, —C(═O)NHCH(CH₃)CH₂OH, —C(═O)NHC(CH₃)₂CH₂OH, —C(═O)NHCH₂CH₂NH₂, —C(═O)NHCH₂CH₂NH(CH₃), —C(═O)NHCH₂CH₂N(CH₃)₂, —C(═O)NHCH₂C(═O)NH₂, —C(═O)N(CH₃)CH₂C(═O)NH₂, —C(═O)NHCH₂CH₂C(═O)NH₂, —C(═O)N(CH₃)CH₂CH₂C(═O)NH₂, —C(═O)N(cyclopropyl)CH₂CH₂OH, —C(═O)NH-oxetanyl, —C(═O)N(CH₃)-oxetanyl, —C(═O)NH-(methyl-oxetanyl), —C(═O)NH-azetidinyl, —C(═O)NH-(methylazetidinyl), —C(═O)NH-(1-acetylazetidinyl), —C(═O)NH-pyrrolidyl, —C(═O)NH-piperidyl, —C(═O)NH-tetrahydrofuranyl, —C(═O)N(CH₃)-tetrahydrofuranyl, —C(═O)NH-tetrahydropyranyl, —C(═O)N(CH₃)-tetrahydropyranyl, —C(═O)NHCH₂-oxetanyl, —C(═O)N(CH₃)CH₂-oxetanyl, —C(═O)NHCH₂-(methyl-oxetanyl), —C(═O)N(CH₃)CH₂-(methyl-oxetanyl), —C(═O)NHCH₂-tetrahydrofuranyl, —C(═O)NHCH₂-tetrahydropyranyl, —C(═O)NHCH₂-dioxanyl, —C(═O)aziridinyl, —C(═O)(methyl-aziridinyl), —C(═O)(dimethyl-aziridinyl), —C(═O)(hydroxymethyl-aziridinyl), —C(═O)azetidinyl, —C(═O)pyrrolidinyl, —C(═O)(hydroxyl-pyrrolidinyl), —C(═O)(hydroxyl,methoxypyrrolidinyl), —C(═O)(dimethoxypyrrolidinyl), —C(═O)morpholinyl, —C(═O)piperazinyl, —C(═O)(methylpiperazinyl), —C(═O)(hydroxy-piperidyl), —C(═O)(fluoropiperidinyl), —(C═O)(methoxy-piperidyl), —C(═NH)NH₂, —NHC(═O)CH₃, —SO₂NHCH₃, —SO₂CH₃, or substituted or unsubstituted pyrazolyl.
 12. The method of claim 7, wherein R² is phenyl, substituted with one or more —CH₃, —CH₂CH₃, —CH₂CH₂CH₃, —CH(CH₃)₂, —CH₂NH₂, —CF₃, —Cl, —F, —CN, —OCH₃, —OCF₃, —C(═O)NH₂, —C(═O)NHCH₃, —C(═O)N(CH₃)₂, —C(═O)NC(CH₃)₃, —C(═O)NHCH₂CH₂F, —C(═O)NHCH₂CF₂CH₃, —C(═O)N(CH₃)CH₂CN, —C(═O)N(CH₃)CH₂CH₂CN, —C(═O)NH-(3-hydroxy-cyclobutyl), —C(═O)NH-cyclopentyl, —C(═O)NH-(2-hydroxycyclopentyl), —C(═O)NHCH₂CH₂OH, —C(═O)NHCH₂CH₂OCH₃, —C(═O)N(CH₃)CH₂CH₂OH, —C(═O)N(CH₃)CH₂CH₂OCH₃, —C(═O)NHCH₂CH₂CH₂OH, —C(═O)N(CH₃)CH₂CH₂CH₂OH, —C(═O)NHCH₂CH(CH₃)OH, —C(═O)NHCH₂C(CH₃)₂OH, —C(═O)NHCH(CH₃)CH₂OH, —C(═O)NHC(CH₃)₂CH₂OH, —C(═O)NHCH₂CH₂NH₂, —C(═O)NHCH₂CH₂NH(CH₃), —C(═O)NHCH₂CH₂N(CH₃)₂, —C(═O)N(CH₃)CH₂C(═O)NH₂, —C(═O)N(CH₃)CH₂CH₂C(═O)NH₂, —C(═O)N(cyclopropyl)CH₂CH₂OH, —C(═O)NH-oxetanyl, —C(═O)N(CH₃)-oxetanyl, —C(═O)NH-(3-methyl-oxetanyl), —C(═O)NH-(1-methylazetidinyl), —C(═O)NH-(1-acetylazetidinyl), —C(═O)NH-piperidyl, —C(═O)NH-tetrahydrofuranyl, —C(═O)NH-tetrahydropyranyl, —C(═O)N(CH₃)-tetrahydropyranyl, —C(═O)NHCH₂-oxetanyl, —C(═O)N(CH₃)CH₂-(3-methyl-oxetanyl), —C(═O)NHCH₂-tetrahydrofuranyl, —C(═O)NHCH₂-tetrahydropyranyl, —C(═O)NHCH₂-dioxanyl, —C(═O)aziridinyl, —C(═O)(2-methyl-aziridinyl), —C(═O)(2,2-dimethyl-aziridinyl), —C(═O)(2-(hydroxymethyl)aziridinyl), —C(═O)azetidinyl, —C(═O)pyrrolidinyl, —C(═O)(3-hydroxy-4-methoxypyrrolidinyl), —C(═O)(3,4-dimethoxypyrrolidinyl), —C(═O)morpholinyl, —C(═O)piperazinyl, —C(═O)(4-methylpiperazinyl), —C(═O)(4-hydroxy-piperidyl), —C(═O)(4,4-difluoropiperidinyl), —(C═O)(4-methoxy-piperidyl), —C(═NH)NH₂, —NHC(═O)CH₃, —SO₂NHCH₃, —SO₂CH₃, or substituted or unsubstituted pyrazolyl.
 13. The method of claim 1, wherein R³ is substituted or unsubstituted heterocyclyl.
 14. The method of claim 13, wherein the heterocyclyl is substituted or unsubstituted pyrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, pyridazinyl, pyrimidyl, pyrazinyl, benztriazolyl, indazolyl, indolyl, benzoxazolyl, benzisoxazolyl, benzthiazolyl, benzoxazolonyl, benzoxadiazolyl, benzimidazolyl, or quinolyl.
 15. The method of claim 13, wherein the heterocyclyl is substituted with one or more substituents selected from substituted or unsubstituted (C₁₋₄)alkyl, halogen, —OR, —CN, —NR₂, —C(═O)NR₂, —NRC(═O)R, or substituted or unsubstituted triazolyl, wherein each R is independently —H or substituted or unsubstituted (C₁₋₄)alkyl.
 16. The method of claim 13, wherein the heterocyclyl is substituted with one or more substituents selected from —CH₃, —CH(CH₃)₂, —F, —Cl, —OH, —OCH₃, —OCH₂CH₃, —CN, —NH₂, —NHCH₃, —N(CH₃)₂, —C(═O)NH(CH₃), —NHC(═O)CH₃, or substituted or unsubstituted triazolyl.
 17. The method of claim 1, wherein R³ is substituted or unsubstituted aryl.
 18. The method of claim 1, wherein the compound is selected from 4-(4-(cyclopentyloxy)-5-(4-hydroxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-methylbenzamide, 4-(4-(cyclopentyloxy)-5-(3-hydroxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-methylbenzamide, 4-(4-(cyclopentyloxy)-5-(4-hydroxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(5-(4-hydroxyphenyl)-4-methoxy-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-methylbenzamide, 4-(2-(1H-indazol-5-ylamino)-4-(cyclohexyloxy)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenol, 4-(2-(4-(1H-pyrazol-4-yl)phenylamino)-4-(cyclohexyloxy)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenol, 4-(5-(2-chloro-4-hydroxyphenyl)-4-(cyclohexyloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-methylbenzamide, 4-(2-(3-(1H-pyrazol-4-yl)phenylamino)-4-(cyclohexyloxy)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenol, 4-(4-(cyclopentyloxy)-5-(4-hydroxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N,3-dimethylbenzamide, 4-(4-(cyclopentyloxy)-5-(4-hydroxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-ethyl-N-methylbenzamide, 4-(4-(cyclopentyloxy)-5-(4-hydroxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-isopropyl-N-methylbenzamide, 4-(4-(cyclopentyloxy)-5-(4-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(4-(cyclopentyloxy)-5-phenyl-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 3-chloro-4-(4-(cyclopentyloxy)-5-(4-hydroxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-methylbenzamide, 4-(4-(cyclopentyloxy)-5-(4-hydroxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-fluoro-N-methylbenzamide, 4-(4-(cyclopentylamino)-5-(4-hydroxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(5-(4-hydroxyphenyl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(5-(4-hydroxyphenyl)-4-(neopentyloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(5-(4-hydroxyphenyl)-4-methoxy-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(4-(cyclopentyloxy)-2-(1-methyl-1H-indazol-5-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenol, 4-(4-(cyclopentyloxy)-2-(6-methyl-1H-indazol-5-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenol, 4-(4-(cyclopentyloxy)-2-(4-methyl-1H-indazol-5-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenol, 4-(4-(cyclopentyloxy)-5-(4-(hydroxymethyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(5-(3-chloro-4-hydroxyphenyl)-4-(cyclopentyloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(4-(cyclopentyloxy)-5-(1H-indazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(4-(cyclopentyloxy)-5-(3-(hydroxymethyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(5-(1H-benzo[d][1,2,3]triazol-6-yl)-4-(cyclopentyloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(5-(4-(4H-1,2,4-triazol-3-yl)phenyl)-4-(cyclopentyloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 3-chloro-4-(5-(4-hydroxyphenyl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-methylbenzamide, 4-(5-(1H-benzo[d]imidazol-6-yl)-4-(cyclopentyloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(4-(cyclopentyloxy)-5-(4-hydroxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N,N-dimethylbenzamide, 4-(4-(cyclopentyloxy)-5-(4-(methyl sulfonamido)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(5-(3-cyano-4-hydroxyphenyl)-4-(cyclopentyloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 3-chloro-4-(4-(cyclopentyloxy)-5-(5-methoxypyridin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-methylbenzamide, 4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(4-(cyclohexylamino)-5-(4-hydroxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(5-(4-aminophenyl)-4-(cyclopentyloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(4-(cyclopentyloxy)-5-(4-ureidophenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(5-(4-hydroxyphenyl)-4-(tetrahydro-2H-pyran-4-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(5-(4-(1H-pyrazol-5-yl)phenyl)-4-(cyclopentyloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(4-(cyclopentyloxy)-5-(3-fluoro-4-hydroxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(4-(cyclopentyloxy)-5-(4-hydroxy-3-methylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(4-(cyclopentyloxy)-5-(4-hydroxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxybenzamide, 4-(4-((1 r,4r)-4-hydroxycyclohexyloxy)-5-(4-hydroxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(4-((1 s,4s)-4-hydroxycyclohexyloxy)-5-(4-hydroxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(4-(cyclopentyloxy)-5-(3-(2-hydroxypropan-2-yl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(5-(4-(1H-imidazol-2-yl)phenyl)-4-(cyclopentyloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(4-(cyclopentyloxy)-5-(4-(2-hydroxypropan-2-yl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(4-(cyclopentyloxy)-2-(2-methoxy-4-(1H-pyrazol-4-yl)phenylamino)-7H-pyrrolo[2, 3-d]pyrimidin-5-yl)phenol, 4-(4-(cyclopentyloxy)-5-(5-hydroxypyridin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(2-(4-(aminomethyl)-2-methoxyphenylamino)-4-(cyclopentyloxy)-7H-pyrrolo[2, 3-d]pyrimidin-5-yl)phenol, 4-(5-(4-(4H-1,2,4-triazol-3-yl)phenyl)-4-methoxy-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-chloro-N,N-dimethylbenzamide, 4-(4-(cyclopentyloxy)-5-(3-fluoro-4-methoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(4-(cyclopentyloxy)-5-(6-methoxypyridin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(5-(3-acetamidophenyl)-4-(cyclopentyloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(4-(cyclopentyloxy)-5-(3-(methyl sulfonamido)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(4-(cyclopentyloxy)-5-(pyridin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(4-(cyclopentyloxy)-5-(3-(methylcarbamoyl)phenyl)-7H-pyrrol o[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(4-(cyclopentyloxy)-5-(3-methoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(4-(cyclopentyloxy)-5-(4-(methyl sulfonyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(5-(4-acetamidophenyl)-4-(cyclopentyloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(4-(cyclopentyloxy)-5-(3-(methyl sulfonyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(4-(cyclopentyloxy)-5-(3,4-dimethoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(5-(3-aminophenyl)-4-(cyclopentyloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(4-(cyclopentyloxy)-5-(pyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(4-(cyclopentyloxy)-5-(6-ethoxypyridin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, (4-(5-(4-(4H-1,2,4-triazol-3-yl)phenyl)-4-methoxy-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-chlorophenyl)(morpholino)-methanone, N,N,3-trimethyl-4-(5-(2-methylbenzo[d]oxazol-6-yl)-4-(tetrahydro-2H-pyran-4-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, N,N,3-trimethyl-4-(5-(2-methylbenzo[d]oxazol-6-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, 4-(5-(2-amino-1H-benzo[d]imidazol-5-yl)-4-methoxy-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-chloro-N,N-dimethylbenzamide, 4-(5-(4-(4H-1,2,4-triazol-3-yl)phenyl)-4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-chloro-N,N-dimethylbenzamide, 4-(4-methoxy-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N,N,3-trimethylbenzamide, (3-methyl-4-(5-(2-methylbenzo[d]oxazol-6-yl)-4-(tetrahydro-2H-pyran-4-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)phenyl)(piperazin-1-yl)methanone, 4-(4-(cyclopentyloxy)-5-(4-(dimethylamino)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(4-(cyclopentyloxy)-5-(4-methoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(5-(4-cyanophenyl)-4-(cyclopentyloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(4-(cyclopentyloxy)-5-(1-methyl-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(4-(cyclopentyloxy)-5-(4-(methylcarbamoyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(4-(cyclopentyloxy)-5-(1H-pyrazol-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(4-(cyclopentyloxy)-5-(1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(4-(cyclopentyloxy)-5-(1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 3-chloro-4-(4-methoxy-5-(2-methyl-1H-benzo[d]imidazol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N,N-dimethylbenzamide, (R)-3-chloro-4-(5-(3-(1-hydroxyethyl)phenyl)-4-(tetrahydro-2H-pyran-4-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N,N-dimethylbenzamide, (S)-3-chloro-4-(5-(3-(1-hydroxyethyl)phenyl)-4-(tetrahydro-2H-pyran-4-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N,N-dimethylbenzamide, (4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methylphenyl)(morpholino)methanone, N-(1H-indazol-5-yl)-4-methoxy-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine, N-(4-(1H-pyrazol-4-yl)phenyl)-4-methoxy-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine, 4-(4-methoxy-5-(pyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N,N,3-trimethylbenzamide, 3-methoxy-N-methyl-4-(5-(2-methylbenzo[d]oxazol-6-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, 4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N,N-dimethylbenzamide, 4-(4-((1r,4r)-4-hydroxycyclohexyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2, 3-d]pyrimidin-2-ylamino)-N,N,3-trimethylbenzamide, N,N,3-trimethyl-4-(5-(pyridin-4-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, 4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N,3-dimethylbenzamide, N,N,3-trimethyl-4-(5-(2-methylbenzo[d]oxazol-6-yl)-4-(1-methylpiperidin-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, (4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxyphenyl)(morpholino)methanone, N,N,3-trimethyl-4-(5-(2-methylbenzo[d]oxazol-6-yl)-4-(piperidin-4-yloxy)-7H-pyrrolo[2, 3-d]pyrimidin-2-ylamino)benzamide, (S)—N,N,3-trimethyl-4-(5-(2-methylbenzo[d]oxazol-6-yl)-4-(tetrahydrofuran-3-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, (R)—N,N,3-trimethyl-4-(5-(2-methylbenzo[d]oxazol-6-yl)-4-(tetrahydrofuran-3-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, N-(2-aminoethyl)-4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxybenzamide, 4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-(2-hydroxyethyl)-3-methoxybenzamide, 4-(5-(6-ethoxypyridin-3-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(cyclopentyloxy)-N-(2-methoxyphenyl)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine, (S)—N,N,3-trimethyl-4-(5-(2-methylbenzo[d]oxazol-6-yl)-4-(tetrahydro-2H-pyran-3-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, N,N,3-trimethyl-4-(5-(3-(methyl sulfonyl)phenyl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, 3-methoxy-N-methyl-4-(5-(3-(methyl sulfonyl)phenyl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, N,N,3-trimethyl-4-(5-(pyrimidin-5-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, 3-methoxy-N-methyl-4-(5-(2-methylbenzo[d]oxazol-6-yl)-4-(tetrahydro-2H-pyran-4-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, 4-(5-(6-ethoxypyridin-3-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N,N,3-trimethylbenzamide, 4-(5-(2-amino-1H-benzo[d]imidazol-6-yl)-4-(cyclopentyloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(5-(1,3,4-oxadiazol-2-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N,N,3-trimethylbenzamide, N,N,3-trimethyl-4-(5-(1-methyl-1H-pyrazol-4-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, N,N,3-trimethyl-4-(5-(1-methyl-1H-pyrazol-3-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, 3-methoxy-N-methyl-4-(5-(pyridin-4-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, N,N,3-trimethyl-4-(5-(oxazol-2-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, 4-(5-(2-amino-1H-benzo[d]imidazol-6-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N,N,3-trimethylbenzamide, N,N,3-trimethyl-4-(5-(2-methylpyridin-4-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2, 3-d]pyrimidin-2-ylamino)benzamide, 3-methoxy-4-(4-methoxy-5-(6-methoxypyridin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-methylbenzamide, 3-methoxy-4-(5-(6-methoxypyridin-3-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-methylbenzamide, 3-methoxy-N-(2-methoxyethyl)-4-(5-(2-methylbenzo[d]oxazol-6-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, (R)—N,N,3-trimethyl-4-(5-(2-methylbenzo[d]oxazol-6-yl)-4-(tetrahydro-2H-pyran-3-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, 4-(5-(1H-pyrazol-4-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 3-methoxy-N-methyl-4-(5-(4-(methylcarbamoyl)phenyl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, 3-methoxy-4-(4-methoxy-5-(4-(methylcarbamoyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-methylbenzamide, 4-(4-isopropoxy-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(5-(6-(dimethylamino)pyri din-3-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2, 3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, N-(2-(dimethylamino)ethyl)-3-methoxy-4-(5-(2-methylbenzo[d]oxazol-6-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, N,N,3-trimethyl-4-(5-(2-methyl-1H-benzo[d]imidazol-6-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, 3-methoxy-4-(4-methoxy-5-(1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-methylbenzamide, 3-methoxy-N-(2-(methylamino)ethyl)-4-(5-(2-methylbenzo[d]oxazol-6-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, 4-(5-(2-(dimethylamino)pyri din-4-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 3-chloro-N-methyl-4-(5-(2-methylbenzo[d]oxazol-6-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, (S)—N,3-dimethyl-4-(5-(2-methylbenzo[d]oxazol-6-yl)-4-(tetrahydrofuran-3-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, (S)-3-chloro-N-methyl-4-(5-(2-methylbenzo[d]oxazol-6-yl)-4-(tetrahydrofuran-3-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, 4-(5-(2,7-dimethylbenzo[d]oxazol-6-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2, 3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(5-(2,5-dimethylbenzo[d]oxazol-6-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2, 3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(4-((1r,4r)-4-hydroxycyclohexyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2, 3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 3-methoxy-N-methyl-4-(4-(2-(methylamino)ethoxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, 3-methoxy-4-(4-(2-methoxyethoxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-methylbenzamide, 4-(5-(2-cyanopyridin-4-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N,N,3-trimethylbenzamide, 4-(5-(4-(1H-imidazol-2-yl)phenyl)-4-methoxy-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(5-(2-aminopyridin-4-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 3-methoxy-4-(5-(2-methoxypyridin-4-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-methylbenzamide, N,3-dimethyl-4-(5-(3-(methylcarbamoyl)phenyl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, N,3-dimethyl-4-(5-(2-methylbenzo[d]oxazol-6-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, 4-(5-(4-(1H-imidazol-2-yl)phenyl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2, 3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(5-(2-hydroxypyridin-4-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(5-(1,2-dimethyl-1H-benzo[d]imidazol-6-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2, 3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(4-methoxy-5-(3-(methylcarbamoyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N, 3-dimethylbenzamide, 4-(4-((1r,4r)-4-hydroxy-4-methylcyclohexyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N,3-dimethylbenzamide, 4-(4-((1 s,4s)-4-hydroxy-4-methylcyclohexyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N,3-dimethylbenzamide, 4-(4-cyclopropoxy-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, (S)—N,3-dimethyl-4-(5-(4-(methylcarbamoyl)phenyl)-4-(tetrahydrofuran-3-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, 3-methoxy-N-methyl-4-(5-(pyrimidin-5-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2, 3-d]pyrimidin-2-ylamino)benzamide, 3-methoxy-N-methyl-4-(5-(2-(methylamino)pyridin-4-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, 4-(4-methoxy-5-(pyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N,3-dimethylbenzamide, 3-chloro-4-(4-methoxy-5-(pyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N,N-dimethylbenzamide, N,3-dimethyl-4-(5-(4-(methyl sulfonyl)phenyl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2, 3-d]pyrimidin-2-ylamino)benzamide, 5-(2-(4-(dimethylcarbamoyl)-2-methylphenylamino)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-N-methylpicolinamide, N-(2-hydroxyethyl)-4-(4-isopropoxy-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2, 3-d]pyrimidin-2-ylamino)-3-methoxybenzamide, (S)-4-(5-(6-ethoxypyridin-3-yl)-4-(tetrahydrofuran-3-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, (S)-4-(5-(6-ethoxypyridin-3-yl)-4-(tetrahydrofuran-3-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N,3-dimethylbenzamide, 3-methoxy-N-methyl-4-(5-(1-methyl-1H-pyrazol-3-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, (S)—N,N,3-trimethyl-4-(5-(1-methyl-1H-pyrazol-4-yl)-4-(tetrahydrofuran-3-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, (S)—N,3-dimethyl-4-(5-(1-methyl-1H-pyrazol-4-yl)-4-(tetrahydrofuran-3-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, 3-methoxy-4-(4-methoxy-5-(2-methylpyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-methylbenzamide, 3-methoxy-N-methyl-4-(5-(2-methylpyridin-4-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, 4-(4-(2-hydroxyethoxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, (S)-3-methoxy-N-methyl-4-(5-(2-methylbenzo[d]oxazol-6-yl)-4-(tetrahydrofuran-3-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, 4-(5-(2-isopropylbenzo[d]oxazol-6-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 3-cyano-N-methyl-4-(5-(2-methylbenzo[d]oxazol-6-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, 3-methoxy-N-methyl-4-(5-(1-methyl-1H-imidazol-2-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, 3-methoxy-N-methyl-4-(5-(oxazol-2-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, 4-(5-(1,3,4-oxadiazol-2-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, (S)-4-(5-(3-(1-hydroxyethyl)phenyl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, (S)—N,N,3-trimethyl-4-(5-(pyridin-4-yl)-4-(tetrahydrofuran-3-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, 3-methoxy-4-(4-methoxy-5-(1-methyl-1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-methylbenzamide, (S)-3-methoxy-N-methyl-4-(5-(2-methylpyridin-4-yl)-4-(tetrahydrofuran-3-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, 3-methoxy-N-methyl-4-(5-(2-methylbenzo[d]oxazol-6-yl)-4-(oxetan-3-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, 3-(4-isopropoxy-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-4-methoxy-N-methylbenzamide, 4-methoxy-N-methyl-3-(5-(2-methylbenzo[d]oxazol-6-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, (S)-3-methoxy-N-methyl-4-(5-(4-(methylcarbamoyl)phenyl)-4-(tetrahydrofuran-3-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, 6-methoxy-N-methyl-5-(5-(2-methylbenzo[d]oxazol-6-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)picolinamide, 3-methoxy-N-methyl-4-(5-(1-methyl-1H-pyrazol-4-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, 4-(4-isopropoxy-5-(2-methoxypyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 3-methoxy-N-methyl-4-(5-(pyrazin-2-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, 4-(4-isopropoxy-5-(3-(methylsulfonyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(4-isopropoxy-5-(4-(methylcarbamoyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(4-isopropoxy-5-(1-methyl-1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 3-methoxy-4-(4-methoxy-5-(pyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-methylbenzamide, N-methyl-4-(5-(2-methylbenzo[d]oxazol-6-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-(trifluoromethyl)benzamide, N-methyl-4-(5-(2-methylbenzo[d]oxazol-6-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-(trifluoromethoxy)benzamide, 4-(5-(4-(1H-imidazol-2-yl)phenyl)-4-isopropoxy-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(5-(2-aminopyridin-4-yl)-4-isopropoxy-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 3-methoxy-N-methyl-4-(5-(4-(1-methyl-1H-imidazol-2-yl)phenyl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, 4-(5-(6-ethoxypyridin-3-yl)-4-isopropoxy-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(5-(4-(4, 5-dimethyl-1H-imidazol-2-yl)phenyl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(4-cyclobutoxy-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(4-isopropoxy-5-(2-(methylamino)pyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 3-isopropyl-N-methyl-4-(5-(pyridin-4-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, 4-(4-isopropoxy-5-(2-methylpyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(4-(isopropylamino)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, (R)-4-(4-sec-butoxy-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, (S)-4-(4-sec-butoxy-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(4-((1 r,4r)-4-hydroxy-4-methylcyclohexyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(4-((1 s,4s)-4-hydroxy-4-methylcyclohexyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 3-methoxy-N-methyl-4-(5-(4-(4-methyl-1H-imidazol-2-yl)phenyl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, (S)-3-isopropyl-N-methyl-4-(5-(1-methyl-1H-pyrazol-4-yl)-4-(tetrahydrofuran-3-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, (S)-3-isopropyl-N-methyl-4-(5-(2-methylbenzo[d]oxazol-6-yl)-4-(tetrahydrofuran-3-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, 3-methoxy-N-methyl-4-(5-(1-methyl-1H-pyrazol-4-yl)-4-(tetrahydro-2H-pyran-4-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, 4-(4-(cyclopropylamino)-5-(1-methyl-1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(4-(cyclopropylamino)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, N-(2-hydroxyethyl)-3-methoxy-4-(5-(2-methylbenzo[d]oxazol-6-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, (R)-4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-(1-hydroxypropan-2-yl)-3-methoxybenzamide, (S)-4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-(1-hydroxypropan-2-yl)-3-methoxybenzamide, 4-(4-cyclopropoxy-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-(2-hydroxyethyl)-3-methoxybenzamide, 4-(4-cyclopropoxy-5-(1-methyl-1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-(2-hydroxyethyl)-3-methoxybenzamide, 4-(4-cyclopropoxy-5-(1-methyl-1H-pyrazol-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 3-methoxy-N-methyl-4-(5-(2-methylbenzo[d]oxazol-6-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzenesulfonamide, 4-(4-isopropoxy-5-(1-methyl-1H-pyrazol-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 3-methoxy-4-(4-(2-methoxyethoxy)-5-(1-methyl-1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N,N-dimethylbenzamide, (R)-3-methoxy-N,N-dimethyl-4-(5-(2-methylbenzo[d]oxazol-6-yl)-4-(tetrahydrofuran-3-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, 3-methoxy-N-methyl-4-(5-(2-methylbenzo[d]thiazol-6-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, N-tert-butyl-4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxybenzamide, (S)-3-isopropyl-N-methyl-4-(5-(1-methyl-1H-pyrazol-5-yl)-4-(tetrahydrofuran-3-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, 4-(4-isopropoxy-5-(1-methyl-1H-pyrazol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(cyclopentyloxy)-N-(2-methoxy-4-(1-methyl-1H-pyrazol-4-yl)phenyl)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine, 4-(cyclopentyloxy)-N-(2-methoxy-4-(1H-pyrazol-1-yl)phenyl)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine, N-cyclopentyl-4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxybenzamide, (R)-4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-(2-hydroxypropyl)-3-methoxybenzamide, (4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxyphenyl)(4-hydroxypiperidin-1-yl)methanone, 4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-(3-hydroxypropyl)-3-methoxybenzamide, 4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-(2-hydroxyethyl)-3-methoxy-N-methylbenzamide, 4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-(1-hydroxy-2-methylpropan-2-yl)-3-methoxybenzamide, 5-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)isoindolin-1-one, 4-(5-(2-acetamidopyridin-4-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-2-fluoro-5-methoxy-N-methylbenzamide, 4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-((1s,3s)-3-hydroxycyclobutyl)-3-methoxybenzamide, 4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-((1r,3r)-3-hydroxycyclobutyl)-3-methoxybenzamide, (S)-4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-(2-hydroxypropyl)-3-methoxybenzamide, azetidin-1-yl(4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxyphenyl)methanone, (R)-4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-((tetrahydrofuran-2-yl)methyl)benzamide, 4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-((tetrahydro-2H-pyran-4-yl)methyl)benzamide, 5-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-2-methylisoindolin-1-one, 4-(5-(4-carbamimidoylphenyl)-4-(cyclopentyloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(4-tert-butoxy-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, N-(4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxyphenyl)acetamide, N-(2-cyanoethyl)-4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2, 3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, (4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxyphenyl)(pyrrolidin-1-yl)methanone, 4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methyl-N-(tetrahydro-2H-pyran-4-yl)benzamide, 4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-cyclopropyl-N-(2-hydroxyethyl)-3-methoxybenzamide, 4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-(tetrahydro-2H-pyran-4-yl)benzamide, 4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-((1R,2S)-2-hydroxycyclopentyl)-3-methoxybenzamide, (S)-4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-((tetrahydrofuran-2-yl)methyl)benzamide, 4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-(oxetan-3-yl)benzamide, 4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-(2-fluoroethyl)-3-methoxybenzamide, N-(3-amino-3-oxopropyl)-4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(4-(cyclopentyloxy)-5-(4-(methylcarbamoyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-(2-hydroxyethyl)-3-methoxybenzamide, (4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxyphenyl)(4-methylpiperazin-1-yl)methanone, 4-(5-(benzo[c][1,2,5]oxadiazol-5-yl)-4-(cyclopentyloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(cyclopentyloxy)-N-(5-fluoro-2-methoxy-4-(methylsulfonyl)phenyl)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine, aziridin-1-yl(4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxyphenyl)methanone, N-(cyanomethyl)-4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-((1 S,2R)-2-hydroxycyclopentyl)-3-methoxybenzamide, 4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-((1 S,2S)-2-hydroxycyclopentyl)-3-methoxybenzamide, 4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-((1R,2R)-2-hydroxycyclopentyl)-3-methoxybenzamide, (S)-4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-(tetrahydrofuran-3-yl)benzamide, N-(2-amino-2-oxoethyl)-4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 3-methoxy-N-methyl-4-(5-(pyridazin-4-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, 3-methoxy-N-methyl-4-(5-(pyrimidin-4-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, 4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methyl-N-((3-methyloxetan-3-yl)methyl)benzamide, 4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methyl-N-(oxetan-3-yl)benzamide, 4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-(tetrahydro-2H-pyran-3-yl)benzamide, 4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-(tetrahydro-2H-pyran-3-yl)benzamide, (4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxyphenyl)(4-methoxypiperidin-1-yl)methanone, (S)-4-(4-sec-butoxy-5-(1-methyl-1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxybenzonitrile, 4-(4-(cyclopentyloxy)-5-(1-methyl-1H-indazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(4-(cyclopentyloxy)-5-(3-methylbenzo[d]isoxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 5-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-4-methoxy-N-methylpicolinamide, N-((1,4-dioxan-2-yl)methyl)-4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxybenzamide, 4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-(oxetan-3-ylmethyl)benzamide, 4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-(3-hydroxypropyl)-3-methoxy-N-methylbenzamide, 4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-(2-methoxyethyl)-N-methylbenzamide, 4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-(2-hydroxy-2-methylpropyl)-3-methoxybenzamide, (S)-4-(4-sec-butoxy-5-(1-methyl-1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-(2-hydroxyethyl)-3-methoxybenzamide, 4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxybenzimidamide, 4-(2-(2-methoxy-4-(methylcarbamoyl)phenylamino)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-N-methylpicolinamide, (4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxyphenyl)(4,4-difluoropiperidin-1-yl)methanone, 4-(5-(4-acetamido-3-hydroxyphenyl)-4-(cyclopentyloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, (4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxyphenyl)((3R,4R)-3-hydroxy-4-methoxypyrrolidin-1-yl)methanone, 4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-(piperidin-1-yl)benzamide, 4-(4-(cyclopentyloxy)-5-(2-ethoxybenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(5-(4-amino-3-hydroxyphenyl)-4-(cyclopentyloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(cyclopentyloxy)-N-(1-methyl-1H-pyrazol-5-yl)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine, 4-(cyclopentyloxy)-N-(1,5-dimethyl-1H-pyrazol-4-yl)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine, 4-(cyclopentyloxy)-N-(1,4-dimethyl-1H-pyrazol-3-yl)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine, 4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N, 5-dimethylbenzamide, 4-(4-(cyclopentyloxy)-5-(2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-(1-methylazetidin-3-yl)benzamide, 4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-(3-methyloxetan-3-yl)benzamide, 4-(4-cyclobutoxy-5-(1-methyl-1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-(oxetan-3-yl)benzamide, 4-(4-(cyclopentyloxy)-5-(1-methyl-1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-(oxetan-3-yl)benzamide, 4-(4-cyclobutoxy-5-(4-(methylcarbamoyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-(oxetan-3-yl)benzamide, 4-(4-(cyclopentyloxy)-5-(4-(methylcarbamoyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-(oxetan-3-yl)benzamide, 4-(4-(cyclopentyloxy)-5-(quinolin-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(cyclopentyloxy)-N-(1,3-dimethyl-1H-pyrazol-4-yl)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine, N-(1-acetylazetidin-3-yl)-4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxybenzamide, 4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-(2,2-difluoropropyl)-3-methoxybenzamide, 3-methoxy-4-(5-(4-(methylcarbamoyl)phenyl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-(oxetan-3-yl)benzamide, (4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxyphenyl)((3R,4R)-3,4-dimethoxypyrrolidin-1-yl)methanone, (4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxyphenyl)(2,2-dimethylaziridin-1-yl)methanone, (S)-(4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxyphenyl)(2-methylaziridin-1-yl)methanone, 4-(4-((1 s,4s)-4-hydroxy-4-methylcyclohexyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-(oxetan-3-yl)benzamide, aziridin-1-yl(4-(4-((1 s,4s)-4-hydroxy-4-methylcyclohexyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxyphenyl)methanone, 4-(4-(cyclopentyloxy)-2-(1-methyl-1H-pyrazol-5-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-N-methylbenzamide, N-methyl-4-(2-(1-methyl-1H-pyrazol-5-ylamino)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)benzamide, methyl 4-(4-(cyclopentyloxy)-2-(2-methoxy-4-(methylcarbamoyl)phenylamino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)benzoate, 4-(4-(cyclopentyloxy)-5-(4-fluoro-2-methylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(4-(cyclopentyloxy)-5-(2,4-dimethoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(4-(cyclopentyloxy)-5-(3,5-dimethylisoxazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(4-(cyclopentyloxy)-5-(3-(dimethylamino)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(4-(cyclopentyloxy)-5-(3-hydroxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(5-(3-cyanophenyl)-4-(cyclopentyloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 3-methoxy-4-(5-(5-methoxypyridin-3-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-methylbenzamide, 3-methoxy-4-(4-(2-methoxyethoxy)-5-(1-methyl-1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-methylbenzamide, N-(2-hydroxyethyl)-3-methoxy-4-(5-(1-methyl-1H-pyrazol-4-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, (S)-3-methoxy-N-methyl-4-(5-(1-methyl-1H-pyrazol-4-yl)-4-(tetrahydrofuran-3-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, N-methyl-4-(2-(1-methyl-1H-pyrazol-5-ylamino)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)benzamide, 4-(4-(cyclopentyloxy)-5-(4-fluoro-2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide, 4-(4-cyclobutoxy-5-(4-(methylcarbamoyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-(2-hydroxyethyl)-3-methoxybenzamide, 4-(4-cyclobutoxy-5-(4-(methylcarbamoyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methyl-N-(oxetan-3-yl)benzamide, 3-chloro-4-(4-cyclobutoxy-5-(4-(methylcarbamoyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-(oxetan-3-yl)benzamide, 4-(4-isopropoxy-5-(4-(methylcarbamoyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-(oxetan-3-yl)benzamide, (R)-(4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxyphenyl)(2-methylaziridin-1-yl)methanone, 4-(2-(4-(aziridine-1-carbonyl)-2-methoxyphenylamino)-4-((1 s,4s)-4-hydroxy-4-methylcyclohexyloxy)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-N-methylbenzamide, 4-(4-((1 s,4s)-4-hydroxy-4-methylcyclohexyloxy)-5-(4-(methylcarbamoyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-(oxetan-3-yl)benzamide, aziridin-1-yl(3-methoxy-4-(4-methoxy-5-(pyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)phenyl)methanone, 4-(4-cyclobutoxy-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-(oxetan-3-yl)benzamide, 4-(4-cyclobutoxy-2-(1,3-dimethyl-1H-pyrazol-4-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-N-methylbenzamide, 4-(4-(3-cyanocyclobutoxy)-5-(4-(methylcarbamoyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-(oxetan-3-yl)benzamide, 4-(2-(5-chloro-1-methyl-1H-pyrazol-4-ylamino)-4-cyclobutoxy-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-N-methylbenzamide, (S)-3-methoxy-4-(5-(2-methylbenzo[d]oxazol-6-yl)-4-(tetrahydrofuran-3-yloxy)-7H-pyrrolo[2, 3-d]pyrimidin-2-ylamino)-N-(oxetan-3-yl)benzamide, 4-(4-cyclopropoxy-5-(4-(methylcarbamoyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-(oxetan-3-yl)benzamide, 4-(4-(3,3-difluorocyclobutoxy)-5-(4-(methylcarbamoyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-(oxetan-3-yl)benzamide, (R)-(4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxyphenyl)(2-(hydroxymethyl)aziridin-1-yl)methanone, 3-methoxy-4-(4-methoxy-5-(pyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-(oxetan-3-yl)benzamide, 4-(4-cyclobutoxy-5-(4-(methylcarbamoyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-(1-methylazetidin-3-yl)benzamide, 4-(4-((1 s,4s)-4-hydroxy-4-methylcyclohexyloxy)-5-(4-(methylcarbamoyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-(1-methylazetidin-3-yl)benzamide, (S)-(4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxyphenyl)(2-(hydroxymethyl)aziridin-1-yl)methanone, N-(5-chloro-1-isopropyl-1H-pyrazol-4-yl)-4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine, 5-(4-cyclobutoxy-2-(2-methoxy-4-(oxetan-3-ylcarbamoyl)phenylamino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-N-methylpicolinamide, 4-(4-cyclobutoxy-2-(2-methoxy-4-(oxetan-3-ylcarbamoyl)phenylamino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-fluoro-N-methylbenzamide, 4-(4-tert-butoxy-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-(1-methylazetidin-3-yl)benzamide, 4-(4-tert-butoxy-5-(4-(methylcarbamoyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-(1-methylazetidin-3-yl)benzamide, 4-(4-isopropoxy-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-(1-methylazetidin-3-yl)benzamide, 4-(4-isopropoxy-5-(4-(methylcarbamoyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-(1-methylazetidin-3-yl)benzamide, 4-(4-((1 s,4s)-4-hydroxy-4-methylcyclohexyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-(1-methylazetidin-3-yl)benzamide, 3-methoxy-4-(5-(4-(methylcarbamoyl)phenyl)-4-(oxetan-3-yl oxy)-7H-pyrrol o[2,3-d]pyrimidin-2-ylamino)-N-(oxetan-3-yl)benzamide, 4-(5-(4-(1H-imidazol-2-yl)phenyl)-4-cyclobutoxy-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-(oxetan-3-yl)benzamide, 4-(5-(4-(1H-imidazol-2-yl)phenyl)-4-(cyclopentyloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-(1-methylazetidin-3-yl)benzamide, 4-(4-isopropoxy-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-(oxetan-3-yl)benzamide, 4-(4-cyclopropoxy-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-(1-methylazetidin-3-yl)benzamide, 4-(4-cyclopropoxy-5-(4-(methylcarbamoyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-(1-methylazetidin-3-yl)benzamide, 3-methoxy-4-(4-(2-methoxyethoxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-(oxetan-3-yl)benzamide, 3-methoxy-N-(1-methylazetidin-3-yl)-4-(5-(4-(methylcarbamoyl)phenyl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, 3-methoxy-N-(1-methylazetidin-3-yl)-4-(5-(2-methylbenzo[d]oxazol-6-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, 3-methoxy-4-(5-(2-methylbenzo[d]oxazol-6-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-(oxetan-3-yl)benzamide, 4-(4-cyclopropoxy-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-(oxetan-3-yl)benzamide, 4-(4-tert-butoxy-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-(oxetan-3-yl)benzamide, 1-(5-chloro-4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-1H-pyrazol-1-yl)-2-methylpropan-2-ol, 4-(2-(5-chloro-1-(2-hydroxy-2-methylpropyl)-1H-pyrazol-4-ylamino)-4-cyclobutoxy-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-N-methylbenzamide, 3-methoxy-4-(4-(2-methoxyethoxy)-5-(4-(methylcarbamoyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-(oxetan-3-yl)benzamide, (S)-3-methoxy-N-(1-methylazetidin-3-yl)-4-(5-(2-methylbenzo[d]oxazol-6-yl)-4-(tetrahydrofuran-3-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, (S)-3-methoxy-N-(1-methylazetidin-3-yl)-4-(5-(4-(methylcarbamoyl)phenyl)-4-(tetrahydrofuran-3-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, (S)-3-methoxy-4-(5-(4-(methylcarbamoyl)phenyl)-4-(tetrahydrofuran-3-oxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-(oxetan-3-yl)benzamide, N-(5-chloro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine, N-(5-chloro-1-(2-methoxyethyl)-1H-pyrazol-4-yl)-4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine, 3-methoxy-4-(5-(2-methylbenzo[d]oxazol-6-yl)-4-(1-methylcyclobutoxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-(oxetan-3-yl)benzamide, 3-methoxy-4-(4-methoxy-5-(3-methylbenzo[d]isoxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-(oxetan-3-yl)benzamide, 4-(5-(2-fluoropyridin-4-yl)-4-methoxy-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-(oxetan-3-yl)benzamide, 3-methoxy-4-(4-methoxy-5-(1-methyl-1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-(oxetan-3-yl)benzamide, 3-methoxy-4-(4-methoxy-5-(2-methylpyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-(oxetan-3-yl)benzamide, 4-(5-(2,6-dimethylpyridin-4-yl)-4-methoxy-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-(oxetan-3-yl)benzamide, N-(5-chloro-1-ethyl-1H-pyrazol-4-yl)-4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine, 3-methoxy-4-(4-(2-methoxyethoxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-(1-methylazetidin-3-yl)benzamide, 4-(5-(1,3-dimethyl-1H-pyrazol-4-yl)-4-methoxy-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-(oxetan-3-yl)benzamide, 3-methoxy-4-(4-methoxy-5-(3-methylbenzo[d]isoxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-methylbenzamide, 3-methoxy-4-(4-methoxy-5-(2-methoxypyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-(oxetan-3-yl)benzamide, 4-(5-(4-fluorophenyl)-4-methoxy-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N,N,3-trimethylbenzamide, 4-(4-methoxy-5-(4-methoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N,N,3-trimethylbenzamide, 3-methoxy-4-(4-methoxy-5-(pyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N,N-dimethylbenzamide, N-(1,3-dimethyl-1H-pyrazol-4-yl)-4-methoxy-5-(pyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine, 4-(5-(2-chloropyridin-4-yl)-4-methoxy-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-(oxetan-3-yl)benzamide, 3-methoxy-4-(4-methoxy-5-(pyrimidin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-(oxetan-3-yl)benzamide, 4-(4-methoxy-5-(pyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methyl-N-(oxetan-3-yl)benzamide, 4-(5-(4-(1H-imidazol-2-yl)phenyl)-4-methoxy-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N,N,3-trimethylbenzamide, 4-(4-methoxy-5-(1-methyl-1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N,N,3-trimethylbenzamide, 4-(4-methoxy-5-(2-methyl-1H-benzo[d]imidazol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N,N,3-trimethylbenzamide, 4-(4-methoxy-5-(3-methylbenzo[d]isoxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N,N,3-trimethylbenzamide, 4-methoxy-N-(1-methyl-1H-pyrazol-5-yl)-5-(pyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine, 4-(5-(2-fluoropyridin-4-yl)-4-isopropoxy-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N,N,3-trimethylbenzamide, 4-(5-(2-fluoropyridin-4-yl)-4-isopropoxy-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N,N-dimethylbenzamide, 3-methoxy-4-(4-methoxy-5-(2-methyl-1H-benzo[d]imidazol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-(oxetan-3-yl)benzamide, 3-methoxy-4-(4-methoxy-5-(pyridazin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-(oxetan-3-yl)benzamide, 4-(4-methoxy-5-(pyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N,3-dimethyl-N-(oxetan-3-yl)benzamide, 4-(5-(1,2-dimethyl-1H-benzo[d]imidazol-6-yl)-4-methoxy-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N,N,3-trimethylbenzamide, 3-methoxy-4-(4-methoxy-5-(3-methylbenzo[d]isoxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N,N-dimethylbenzamide, 4-(5-(2-fluoropyridin-4-yl)-4-methoxy-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N,N,3-trimethylbenzamide, 4-(5-(1,2-dimethyl-1H-benzo[d]imidazol-5-yl)-4-methoxy-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N,N,3-trimethylbenzamide, 4-(4-methoxy-5-(4-(methylsulfonyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N,N,3-trimethylbenzamide, 4-(5-(2-fluoropyridin-4-yl)-4-methoxy-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N,N-dimethylbenzamide, 4-(5-(2-fluoropyridin-4-yl)-4-methoxy-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methyl-N-(oxetan-3-yl)benzamide, 4-methoxy-N-(4-methyl-1H-indazol-5-yl)-5-(pyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine, 5-(5-(2-fluoropyridin-4-yl)-4-methoxy-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-4-methoxy-N,N-dimethylpicolinamide, 5-(2-fluoropyridin-4-yl)-4-methoxy-N-(4-methoxy-6-(tetrahydro-2H-pyran-4-yl)pyridin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine, 4-(5-(3-chloro-1-methyl-1H-pyrazol-4-yl)-4-methoxy-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-(oxetan-3-yl)benzamide, 4-(5-(2-fluoro-6-methylpyridin-4-yl)-4-methoxy-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N,N-dimethylbenzamide, N-(1,4-dimethyl-1H-indazol-5-yl)-4-methoxy-5-(pyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine, 4-(5-(2-fluoro-6-methylpyridin-4-yl)-4-methoxy-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N,N,3-trimethylbenzamide, 3-chloro-N-methyl-4-(5-(4-(methylcarbamoyl)phenyl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, 3-chloro-4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-methylbenzamide, 3-chloro-N-methyl-4-(5-(1-methyl-1H-pyrazol-4-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, 4-(5-(2-fluoro-6-methylpyridin-4-yl)-4-methoxy-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-(oxetan-3-yl)benzamide, 3-chloro-4-(4-(cyclopentyloxy)-5-(4-(methylcarbamoyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-methylbenzamide, 3-chloro-4-(4-isopropoxy-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-methylbenzamide, 3-chloro-4-(4-methoxy-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-methylbenzamide, 3-chloro-4-(4-methoxy-5-(4-(methylcarbamoyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-methylbenzamide, 3-chloro-4-(4-((1 s,4s)-4-hydroxy-4-methylcyclohexyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-methylbenzamide, 3-chloro-N-methyl-4-(5-(2-methylbenzo[d]oxazol-6-yl)-4-(tetrahydro-2H-pyran-4-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, 3-chloro-N-(2-hydroxyethyl)-4-(5-(2-methylbenzo[d]oxazol-6-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, 3-chloro-4-(4-isopropoxy-5-(4-(methylcarbamoyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-methylbenzamide, 3-chloro-N-methyl-4-(5-(4-(methylcarbamoyl)phenyl)-4-(tetrahydro-2H-pyran-4-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, (R)-3-chloro-N-methyl-4-(5-(4-(methylcarbamoyl)phenyl)-4-(tetrahydrofuran-3-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, 3-ethyl-N-methyl-4-(5-(2-methylbenzo[d]oxazol-6-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, N-methyl-4-(5-(2-methylbenzo[d]oxazol-6-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-propylbenzamide, 4-(5-(2-chloro-6-methylpyridin-4-yl)-4-methoxy-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-(oxetan-3-yl)benzamide, 3-chloro-4-(5-(2-methylbenzo[d]oxazol-6-yl)-4-(tetrahydro-2H-pyran-4-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-(oxetan-3-yl)benzamide, or a pharmaceutically acceptable salt, tautomer, stereoisomer, enantiomer, or isotopologue thereof. 